"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04333550","Application of Desferal to Treat COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Deferoxamine","Mortality rate|change in patients clinical manifestation|change in patients PaO2|Length of hospitalization|C-reactive protein|lymphocyte count|length of intensive care unit stay","Kermanshah University of Medical Sciences","All","3 Years to 99 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","1398.1224","April 2020","September 2020","March 2021","April 3, 2020",,"April 6, 2020","Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04333550"
2,"NCT04336904","Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19",,"Active, not recruiting","No Results Available","COVID-19","Drug: Favipiravir|Other: Placebo","Time from randomization to clinical recovery|Time from randomization to negativity in RT-PCR nucleic acid test|Incidence of deterioration/aggravation of pneumonia|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy|ICU admission rate|Mortality","Giuliano Rizzardini|ASST Fatebenefratelli Sacco","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","HS216C17-PHASE III","March 25, 2020","July 2020","July 2020","April 7, 2020",,"April 8, 2020","Asst Fatebenefratelli Sacco, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04336904"
3,"NCT04331509","COVID-19 Symptom Tracker",,"Recruiting","No Results Available","COVID-19","Other: No Intervention","Physical health symptoms|Lack of physical health symptoms|Fever","King's College London|Zoe Global Limited|Massachusetts General Hospital|Harvard School of Public Health|Stanford University","All","18 Years and older   (Adult, Older Adult)",,"10000000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-19 Symptom tracker","March 23, 2020","March 23, 2022","March 23, 2022","April 2, 2020",,"April 7, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04331509"
4,"NCT04333407","Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.","C-19-ACS","Not yet recruiting","No Results Available","COVID-19","Drug: Aspirin 75mg|Drug: Clopidogrel 75mg|Drug: Rivaroxaban 2.5 MG|Drug: Atorvastatin 40mg|Drug: Omeprazole 20mg","All-cause mortality at 30 days after admission|Absolute change in serum troponin from admission to peak value|Discharge Rate|Intubation Rate","Imperial College London","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","3170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20HH5868","March 31, 2020","March 30, 2021","March 30, 2021","April 3, 2020",,"April 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04333407"
5,"NCT04291053","The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Huaier Granule","Mortality rate|Clinical status assessed according to the official guideline|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|Length of hospital stay (days)|Length of ICU stay (days)|Pulmonary function","Tongji Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TJ-IRB20200205","April 1, 2020","August 1, 2020","September 1, 2020","March 2, 2020",,"March 17, 2020",,,"https://ClinicalTrials.gov/show/NCT04291053"
6,"NCT04336462","Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19","COVID-19","Recruiting","No Results Available","COVID-19","Device: oxyhydrogen|Device: Oxygen","Recovery time|Clinical Symptom Remission time|fever duration|Leicester cough questionaire (LCQ)|minimum oxygen|Negative conversion rate|white blood cell(WBC)|Red blood cells(RBC)|Hemoglobin(Hb )|Platelets(PLT)|Lymphocyte count|The percentage of lymphocyte|neutrophils|C-reactive protein (CRP)|Myocardial enzyme|liver function|Renal function|Muscle enzyme","Shanghai Asclepius Meditec Inc.|Shanghai Public Health Clinical Center|Henan Provincial People's Hospital|Shenzhen Third People's Hospital|The First People's Hospital of Yunnan|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai 6th People's Hospital|Guangdong Provincial Hospital of Traditional Chinese Medicine","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","100","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JT202002LZ","February 15, 2020","February 21, 2020","August 1, 2020","April 7, 2020",,"April 7, 2020","First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04336462"
7,"NCT04324489","DAS181 for Severe COVID-19: Compassionate Use",,"Recruiting","No Results Available","COVID-19","Drug: DAS181","Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death","Renmin Hospital of Wuhan University|Ansun Biopharma, Inc.","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","4","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DAS181-SARS-CoV-2","March 6, 2020","April 25, 2020","April 30, 2020","March 27, 2020",,"April 2, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04324489"
8,"NCT04323228","Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19","ONSCOVID19","Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants|Dietary Supplement: isocaloric/isonutrigenous ONS","Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial|Change from baseline Serum ferritin level at end of the trial|Change from baseline serum Interleukin-6 concentration at end of the trial|Change from baseline serum C-reactive protein concentration at end of the trial|Change from baseline serum Tumor necrosis factor-α concentration at end of the trial|Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial|Change from baseline Weight at end of the trial|Height|Change from baseline BMI at end of the trial|Change from baseline mid arm circumference at end of the trial|Change from baseline triceps skin-fold thickness at end of the trial|Change from baseline MAMA at end of the trial|Change from baseline percentage of peripheral O2 saturation at end of the trial|Change from baseline degree of body temperature at end of the trial|Change from baseline count the total leukocyte at end of the trial|Change from baseline differential lymphocytic count at end of the trial|Change from baseline Neutrophil count at end of the trial|Change from baseline neutrophil to lymphocyte ratio at end of the trial","King Saud University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 4","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","ONS_COVID-19","April 1, 2020","October 1, 2020","October 30, 2020","March 26, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04323228"
9,"NCT04335123","Study of Open Label Losartan in COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Losartan","Number of participants with treatment-related adverse events as assessed by protocol definition of AE|Number of days on supplemental oxygen in respiratory failure due to COVID-19|Incidence of mechanical ventilation use|Days on mechanical ventilation|Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use|Days on non-invasive positive pressure ventilation or high flow nasal cannula|Incidence of transfer to ICU from non-ICU hospital bed|ICU length of stay (days)|30-day mortality rate|Hospital length of stay (days)|Cumulative incidence of severe adverse events|Cumulative incidence of adverse events|Change from baseline in oxygenation|Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)|Incidence (and length in days) of extracorporeal membrane oxygenation use|Incidence (and length in days) of renal replacement therapy use|Intolerance of high dose (50mg) losartan after tolerating 25mg","University of Kansas Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00145514","March 25, 2020","September 2020","October 2020","April 6, 2020",,"April 6, 2020","University of Kansas Medical Center, Kansas City, Kansas, United States",,"https://ClinicalTrials.gov/show/NCT04335123"
10,"NCT04333420","Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia","PANAMO","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Best supportive Care (BSC) + IFX-1|Drug: Best supportive care only","Change in PaO2/FiO2|Patients achieving early response","InflaRx GmbH","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","130","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IFX-1-P2.9","March 31, 2020","October 31, 2020","December 31, 2020","April 3, 2020",,"April 7, 2020","University Amsterdam, Amsterdam, Netherlands",,"https://ClinicalTrials.gov/show/NCT04333420"
11,"NCT04329611","ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Composite of hospitalization, invasive mechanical ventilation or death within 30 days|mortality|Symptom duration|Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased.","Dr. Michael Hill|University of Calgary","All","18 Years and older   (Adult, Older Adult)","Phase 3","1660","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ABCOV-01 version 1.1","April 15, 2020","July 31, 2020","August 31, 2020","April 1, 2020",,"April 7, 2020","University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04329611"
12,"NCT04321421","Hyperimmune Plasma for Critical Patients With COVID-19","COV19-PLASMA","Active, not recruiting","No Results Available","COVID-19","Other: hyperimmune plasma","death|time to extubation|length of intensive care unit stay|time to CPAP weaning|viral load|immune response","Foundation IRCCS San Matteo Hospital|OSPEDALE CARLO POMA ASST MANTOVA|OSPEDALE MAGGIORE LODI|OSPEDALE ASST CREMONA","All","18 Years and older   (Adult, Older Adult)","Not Applicable","49","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRCCSSanMatteoH","March 17, 2020","May 31, 2020","May 31, 2020","March 25, 2020",,"March 25, 2020","Catherine Klersy, Pavia, PV, Italy",,"https://ClinicalTrials.gov/show/NCT04321421"
13,"NCT04325633","Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection","ENACOVID","Not yet recruiting","No Results Available","COVID-19","Drug: 1: Naproxen|Drug: 2: Standard of care","Mortality all causes at day30|Number of days alive free of mechanical ventilation|Number of days alive outside|Number of days alive outside hospital|Maximal changes in Sofa score|Time to negativation of virus titer in the nasopharyngeal aspirate (NPA)","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 3","584","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200387","March 27, 2020","April 27, 2021","June 27, 2021","March 27, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04325633"
14,"NCT04323332","Traditional Chinese Medicine for Severe COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Traditional Chinese Medicine Prescription","Length of hospital stay (days)|Duration (days) of supplemental oxygenation|CT imaging changes|Mortality rate|Time to Clinical Improvement (TTCI)|The pneumonia severity index scores|Time to COVID-19 nucleic acid testing negativity in throat swab|Blood immune cell count|Serum inflammatory markers|Erythrocyte sedimentation rate|Platelet and D-dimer changes|Creatinine changes|Muscle enzymes changes|Usage of antibiotics|Usage of glucocorticoids|Frequency of adverse events","Xiyuan Hospital of China Academy of Chinese Medical Sciences","All","up to 85 Years   (Child, Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020XLA015-1","March 2020","March 2020","April 2020","March 26, 2020",,"March 26, 2020","Hao Li, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04323332"
15,"NCT04306497","Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.","CTOROTSADTOC","Recruiting","No Results Available","COVID-19","Drug: TCM prescriptions","The relief / disappearance rate of main symptoms|Chest CT absorption|Virus antigen negative conversion rate|Clinical effective time: the average effective time|The number of severe and critical conversion cases|Incidence of complications|Traditional Chinese Medicine Syndrome Score","Jiangsu Famous Medical Technology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)",,"340","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","JSZYJ202001","March 2, 2020","May 2020","May 2020","March 13, 2020",,"March 17, 2020","Huai'an fourth people's Hospital, Huaian, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04306497"
16,"NCT04287686","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19",,"Withdrawn","No Results Available","COVID-19","Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2)","Time course of body temperature (fever)|Viral load over time|P/F ratio over time|Sequential organ failure assessment score(SOFA score) over time|Pulmonary Severity Index (PSI)|Image examination of chest over time|Proportion of subjects who progressed to critical illness or death|Time from first dose to conversion to normal or mild pneumonia|T-lymphocyte counts over time|C-reactive protein levels over time|Angiotensin II (Ang II) changes over time|Angiotensin 1-7 (Ang 1-7) changes over time|Angiotensin 1-5 (Ang 1-5) changes over time|Renin changes over time|Aldosterone changes over time|Angiotensin-converting enzyme (ACE) changes over time|Angiotensin-converting enzyme 2 (ACE2) changes over time|Interleukin 6 (IL-6) changes over time|Interleukin 8 (IL-8) changes over time|Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time|Plasminogen activator inhibitor type-1 (PAI-1) changes over time|Von willebrand factor (vWF) changes over time|Tumor necrosis factor-α (TNF-α) changes over time|Soluble receptor for advanced glycation end products (sRAGE) changes over time|Surfactant protein-D (SP-D) changes over time|Angiopoietin-2 changes over time|Frequency of adverse events and severe adverse events","The First Affiliated Hospital of Guangzhou Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIRH-APN01","February 2020","April 2020","April 2020","February 27, 2020",,"March 17, 2020","GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04287686"
17,"NCT04324996","A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19",,"Recruiting","No Results Available","COVID-19","Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells","Clinical response|Side effects in the treatment group","Chongqing Public Health Medical Center|Chongqing Sidemu Biotechnology Technology Co.,Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ChongqingPublicHMC","March 21, 2020","May 31, 2020","September 30, 2020","March 27, 2020",,"March 27, 2020","Chongqing Public Health Medical Center, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04324996"
18,"NCT04321993","Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients",,"Not yet recruiting","No Results Available","COVID-19","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate|Drug: Baricitinib (janus kinase inhibitor)|Drug: Sarilumab (anti-IL-6 receptor)","Clinical status of subject at day 15 (on a 7 point ordinal scale).|Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.|Length of time to clinical improvement|Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29|Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment|Length of time to clinical progression|Cause of death (if applicable)|Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean)|Length of time to normalization of fever|Length of time to normalization of oxygen saturation|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Duration of hospitalization|Adverse events","Lisa Barrett|Nova Scotia Health Authority|Dalhousie University","All","18 Years and older   (Adult, Older Adult)","Phase 2","1000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SAIL-004","April 2020","February 2021","July 2021","March 26, 2020",,"April 7, 2020","Nova Scotia Health Authority, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT04321993"
19,"NCT04329832","Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19","HAHPS","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score","Intermountain Health Care, Inc.|University of Utah","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1051355","April 1, 2020","December 31, 2020","December 31, 2021","April 1, 2020",,"April 1, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04329832"
20,"NCT04331171","Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage","COVID CALL 15","Recruiting","No Results Available","COVID-19","Device: Web application users","To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/|To assess the evolution over time of the COVID 19 epidemic|To assess the evolution over space of the COVID 19 epidemic|To assess symptoms|To assess the users population","Weprom|Institut Pasteur|Assistance Publique - Hôpitaux de Paris|DOCAPOST|Direction Générale de l'Offre de Soins","All","18 Years and older   (Adult, Older Adult)",,"3000000","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","WP-2020-02","March 17, 2020","March 31, 2020","July 31, 2020","April 2, 2020",,"April 6, 2020","All French Emergency services, Le Mans, France",,"https://ClinicalTrials.gov/show/NCT04331171"
21,"NCT04317092","Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)","TOCIVID-19","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab Injection","One-month mortality rate|Interleukin-6 level|Lymphocyte count|CRP (C-reactive protein) level|PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)|Change of the SOFA (Sequential Organ Failure Assessment)|Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0|Radiological response|Duration of hospitalization|Remission of respiratory symptoms","National Cancer Institute, Naples","All","Child, Adult, Older Adult","Phase 2","400","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOCIVID-19|2020-001110-38","March 19, 2020","December 19, 2020","December 19, 2022","March 20, 2020",,"April 7, 2020","Azienda Ospedaliera ""SS. Antonio e Biagio e C. Arrigo"" (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy|Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy|A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy|AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy|Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy|ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy|Azienda Ospedaliero-Universitaria di Modena, Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy|A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy|A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy|Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy|National Cancer Institute, Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy|A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy|A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy|Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy|Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy|Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy|Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy|Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy|ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy|ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy|ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy|ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy|A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy|Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy",,"https://ClinicalTrials.gov/show/NCT04317092"
22,"NCT04328285","Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers","COVIDAXIS","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo of Hydroxychloroquine|Drug: Lopinavir and ritonavir|Drug: Placebo of LPV/r Tablets","Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)|Evaluation of the occurrence of adverse events in each arm,|Evaluation of the discontinuation rates of the investigational drug in each arm,|Evaluation of the adherence of participants to study drug,|Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,|Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm|Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.","Centre Hospitalier Universitaire de Saint Etienne|Institut Pasteur","All","18 Years and older   (Adult, Older Adult)","Phase 3","1200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","20PH061|2020-001188-96","March 30, 2020","November 30, 2020","November 30, 2020","March 31, 2020",,"March 31, 2020","CHU d'Angers, Angers, France|AP-HP - Hôpital Bichat, Paris, France|CHU de Saint-Etienne, Saint-Étienne, France",,"https://ClinicalTrials.gov/show/NCT04328285"
23,"NCT04330586","A Trial of Ciclesonide in Adults With Mild COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Ciclesonide Metered Dose Inhaler [Alvesco]|Drug: Hydroxychloroquine","Rate of SARS-CoV-2 eradication at day 14 from study enrollment|Rate of SARS-CoV-2 eradication at day 7 from study enrollment|Time to SARS-CoV-2 eradication (days)|Viral load area-under-the-curve (AUC) reduction versus control|Time to clinical improvement (days)|Proportion of clinical failure","Korea University Guro Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","141","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KUMC-COVID-19","April 1, 2020","June 30, 2020","September 30, 2020","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330586"
24,"NCT04275947","The COVID-19 Mobile Health Study (CMHS)","CMHS","Recruiting","No Results Available","COVID-19","Other: nCapp, a cell phone-based auto-diagnosis system","Accuracy of nCapp COVID-19 risk diagnostic model","Chinese Alliance Against Lung Cancer|Shanghai Respiratory Research Institution","All","18 Years to 90 Years   (Adult, Older Adult)",,"450","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CAALC-008-CMHS","February 14, 2020","April 30, 2020","May 31, 2020","February 19, 2020",,"February 19, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04275947"
25,"NCT04331899","Mild COVID-19 Peginterferon Lambda","COVID-Lambda","Not yet recruiting","No Results Available","COVID-19","Drug: Peginterferon Lambda-1a|Other: Standard of Care Treatment","Duration of Viral shedding of SARS-CoV-2 by qRT-PCR","Stanford University","All","18 Years to 64 Years   (Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","55619","April 15, 2020","May 31, 2021","May 31, 2022","April 2, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04331899"
26,"NCT04337996","Dynamic Evaluation of COVID-19 Diagnostic Tests","TRODVID-19","Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: COVID-19 diagnostic test","Positive or negative character of the three tests|sensitivity and specificity of the tests according to the time elapsed since the first symptoms","Tourcoing Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","176","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","RIPH_2020_6","April 2020","July 2020","October 2020","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04337996"
27,"NCT04315298","Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Sarilumab|Drug: Placebo","Percent change in C-reactive protein (CRP) levels|Time to improvement (2 points) in clinical status assessment using the 7-point ordinal scale in patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal|Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels|Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever|Time to resolution of fever for at least 48 hours without antipyretics by clinical severity|Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels|Time to improvement in oxygenation for at least 48 hours|Time to improvement in oxygenation for at least 48 hours by clinical severity|Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels|Time to resolution of fever and improvement in oxygenation for at least 48 hours|Mean change in the 7-point ordinal scale|Percentage of patients in each clinical status category using the 7-point ordinal scale|Time to discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours|Change from baseline in NEWS2 scoring system|Number of days with fever|Proportion of patients alive, off oxygen|Number of days of resting respiratory rate >24 breaths/min|Number of days with hypoxemia|Number of days of supplemental oxygen use|Time to saturation ≥94% on room air|Number of ventilator free days in the first 28 days|Number of patients requiring initiation of mechanical ventilation|Number of patients requiring non-invasive ventilation|Number of patients requiring the use of high flow nasal cannula|Number of patients admitted into an intensive care unit (ICU)|Number of days of hospitalization among survivors|Number of deaths due to any cause|Change in serum CRP levels|Incidence of serious adverse events|Incidence of Grade 4 neutropenia (ANC <500/mm3)|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection|Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia|Incidence of hypersensitivity reactions|Incidence of infusion reactions|Incidence of gastrointestinal perforation|White blood cell count|Hemoglobin levels|Platelet count|Creatinine levels|Total bilirubin level|Alanine aminotransferase (ALT) level|Aspartate aminotransferase (AST) level","Regeneron Pharmaceuticals|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","6R88-COV-2040","March 18, 2020","March 9, 2021","April 1, 2021","March 19, 2020",,"April 6, 2020","Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Sacramento, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Aurora, Colorado, United States|Regeneron Study Site, Denver, Colorado, United States|Regeneron Study Site, New Haven, Connecticut, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, Coral Gables, Florida, United States|Regeneron Study Site, Gainesville, Florida, United States|Regeneron Study Site, Orlando, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Decatur, Georgia, United States|Regeneron Study Site, Marietta, Georgia, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, Chicago, Illinois, United States|Regeneron Study Site, New Orleans, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Boston, Massachusetts, United States|Regneron Study Site, Boston, Massachusetts, United States|Regeneron Study Site, Ann Arbor, Michigan, United States|Regeneron Study Site, Detroit, Michigan, United States|Regeneron Study Site, Rochester, Minnesota, United States|Regeneron Study Site, Edison, New Jersey, United States|Regeneron Study Site, Hackensack, New Jersey, United States|Regeneron Study Site, Livingston, New Jersey, United States|Regeneron Study Site, Morristown, New Jersey, United States|Regeneron Study Site, Neptune, New Jersey, United States|Regeneron Study Site, Newark, New Jersey, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site 1, Bronx, New York, United States|Regeneron Study Site 2, Bronx, New York, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, Brooklyn, New York, United States|Regeneron Study Site, Elmhurst, New York, United States|Regeneron Study Facility 2, Manhasset, New York, United States|Regeneron Study Site 1, Manhasset, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site 1, New York, New York, United States|Regeneron Study Site 2, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Stony Brook, New York, United States|Regeneron Study Site, Valhalla, New York, United States|Regeneron Study Site, Tulsa, Oklahoma, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Portland, Oregon, United States|Regeneron Study Site, Danville, Pennsylvania, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Scranton, Pennsylvania, United States|Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Dallas, Texas, United States|Regeneron Study Site, Murray, Utah, United States|Regeneron Study Site, Falls Church, Virginia, United States|Regeneron Study Site, Everett, Washington, United States|Regeneron Study Site, Renton, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04315298"
28,"NCT04337762","Beat COVID-19 - Observational Trial","JUPITER","Recruiting","No Results Available","COVID-19",,"Health Outcomes","Beat COVID LLC","All","18 Years to 110 Years   (Adult, Older Adult)",,"100000","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20200835","April 6, 2020","December 2020","July 2021","April 8, 2020",,"April 8, 2020","Beat COIVD, LLC, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04337762"
29,"NCT04330638","Treatment of COVID-19 Patients With Anti-interleukin Drugs","COV-AID","Recruiting","No Results Available","COVID-19","Other: Usual Care|Drug: Anakinra|Drug: Siltuximab|Drug: Tocilizumab","Time to Clinical Improvement|Time to improvement in oxygenation|Mean change in oxygenation|Number of days with hypoxia|Number of days of supplemental oxygen use|Time to absence fever for more than 48h without antipyretics|Number of days with fever|Time to halving of CRP levels compared to peak value during trial|Time to halving of ferritin levels compared to peak value during trial|Incidence of AEs (Adverse Events)|Incidence of SAEs (Serious Adverse Events)|Duration of hospital stay|Duration of hospital stay in survivors|Mean change in clinical sign score between day 1 and day 7|Mean change in clinical sign score between day 1 and day 15|Time to clinical sign score <6 maintained for 24h|Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7|Mean change of SOFA score between day 1 and day 15|Mean change NEWS2 (National Early Warning) score between day 1 and day 7|Mean change NEWS2 score between day 1 and day 15|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1|Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6|Incidence of nosocomial bacterial or invasive fungal infection|incidence of secondary haemophagocytic lymphohistiocytosis|Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1|Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6|Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients|Time to first use of salvage systemic steroids in ventilated patients|Number of ventilator free days|Duration of mechanical ventilation in ventilated patients|Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation|Time to progression to ARDS in ventilated patients|Time to progression to ARDS in ventilated patients according to IL-1|Time to progression to ARDS in ventilated patients according to IL-6|All-cause mortality rate (excluding group that entered during ventilation)|Percentage of patients in clinical status on 6-point Ordinal Scale|Incidence of lung function abnormalities|Incidence of lung fibrosis on chest CT scan|All-cause mortality rate","University Hospital, Ghent|Belgium Health Care Knowledge Centre","All","18 Years and older   (Adult, Older Adult)","Phase 3","342","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COV-AID","April 2020","September 2020","December 2020","April 1, 2020",,"April 8, 2020","AZ Sint-Jan Brugge, Brugge, Belgium|University Hospital Saint-Pierre, Brussels, Belgium|Erasmus University Hospital, Brussels, Belgium|University Hospital Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Ziekenhuis Oost-Limurg, Genk, Belgium|University Hospital Ghent, Gent, Belgium|University Hospital Brussels, Jette, Belgium|University Hospital Liège, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT04330638"
30,"NCT04332081","Hyperbaric Oxygen for COVID-19 Patients",,"Not yet recruiting","No Results Available","COVID-19","Device: hyperbaric oxygen therapy (HBOT)","Mortality|Days on invasive mechanical ventilation","NYU Langone Health","All","18 Years and older   (Adult, Older Adult)","Not Applicable","40","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","s20-00399","April 2020","July 2020","July 2020","April 2, 2020",,"April 8, 2020","NYU Winthrop Hospital, Mineola, New York, United States",,"https://ClinicalTrials.gov/show/NCT04332081"
31,"NCT04304313","A Pilot Study of Sildenafil in COVID-19",,"Recruiting","No Results Available","COVID-19","Drug: Sildenafil citrate tablets","Rate of disease remission|Rate of entering the critical stage|Time of entering the critical stage|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of C-reactive protein (CRP) recovery|Rate of Biochemical criterion (CK, ALT, Mb) recovery|Rate of undetectable viral RNA (continuous twice)|Time for hospitalization|Rate of adverse event","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GST-G1","February 9, 2020","March 1, 2020","November 9, 2020","March 11, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04304313"
32,"NCT04337541","Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System",,"Recruiting","No Results Available","COVID-19","Other: Surgical facial mask","Reduction in COVID-19 infection frequency|Antibody-screening","Rigshospitalet, Denmark|Nordsjaellands Hospital|Hvidovre University Hospital|Herlev Hospital|Technical University of Denmark","All","18 Years and older   (Adult, Older Adult)","Not Applicable","6000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020-04-02","April 2, 2020","July 1, 2020","July 1, 2020","April 7, 2020",,"April 7, 2020","Rigshospitalet, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT04337541"
33,"NCT04326920","Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)","SARPAC","Recruiting","No Results Available","COVID-19","Drug: Sargramostim|Other: Control","Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure|Incidence of AE (Adverse Event)|Incidence of SAEs (Serious Adverse Event)|Clinical Status using 6-point ordinal scale|Clinical Status using Clincal sign score|Clinical Status using SOFA score (Sequential Organ Failure Assessment score),|Clinical Status using NEWS2 score (National Early Warning Score)|incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection|number of patients requiring initiation of mechanical ventilation|Number of deaths due to any cause at 4 weeks|Number of deaths due to any cause at 20 weeks|number of patients developing features of secondary haemophagocytic lymphohistiocytosis|long term Clinical status defined by 6-point ordinal scale|long term Clinical status defined by chest X-ray|long term Clinical status defined lung function","University Hospital, Ghent|Flanders Institute of Biotechnology","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 4","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SARPAC","March 24, 2020","October 31, 2020","December 31, 2020","March 30, 2020",,"April 2, 2020","AZ Sint Jan Brugge, Brugge, Belgium|University Hospital Ghent, Gent, Belgium",,"https://ClinicalTrials.gov/show/NCT04326920"
34,"NCT04338347","CAP-1002 in Severe COVID-19 Disease",,"Available","No Results Available","COVID-19","Biological: CAP-1002 Allogeneic Cardiosphere-Derived Cells",,"Capricor Inc.","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"CAP-1002-COVID-19",,,,"April 8, 2020",,"April 8, 2020","Cedars-Sinai Medical Center, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT04338347"
35,"NCT04334512","A Study of Quintuple Therapy to Treat COVID-19 Infection","HAZCpaC","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","Successful treatment as determined by Negative Test and resolution of symptoms|Safety of Quintuple Therapy","ProgenaBiome","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRG-044","April 2020","April 2021","July 2021","April 6, 2020",,"April 6, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04334512"
36,"NCT04327674","The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19",,"Recruiting","No Results Available","COVID-19",,"FLUS findings and respiratory failure|FLUS findings and chest x-ray.|FLUS findings and admission to intensive care.|FLUS findings and SAR-CoV-2 PCR-test result.","University of Aarhus","All","18 Years and older   (Adult, Older Adult)",,"375","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-FLUS","March 14, 2020","May 15, 2020","May 15, 2020","March 31, 2020",,"March 31, 2020","Lungemedicinsk Forskningsafdeling. Aarhus University Hospital, Aarhus, Denmark|Regionshospitalet Horsens., Horsens, Denmark",,"https://ClinicalTrials.gov/show/NCT04327674"
37,"NCT04329923","The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)","PATCH","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate 400 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg twice a day|Drug: Hydroxychloroquine Sulfate 600 mg once a day|Drug: Placebo oral tablet","Median release from quarantine time|Rate of hospital discharge|Rate of infection|Rate of housemate infection|Rate of hospitalization|Cohort 1 adverse event rate|Time to condition appropriate for discharge|Rate of ICU admission|Time to PCR negativity|Cohort 2 adverse events|Scheduled shifts missed|Cohort 3 adverse events","Ravi Amaravadi, MD|University of Pennsylvania","All","18 Years and older   (Adult, Older Adult)","Phase 2","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","842838","April 8, 2020","April 1, 2021","December 1, 2021","April 1, 2020",,"April 7, 2020","University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04329923"
38,"NCT04330690","Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial","CATCO","Active, not recruiting","No Results Available","COVID-19","Drug: Lopinavir/ritonavir","Efficacy of Intervention|Time to improvement of one catergory from admission|Subject clinical status|Change in Subject clinical status|Oxygen free days|Incidence of oxygen use|Duration of oxygen use|Incidence of new mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Mortality|Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)","Sunnybrook Health Sciences Centre|AbbVie","All","6 Months and older   (Child, Adult, Older Adult)","Phase 2","440","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2114","March 18, 2020","March 18, 2022","May 18, 2022","April 1, 2020",,"April 7, 2020","Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04330690"
39,"NCT04318418","ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19","CODIV-ACE","Not yet recruiting","No Results Available","COVID-19",,"Severe COVID-19|Death","Neuromed IRCCS","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","DEP_012020","March 23, 2020","April 10, 2020","April 30, 2020","March 24, 2020",,"March 24, 2020","IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy",,"https://ClinicalTrials.gov/show/NCT04318418"
40,"NCT04333628","Chloroquine for Mild Symptomatic and Asymptomatic COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: chloroquine|Other: standard care","change in virus duration (viral shedding)|change in the number of patients going from asymptomatic to moderately disease","HaEmek Medical Center, Israel","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EMC 0045-20","April 2020","April 2021","December 2021","April 3, 2020",,"April 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04333628"
41,"NCT04285801","Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study",,"Completed","No Results Available","COVID-19",,"28 day mortality|vasopressor days|days on mechanical ventilation|sequential organ function assessment score|ECMO use|percentage nitric oxide use|percentage free from oxygen supplement","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"8","Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","2020.059","February 14, 2020","February 25, 2020","February 25, 2020","February 26, 2020",,"March 10, 2020","Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04285801"
42,"NCT04304053","Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention","HCQ4COV19","Recruiting","No Results Available","COVID-19","Drug: Antiviral treatment and prophylaxis|Other: Standard Public Health measures","Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3|The mortality rate of subjects at weeks 2|Proportion of participants that drop out of study|Proportion of participants that show non-compliance with study drug","Fundacio Lluita Contra la SIDA|Germans Trias i Pujol Hospital|Department of Health, Generalitat de Catalunya|FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA|Laboratorios Gebro Pharma SA|Laboratorios Rubió|Institut Catala de Salut","All","18 Years and older   (Adult, Older Adult)","Phase 3","3040","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HCQ4COV19|2020-001031-27","March 18, 2020","June 15, 2020","June 15, 2020","March 11, 2020",,"April 8, 2020","Departament de Salut, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04304053"
43,"NCT04319315","Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak",,"Recruiting","No Results Available","COVID-19","Other: survey","Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice","Assiut University","All","25 Years to 65 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Prospective","AssiutU-3-2020","March 11, 2020","April 1, 2020","April 16, 2020","March 24, 2020",,"April 7, 2020","Assiut University Hospitals, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04319315"
44,"NCT04334382","Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19","HyAzOUT","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Azithromycin","Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days","Intermountain Health Care, Inc.|University of Utah|Utah Department of Health","All","45 Years and older   (Adult, Older Adult)","Phase 3","1550","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1051360","April 1, 2020","December 31, 2020","December 31, 2021","April 6, 2020",,"April 6, 2020","Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04334382"
45,"NCT04333355","Safety in Convalescent Plasma Transfusion to COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: Convalescent Plasma","Side effects|Heart Failure|Pulmonary Edema|Allergic Reaction|Lung infiltrates|Viral load of SARS-CoV-2","Hospital San Jose Tec de Monterrey|Tecnologico de Monterrey","All","18 Years and older   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PC-TecSalud Fase I","April 15, 2020","December 20, 2020","April 30, 2021","April 3, 2020",,"April 3, 2020","Hospital San José, Monterrey, Nuevo Leon, Mexico",,"https://ClinicalTrials.gov/show/NCT04333355"
46,"NCT04335136","Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19","APN01-COVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: RhACE2 APN01|Drug: Physiological saline solution","Cause of death or invasive mechanical ventilation|LDH level|Mortality|VFD|Time to death","Apeiron Biologics","All","35 Years to 80 Years   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","APN01-01-COVID19","April 2020","September 2020","November 2020","April 6, 2020",,"April 6, 2020","Medizinische Universität Innsbruck, Innsbruck, Austria|Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria|Medizinische Universität Wien, Wien, Austria|The National University Hospital, Rigshospitalet, Copenhagen, Denmark|Herlev Gentofte Hospital, Herlev, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum rechts der Isar, Technische Universität München, München, Germany",,"https://ClinicalTrials.gov/show/NCT04335136"
47,"NCT04331366","Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19","GO2 PEEP","Not yet recruiting","No Results Available","COVID-19","Device: GO2 PEEP MOUTHPIECE","Change in Oxygen Saturation by Pulse Oximetry|Change in Respiratory Rate|Change in Heart Rate|Change in Blood Pressure|Change in Subjective Work of Breathing|Change in Partial Pressure of Oxygen (PaO2)|Change in Partial Pressure of Carbon Dioxide (PaCO2)|Change in pH|Change in Bicarbonate (HCO3)|Change in Oxygen Saturation (O2Sat) by Arterial Blood Gas Test","Emory University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","STUDY00000381","April 2020","April 2020","April 2020","April 2, 2020",,"April 2, 2020","Emory University Hospital, Atlanta, Georgia, United States|Emory St. Joseph's Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04331366"
48,"NCT04331795","Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis","COVIDOSE","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab","Clinical response|Biochemical response|Overall survival|Survival to hospital discharge|Progression of COVID-19 pneumonitis|Rate of non-elective mechanical ventilation|Duration of mechanical ventilation|Time to mechanical ventilation|Rate of vasopressor/inotrope utilization|Duration of vasopressor/inotrope utilization|Time to vasopressor or inotropic utilization|Number of ICU days","University of Chicago","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB20-0515","April 2020","July 2020","December 2020","April 2, 2020",,"April 8, 2020","University of Chicago Medicine, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04331795"
49,"NCT04333225","Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers",,"Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine","Rate of COVID-19 positive conversion|Time-to-first clinical event","Baylor Research Institute","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","360","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","020-132","April 3, 2020","July 30, 2020","July 30, 2020","April 3, 2020",,"April 7, 2020","Baylor University Medical Center, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04333225"
50,"NCT04335084","A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection","HELPCOVID-19","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc","Prevention of COVID-19 measured by negative testing with RT-PCR|Safety as determined by blood pressure readings|Safety as determined by presence of side effects","ProgenaBiome","All","18 Years and older   (Adult, Older Adult)","Phase 2","600","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","PRG-042","April 2020","April 2021","July 2021","April 6, 2020",,"April 6, 2020","ProgenaBiome, Ventura, California, United States",,"https://ClinicalTrials.gov/show/NCT04335084"
51,"NCT04313023","The Use PUL-042 Inhalation Solution to Prevent COVID-19 in Adults Exposed to SARS-CoV-2",,"Not yet recruiting","No Results Available","COVID-19","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Prevention of COVID-19","Pulmotect, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PUL-042-501","April 2020","September 2020","October 2020","March 18, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04313023"
52,"NCT04307693","Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)",,"Recruiting","No Results Available","COVID-19","Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine sulfate","Viral load|Viral load change|Time to clinical improvement (TTCI)|Percentage of progression to supplemental oxygen requirement by day 7|Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7|Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission|Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7|adverse effects|Concentration of Lopinavir/ritonavir and hydroxychloroquine","Asan Medical Center","All","16 Years to 99 Years   (Child, Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","S2020-0472-0001","March 11, 2020","May 2020","May 2020","March 13, 2020",,"March 13, 2020","Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04307693"
53,"NCT04323631","Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Other: The control group will not receive hydroxychloroquine","Number patients developing severe infection or death","Rambam Health Care Campus|Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","1116","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0154-20-RMB","March 2020","December 2020","December 2020","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04323631"
54,"NCT04331834","Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic","PrEP_COVID","Recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebos","Confirmed cases of a COVID-19|SARS-CoV-2 seroconversion|Occurrence of any adverse event related with hydroxychloroquine treatment|Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers|Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19|COVID-19 Biobank","Barcelona Institute for Global Health|Hospital Clinic of Barcelona|Laboratorios Rubió","All","18 Years and older   (Adult, Older Adult)","Phase 3","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","PrEP_COVID","April 3, 2020","October 3, 2020","October 30, 2020","April 2, 2020",,"April 7, 2020","ISGlobal, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04331834"
55,"NCT04337216","Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation",,"Not yet recruiting","No Results Available","COVID-19","Drug: Mavrilimumab","Time to resolution of fever|Change in clinical status|Mortality|Change in CRP|Change in IL-6","Virginia Commonwealth University","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM20019145","April 2020","July 2020","July 2020","April 7, 2020",,"April 7, 2020","Virginia Commonwealth University, Richmond, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT04337216"
56,"NCT04336254","Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients",,"Recruiting","No Results Available","COVID-19","Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)|Other: Intravenous saline injection (Placebo)","TTCI|Lung lesion|Immune function|Time of SARS-CoV-2 clearance|Blood test|SPO2|RR|Body temperature|Side effects in the treatment group|C-reactive protein (mg/L)","Renmin Hospital of Wuhan University|Beijing SH Bio-Tech Corporation, Beijing (CN)|Utooth Biological Technology Co., Ltd. Hubei (CN)","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020K-G005|hDPSC-CoVID-2019-02-2020","April 6, 2020","December 31, 2020","March 31, 2021","April 7, 2020",,"April 7, 2020","Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04336254"
57,"NCT04332094","Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19","TOCOVID","Recruiting","No Results Available","COVID-19","Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin","In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit","Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Instituto de Salud Carlos III","All","18 Years and older   (Adult, Older Adult)","Phase 2","276","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IIBSP-COV-2020-23","April 2, 2020","September 2020","October 2020","April 2, 2020",,"April 7, 2020","Hospital de la Santa Creu i Sant Pau, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04332094"
58,"NCT04292899","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)",,"Recruiting","No Results Available","COVID-19","Drug: Remdesivir|Drug: Standard of Care","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14|Proportion of Participants Experiencing any Treatment-Emergent Adverse Events","Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","2400","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-540-5773|2020-000841-15","March 6, 2020","May 2020","May 2020","March 3, 2020",,"April 8, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente Oakland Medical Center, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd, San Francisco, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|Yale-New Haven Hospital, New Haven, Connecticut, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, 1 RWJ Place, New Brunswick, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, 270-05 76th Ave, Manhasset, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States|New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|Inova Fairfax Medical Campus, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|Chu Montpellier, Montpelier Cedex 5, France|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy|UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Leiden University Medical Center, Leiden, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|King's College Hospital NHS Trust, London, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04292899"
59,"NCT04334980","Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: bacTRL-Spike","Frequency of Adverse Events|SARS-CoV-2 Antibodies|Incidence of COVID-19 infection|bacTRL-Spike in stool post-vaccination","Symvivo Corporation","All","19 Years to 55 Years   (Adult)","Phase 1","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","bacTRL-Spike-1","April 30, 2020","August 31, 2021","December 31, 2021","April 6, 2020",,"April 6, 2020","Vaccine Evaluation Center, BC Children's Research Institute, University of British Columbia., Vancouver, British Columbia, Canada|Canadian Center for Vaccinology Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada",,"https://ClinicalTrials.gov/show/NCT04334980"
60,"NCT04312997","The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection",,"Not yet recruiting","No Results Available","COVID-19","Drug: PUL-042 Inhalation Solution|Drug: Placebo","Severity of COVID-19|All cause mortality","Pulmotect, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PUL-042-502","April 2020","September 2020","October 2020","March 18, 2020",,"March 24, 2020","Houston Methodist Hospital, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04312997"
61,"NCT04329572","Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets","Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days","Azidus Brasil|PREVENT SENIOR PRIVATE OPERADORA DE SAÚDE LTDA","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","400","Industry|Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HIAPRE0320OR","April 3, 2020","May 31, 2020","June 30, 2020","April 1, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04329572"
62,"NCT04292730","Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment",,"Recruiting","No Results Available","COVID-19","Drug: Remdesivir|Drug: Standard of Care","The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11|Proportion of Participants experiencing Treatment-Emergent Adverse Events","Gilead Sciences","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","1600","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GS-US-540-5774|2020-000842-32","March 15, 2020","May 2020","May 2020","March 3, 2020",,"April 8, 2020","Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States|Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States|Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States|St Joseph Hospital Eureka, Fortuna, California, United States|Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States|Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States|Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|Kaiser Permanente-Oakland/San Francisco, Oakland, California, United States|Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States|Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States|Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States|Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States|California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States|Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd, San Francisco, California, United States|Providence St. Johns Medical Center, Santa Monica, California, United States|Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States|Stanford Hospital, Stanford, California, United States|University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Cook County General Hospital, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|Holy Cross Hospital, Silver Spring, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Brigham & Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States|Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Hennepin Healthcare, Minneapolis, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States|Hackensack Medical Center, Hackensack, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, Hillsborough, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, 1 RWJ Place, New Brunswick, New Jersey, United States|RBWJ University Hospital/Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark, New Jersey, United States|Jacobi Medical Center, Bronx, New York, United States|James J. Peters Veterans Administration Medical Center, Bronx, New York, United States|Jamaica Hospital Medical Center, Jamaica, New York, United States|Danbury Hospital, Lagrangeville, New York, United States|North Shore University Hospital, Manhasset, New York, United States|North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States|Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States|Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States|Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Columbia University Irving Medical Center, New York, New York, United States|Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States|Providence Portland Medical Center, Portland, Oregon, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Kaiser Sunnyside Medical Center, Portland, Oregon, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|The Miriam Hospital, Providence, Rhode Island, United States|Prisma Health Richland Hospital, Columbia, South Carolina, United States|UTSW Medical Center, Dallas, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States|UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States|Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States|Houston Methodist Hospital, Houston, Texas, United States|Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|VCU Health Medical Center, Richmond, Virginia, United States|Providence Medical Research Center, Everett, Washington, United States|Providence St. Peter Hospital, Olympia, Washington, United States|Virginia Mason Medical Center, Seattle, Washington, United States|Swedish Center for Comprehensive Care, Seattle, Washington, United States|MultiCare Deaconess Hospital, Spokane, Washington, United States|MultiCare Tacoma General Hospital, Tacoma, Washington, United States|St Joseph Medical Center, Tacoma, Washington, United States|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China|Chu Montpellier, Montpelier Cedex 5, France|Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany|Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany|Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany|Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany|Prince of Wales Hospital, Hong Kong, Hong Kong|Princess Margaret Hospital, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|ASST degli Spedali Civili di Brescia, Brescia, Italy|ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy|ASST Fatebenefratelli Sacco, Milano, Italy|UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy|Kyungpook National University Hospital, Daegu, Korea, Republic of|Seoul Medical Center, Seoul, Korea, Republic of|National Medical Center, Seoul, Korea, Republic of|Leiden University Medical Center, Leiden, Netherlands|National University Hospital, Singapore, Singapore|Singapore General Hospital, Singapore, Singapore|National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Cruces, Bizkaia, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hopitaux Universitaires de Genève, Genève 14, Switzerland|Ospedale Regionale di Locarno La Carità, Lugano, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Taiwan University Hospital, Taipei City, Taiwan|King's College Hospital NHS Trust, London, United Kingdom|Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom|Sheffield Teaching Hospitals, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04292730"
63,"NCT04336956","Covid-19 Pediatric Observatory","PANDOR","Not yet recruiting","No Results Available","COVID-19","Other: hospitalized children with Covid19","Percentage of children with severe or critical form.|Percentage of children requiring intensive care support|Clinical symptoms of children|Biological results of children|CT chest of children|Pulmonary echography|nasopharynx SARScov2 PCR|nasopharynx sarscov2 load|nasopharynx multiplex PCR|number of hospital days","Centre Hospitalier Intercommunal Creteil|ACTIV|GPIP|Société Française de Pédiatrie|GFRUP","All","up to 18 Years   (Child, Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Other","PANDOR","April 1, 2020","June 30, 2021","June 30, 2021","April 7, 2020",,"April 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04336956"
64,"NCT04331470","Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Drug: Levamisole Pill + Budesonide+Formoterol inhaler|Drug: Lopinavir/Ritonavir + hydoxychloroquine","Clear chest CT-scan|PCR test|Physical statues of patient","Fasa University of Medical Sciences","All","15 Years to 100 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","97548","March 31, 2020","April 20, 2020","May 20, 2020","April 2, 2020",,"April 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04331470"
65,"NCT04315987","NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia","HOPE","Not yet recruiting","No Results Available","COVID-19 Pneumonia","Biological: NestCell®","Disappear time of ground-glass shadow in the lungs|Rate of mortality within 28-days|Change of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|CD4+ and CD8+ T cell count|Changes of blood oxygen|Side effects in the treatment group","Azidus Brasil|Cellavita Pesquisa Científica Ltda|Hospital Vera Cruz","All","18 Years and older   (Adult, Older Adult)","Phase 1","66","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HOPE","April 2020","May 2020","June 2020","March 20, 2020",,"March 31, 2020","Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04315987"
66,"NCT04305106","Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT","BEST-RCT","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Bevacizumab","The time from randomization to clinical improvement","Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Ialy Moriggia Pelascini Gravedona Hospital S.p.A|Wuhan University|Jiangbei Union Hospital of Huazhong University of science and technology|Shandong Provincial Chest Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","QLEmer","March 17, 2020","June 30, 2020","July 31, 2020","March 12, 2020",,"March 26, 2020","Qilu Hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04305106"
67,"NCT04313322","Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells",,"Recruiting","No Results Available","Use of Stem Cells for COVID-19 Treatment","Biological: WJ-MSCs","Clinical outcome|CT Scan|RT-PCR results","Stem Cells Arabia","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19","March 16, 2020","June 30, 2020","September 30, 2020","March 18, 2020",,"March 18, 2020","Stem Cells Arabia, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04313322"
68,"NCT04320615","A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","COVACTA","Recruiting","No Results Available","COVID-19 Pneumonia","Drug: Tocilizumab (TCZ)|Drug: Placebo","Clinical Status Assessed Using a 7-Category Ordinal Scale|Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of </= 2 Maintained for 24 Hours|Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status|Incidence of Mechanical Ventilation|Ventilator-Free Days to Day 28|Organ Failure-Free Days to Day 28|Incidence of Intensive Care Unit (ICU) Stay|Duration of ICU Stay|Time to Clinical Failure|Mortality Rate|Time to Hospital Discharge|Duration of Time on Supplemental Oxygen|Percentage of Participants with Adverse Events|COVID-19 (SARS-CoV-2) Viral Load Over Time|Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity|Proportion of Participants with Post-Treatment Infection|Serum Concentration of IL-6|Serum Concentration of sIL-6R|Serum Concentration of Ferritin|Serum Concentration of C-Reactive Protein (CRP)|Serum Concentration of TCZ","Hoffmann-La Roche","All","18 Years and older   (Adult, Older Adult)","Phase 3","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","WA42380|2020-001154-22","April 3, 2020","August 31, 2021","September 30, 2021","March 25, 2020",,"April 8, 2020","University of California San Diego, La Jolla, California, United States|eStudySite, La Mesa, California, United States|David Geffen School of Medicine UCLA, Los Angeles, California, United States|Denver Health Medical Center, Denver, Colorado, United States|University of Chicago, Chicago, Illinois, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Baystate Health System, Springfield, Massachusetts, United States|Mayo Clinic - PPDS, Rochester, Minnesota, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States|New York University Langone Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Baylor University Medical Center; Valdez/ Rhone, Dallas, Texas, United States|Swedish Hospital Medical Center, Seattle, Washington, United States|McMaster University Medical Centre, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Clinical Research Institute of Montreal, Montreal, Quebec, Canada|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense Universitetshospital, Odense C, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France|Centre Hospitalier et Universitaire de Limoges, Limoges, France|Hôpital de La Croix Rousse, Lyon, France|Hotel Dieu - Nantes, Nantes, France|Hopital de la Pitie Salpetriere, Paris, France|CHRU de Tours, Pharmacie, Tours, France|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany|Uniklinik Köln, Köln, Germany|LMU Klinikum der Universitat Munchen, Munchen, Germany|Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy|Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy|ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy|ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy|Amphia Ziekenhuis, Breda, Netherlands|St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands|Erasmus MC, Rotterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Royal Free Hospital, London, United Kingdom|Imperial College London, London, United Kingdom|North Manchester General Hospital, Manchester, United Kingdom|Salford Royal Hospital, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04320615"
69,"NCT04308317","Tetrandrine Tablets Used in the Treatment of COVID-19","TT-NPC","Enrolling by invitation","No Results Available","Corona Virus Disease 2019,COVID-19","Drug: Tetrandrine","Survival rate|body temperature","Henan Provincial People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TT-NPC","March 5, 2020","March 1, 2021","May 1, 2021","March 16, 2020",,"March 16, 2020","Tetrandrine Tablets, Jinhua, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04308317"
70,"NCT04273529","The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia",,"Not yet recruiting","No Results Available","COVID-19 Thalidomide","Drug: thalidomide|Drug: placebo","Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence","First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20200214-COVID-19-M-T","February 20, 2020","May 30, 2020","June 30, 2020","February 18, 2020",,"February 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04273529"
71,"NCT04273581","The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19",,"Not yet recruiting","No Results Available","COVID-19 Thalidomide","Drug: placebo|Drug: Thalidomide","Time to Clinical Improvement (TTCI)|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events|Serum TNF-α, IL-1β, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1α and other cytokine expression levels before and after treatment","First Affiliated Hospital of Wenzhou Medical University|Second Affiliated Hospital of Wenzhou Medical University|Wenzhou Central Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20200214-COVID-19-S-T","February 18, 2020","April 30, 2020","May 30, 2020","February 18, 2020",,"February 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04273581"
72,"NCT04312464","Myocardial Damage in COVID-19",,"Enrolling by invitation","No Results Available","COVID-19|Cardiovascular Diseases","Other: non","The myocardial injury incidence|The risk factors analysis for the death|Clinical characteristics|Clinical course|Cardiovascular comorbidity|Analysis of causes of death","Wuhan Union Hospital, China","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","MD-COVID-19","January 1, 2020","March 15, 2020","March 18, 2020","March 18, 2020",,"March 18, 2020","Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04312464"
73,"NCT04338074","TXA and Corona Virus 2019 (COVID19) in Outpatients","TCOutpatient","Not yet recruiting","No Results Available","COVID-19","Drug: Tranexamic acid tablets|Drug: Placebo oral tablet","Hospitalization","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TXACOVID1","April 15, 2020","October 15, 2020","October 30, 2020","April 8, 2020",,"April 8, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04338074"
74,"NCT04329650","Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19","Drug: Siltuximab|Drug: Methylprednisolone","Proportion of patients requiring ICU admission at any time within the study period.|Days of stay in the ICU during the study period.|Days until resolution of fever defined as body temperature (axillary ≤ 36.6 ° C, oral ≤ 37.2 ° C, or rectal or tympanic ≤ 37.8 ° C) for at least 48 hours, without administration of antipyretics or until hospital discharge.|Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.|Days with hypoxemia (SpO2 <93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.|Proportion of patients using mechanical ventilation at 29 days.|Days with use of mechanical ventilation at 29 days.|Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.|Days of hospitalization among survivors at 29 days.|Mortality rate from any cause at 29 days.|Proportion of patients with serious adverse events at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute <500 / mm3) at 29 days.|Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.|Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.|Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.|Proportion of patients with gastrointestinal perforation at 29 days.|Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.|Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.|Proportion of patients with ALT≥ 3 times ULN (for patients with initial values normal) or> 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.|Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.|Changes from baseline in chest Rx at days 1, 3 and 5.","Judit Pich Martínez|Fundacion Clinic per a la Recerca Biomédica","All","18 Years and older   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SILCOR-COVID-19","April 1, 2020","May 20, 2020","May 20, 2020","April 1, 2020",,"April 6, 2020","Hospital Clínic de Barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04329650"
75,"NCT04331600","ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020","QUARANTINE2020","Not yet recruiting","No Results Available","COVID-19","Drug: Chloroquine phosphate|Other: Telemedicine","COVID-19-related hospitalization or all-cause death|Decrease in COVID-19 symptoms|Development of pneumonia|Development of coronavirus infection-related complications","Wroclaw Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QUARANTINE2020","April 6, 2020","September 30, 2020","December 31, 2020","April 2, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04331600"
76,"NCT04280588","Fingolimod in COVID-19",,"Recruiting","No Results Available","Coronavirus Disease (COVID-19)","Drug: Fingolimod 0.5 mg","The change of pneumonia severity on X-ray images","First Affiliated Hospital of Fujian Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRCTA, ECFAH of FMU [2020]027","February 22, 2020","July 1, 2020","July 1, 2020","February 21, 2020",,"February 21, 2020","Wan-Jin Chen, Fuzhou, China",,"https://ClinicalTrials.gov/show/NCT04280588"
77,"NCT04325061","Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19","DEXA-COVID19","Recruiting","No Results Available","Acute Respiratory Distress Syndrome Caused by COVID-19","Drug: Dexamethasone","60-day mortality|Ventilator-free days","Dr. Negrin University Hospital|Li Ka Shing Knowledge Institute|Consorcio Centro de Investigación Biomédica en Red, M.P.","All","18 Years and older   (Adult, Older Adult)","Phase 4","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-001278-31","April 3, 2020","October 30, 2020","October 30, 2020","March 27, 2020",,"April 8, 2020","ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain|Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain|Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain|AVI, Hospital Clinic, Barcelona, Spain|Cardiac ICU, Hospital Clinic, Barcelona, Spain|Department of Anesthesia, Hospital Clinic, Barcelona, Spain|Hepatic ICU, Hospital Clínic, Barcelona, Spain|UVIR, Hospital Clinic, Barcelona, Spain|Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain|Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain|Intensive Care Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain|Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain|Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain|Department of Anesthesia, Hospital Universitario Virgen de Arrixaca, Murcia, Spain|Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain|Anesthesia, Hospital General Universitario de Valencia, Valencia, Spain|Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain|Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain|Department of Anesthesia, Hospital Clínico Universitario, Valladolid, Spain|Intensive Care Unit, Hospital Universitario Río Hortega, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT04325061"
78,"NCT04315896","Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)","HYDRA","Not yet recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","All-cause hospital mortality|Length of hospital stay|Need of mechanical ventilation|Ventilator free days|Grade 3-4 adverse reaction","National Institute of Respiratory Diseases, Mexico|Sanofi","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","500","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HidroxycloroquinaCOVID19","March 23, 2020","October 31, 2020","March 22, 2021","March 20, 2020",,"March 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04315896"
79,"NCT04335201","Defibrotide in COVID-19 Pneumonia","DEFI-VID19","Not yet recruiting","No Results Available","Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure","Drug: Defibrotide Injection","to able to reduce the progression of acute respiratory failure|Adverse events|duration of hospitalization|systemic inflammation|overall survival","IRCCS San Raffaele","All","18 Years and older   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DEFI-VID19","April 6, 2020","September 30, 2020","December 31, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335201"
80,"NCT04329559","COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study",,"Recruiting","No Results Available","COVID-19|Liver Cirrhosis",,"All-cause mortality of COVID-19 patients with liver cirrhosis|Liver-related mortality of COVID-19 patients with liver cirrhosis|Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis|Baseline characteristics of COVID-19 patients with liver cirrhosis","Hepatopancreatobiliary Surgery Institute of Gansu Province|Renmin Hospital of Wuhan University|LanZhou University|Minda Hospital Affiliated to Hubei University for Nationalities|Wuhan Union Hospital, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture|Tianjin Second People's Hospital|Sixth People’s Hospital of Shenyang|Guangxi Zhuang Autonomous Region|Shenzhen Third People's Hospital|Ankang Central Hospital|Xingtai People's Hospital|Dalian Sixth People’s Hospital|The Central Hospital of Lishui City|The Affiliated Third Hospital of Jiangsu University|Suizhou Hospital, Hubei University of Medicine","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","CHESS2002","March 30, 2020","June 29, 2020","June 29, 2021","April 1, 2020",,"April 1, 2020","Dalian Sixth People's Hospital, Dalian, China|Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China|The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China|The First Hospital of Lanzhou University, Lanzhou, China|The Central Hospital of Lishui City, Lishui, China|Guangxi Zhuang Autonomous Region, Nanning, China|The Sixth Peoples Hospital of Shenyang, Shenyang, China|Shenzhen Third People's Hospital, Shenzhen, China|Suizhou Hospital, Hubei University of Medicine, Suizhou, China|Tianjin Second People's Hospital, Tianjin, China|Ankang Central Hospital, Wuhan, China|Renmin Hospital of Wuhan University, Wuhan, China|Wuhan Union Hospital, Wuhan, China|Xingtai People's Hospital, Xingtai, China|The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China",,"https://ClinicalTrials.gov/show/NCT04329559"
81,"NCT04318301","Hypertension in Patients Hospitalized With COVID-19","HT-COVID19","Active, not recruiting","No Results Available","COVID-19|Hypertension",,"Rate of Death|the severity of pneumonia","Zhenhua Zen|Nanfang Hospital of Southern Medical University","All","18 Years to 100 Years   (Adult, Older Adult)",,"275","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","HT-COVID19","March 21, 2020","March 28, 2020","March 30, 2020","March 23, 2020",,"April 7, 2020","Hankou Hospital, Hankou, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04318301"
82,"NCT04337359","Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness",,"Available","No Results Available","Severe/Very Severe COVID-19 Illness","Drug: Ruxolitinib",,"Novartis Pharmaceuticals|Novartis","All","6 Years and older   (Child, Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"CINC424A2001M",,,,"April 7, 2020",,"April 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04337359"
83,"NCT04332107","Azithromycin for COVID-19 Treatment in Outpatients Nationwide","ACTION","Not yet recruiting","No Results Available","COVID-19|SARS-CoV-2","Drug: Azithromycin|Drug: Placebos","Hospitalization|Viral load|Mortality|Adverse events|Positive SARS-CoV-2 test - nasal swab|Positive SARS-CoV-2 test - saliva swab|Positive SARS-CoV-2 test - rectal swab|Genetic macrolide resistance determinants|COVID-19 symptoms|Number of emergency room visits|Number of household members with COVID-19 (confirmed or symptomatic)","University of California, San Francisco","All","18 Years and older   (Adult, Older Adult)","Phase 3","2271","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20-30504","April 1, 2020","July 30, 2020","July 30, 2021","April 2, 2020",,"April 8, 2020","University of California San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04332107"
84,"NCT04328441","Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine","BCG-CORONA","Recruiting","No Results Available","COVID-19","Drug: BCG Vaccine|Drug: Placebo","Health Care Workers absenteeism|The cumulative incidence of documented SARS-CoV-2 infection|The number of days of unplanned absenteeism, because of documented SARS-CoV-2 infection|The number of days of absenteeism, because of imposed quarantine as a result of exposure to SARS-CoV-2 infection|The number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented SARS-CoV-2 infection|The number of days of unplanned absenteeism because of self-reported acute respiratory symptoms|The number of days of self-reported fever (≥38 gr C)|The number of days of self-reported acute respiratory symptoms|The cumulative incidence of self-reported acute respiratory symptoms|The cumulative incidence of death for any reason|The cumulative incidence of death due to documented SARS-CoV-2 infection|The cumulative incidence of Intensive Care Admission for any reason|The cumulative incidence of Intensive Care Admission due to documented SARS-CoV-2 infection|The cumulative incidence of Hospital Admission for any reason|The cumulative incidence of Hospital Admission due to documented SARS-CoV-2 infection|The incidence and magnitude of SARS-CoV-2 antibodies at the end of the study period","UMC Utrecht|Radboud University","All","18 Years and older   (Adult, Older Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NL73249.041.20","March 25, 2020","October 25, 2020","December 25, 2020","March 31, 2020",,"April 3, 2020","Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands|Radboud UMC, Nijmegen, Gelderland, Netherlands|Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands|Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands|Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands|Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands|Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04328441"
85,"NCT04334044","Treatment of SARS Caused by COVID-19 With Ruxolitinib",,"Not yet recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome Coronavirus 2","Drug: Ruxolitinib Oral Tablet","Recovery of Pneumonia|Response of C-reactive protein|Response of Ferritin|Response of D-dimer|Rate of ICU admission|Rate of mechanical ventilation|Overall Survival|Toxicity Rate","Grupo Cooperativo de Hemopatías Malignas","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HAL 345/2020","April 1, 2020","June 1, 2020","June 1, 2020","April 3, 2020",,"April 3, 2020","Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico",,"https://ClinicalTrials.gov/show/NCT04334044"
86,"NCT04332913","Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia","TOSCA","Not yet recruiting","No Results Available","COVID-19 Pneumonia",,"Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.|Percentage of patients achieving a score <3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration.|Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.|Duration of hospitalization|Time to the first negative SARS-CoV-2 negative RT-PCR test|Changes from the baseline in the white blood cell count|Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17)|Changes from the baseline of c-reactive protein (CRP) values|Changes from the baseline of Ferritin values|Changes from the baseline of BNP values|Changes from the baseline of CK-MB values|Changes from the baseline of Troponin values|Changes from the baseline of LDH values|Changes from the baseline of myoglobulin values|Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO)|Rate of adverse events report during and after tocilizumab|Mortality (number of Partecipants, cause and timing)|Percentage of patients who develop autoimmune diseases","University of L'Aquila","All","18 Years and older   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","0064468/20","April 1, 2020","December 31, 2020","March 31, 2021","April 3, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04332913"
87,"NCT04328493","The Vietnam Chloroquine Treatment on COVID-19","VICO","Not yet recruiting","No Results Available","SARS-CoV-2 Infection|COVID-19","Drug: Chloroquine phosphate","Viral clearance time|Lengh of hospital stay|Ventilator free days|Oxygene free days|Time to death|Adverse events|Time to viral PCR negative from rectal swab|fever clearance time|Ordinal outcome scale|Development of ARDS","Oxford University Clinical Research Unit, Vietnam|Ministry of Health, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Vietnam|Can Gio COVID Hospital, Vietnam|Cho Ray Hospital, Vietnam|National Hospital for Tropical Diseases, Hanoi, Vietnam|Department of Health, Ho Chi Minh city","All","18 Years and older   (Adult, Older Adult)","Phase 2","250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID","April 1, 2020","April 1, 2021","April 1, 2022","March 31, 2020",,"March 31, 2020","National Hospital for Tropical Diseases, Hanoi, Vietnam|Can Gio COVID Hospital, Ho Chi Minh City, Vietnam|Cho Ray Hospital, Ho Chi Minh City, Vietnam|Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",,"https://ClinicalTrials.gov/show/NCT04328493"
88,"NCT04330521","Impact of the Coronavirus (COVID-19) on Patients With Cancer",,"Not yet recruiting","No Results Available","Cancer|COVID-19",,"Number of participants who fill out the survey and participate in the semi-structured interviews.","Stanford University","All","18 Years to 99 Years   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","55596","April 2020","May 2022","May 2022","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330521"
89,"NCT04317040","CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment","SAC-COVID","Not yet recruiting","No Results Available","Severe Coronavirus Disease (COVID-19)","Drug: CD24Fc|Drug: Placebo","Improvement of COVID-19 disease status|Conversion rate of clinical status at Day 8|Conversion rate of clinical status at Day 15|Hospital discharge time|All cause of death|Duration of mechanical ventilation|Duration of pressors|Duration of ECMO|Duration of oxygen therapy|Length of hospital stay|Absolute lymphocyte count","OncoImmune, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 3","230","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CD24Fc-007","May 2020","May 2021","May 2022","March 20, 2020",,"March 23, 2020","Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04317040"
90,"NCT04336332","Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19",,"Not yet recruiting","No Results Available","SARS-CoV-2|COVID-19","Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate","Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Nasal swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood","Rutgers, The State University of New Jersey","All","18 Years and older   (Adult, Older Adult)","Phase 2","160","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","002011|Pro2020000712","April 6, 2020","April 30, 2021","April 30, 2021","April 7, 2020",,"April 7, 2020","Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04336332"
91,"NCT04336657","Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?",,"Recruiting","No Results Available","COVID-19","Other: Questionnaire|Diagnostic Test: IgG","Measure frequency of people suffered from unusual flu-like symptoms before December 2019|Measure remote immunity for COVID-19 in subject with past history of severe flu before WHO announcement date- if possible","Assiut University","All","8 Years to 80 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","AssiutU11","April 2020","May 2020","May 2020","April 7, 2020",,"April 7, 2020","AssiutU, Assiut, Egypt",,"https://ClinicalTrials.gov/show/NCT04336657"
92,"NCT04338932","COVID-19 and Deep Venous Thrombosis",,"Not yet recruiting","No Results Available","COVID-19|Deep Vein Thrombosis (DVT)/Thrombophlebitis",,"to investigate the prevalence and identify possible risk factors of the occurrence of a DVT in these patients at the ICU.","Jessa Hospital","All","18 Years and older   (Adult, Older Adult)",,"12","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","JessaH_COVID19_DVT","April 17, 2020","September 30, 2020","December 30, 2020","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04338932"
93,"NCT04334005","Vitamin D on Prevention and Treatment of COVID-19","COVITD-19","Not yet recruiting","No Results Available","Patients Infected With COVID-19","Dietary Supplement: Vitamin D","Composite of cumulative death (i.e. mortality) for all causes and for specific causes.|Necessity of invasive assisted ventilation|Necessity of non-invasive assisted ventilation|Intensive care unit admission|Post-anesthesia care unit admission|Hospital admission|Medical consultation|Home care and isolation time|Bed rest time|symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19)|Subjective perception of recovery","Universidad de Granada","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVITD-19","April 10, 2020","June 30, 2020","June 30, 2020","April 3, 2020",,"April 7, 2020","Universidad de Granada, Granada, Andalucia, Spain|Medicine Faculty, Granada, Spain",,"https://ClinicalTrials.gov/show/NCT04334005"
94,"NCT04288102","Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)",,"Recruiting","No Results Available","Corona Virus Disease 2019(COVID-19)","Biological: MSCs|Biological: Saline containing 1% Human serum albumin（solution of MSC）","Size of lesion area and severity of pulmonary fibrosis by chest CT|mMRC (Modified Medical Research Council) dyspnea scale|Oxygenation index( PaO2/FiO2)|Duration of oxygen therapy(days)|Duration of hospitalization(days)|Blood oxygen saturation|CD4+ T cell count and cytokine level|Side effects in the MSCs treatment group|6-minute walk test|Maximum vital capacity (VCmax)|Diffusing Capacity (DLCO)","Beijing 302 Hospital|Wuhan Huoshenshan Hospital, Wuhan, China|Maternal and Child Health Hospital of Hubei Province|General Hospital of Central Theater Command, Wuhan, China|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-013-D","March 5, 2020","July 15, 2020","July 31, 2020","February 28, 2020",,"April 7, 2020","Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China|Wuhan Huoshenshan Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04288102"
95,"NCT04286503","The Clinical Study of Carrimycin on Treatment Patients With COVID-19",,"Not yet recruiting","No Results Available","Novel Coronavirus Infectious Disease (COVID-19)","Drug: Carrimycin|Drug: lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate|Drug: basic treatment","Fever to normal time (day)|Pulmonary inflammation resolution time (HRCT) (day)|Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment","Beijing YouAn Hospital|Shenyang Tonglian Group Co., Ltd.|Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences|Huangshi Central Hospital|Shenyang Pharmaceutical University|First Affiliated Hospital of Chongqing Medical University|The Second Affiliated Hospital of Harbin Medical University|No.2 People's Hospital of Fuyang City|First Affiliated Hospital Bengbu Medical College|Renmin Hospital of Wuhan University|The sixth people's hospital of Shenyang|Nanyang Central Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","520","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BeijingYouan Hospital","February 23, 2020","February 28, 2021","February 28, 2021","February 27, 2020",,"February 27, 2020",,"""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/Prot_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04286503"
96,"NCT04293692","Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus",,"Withdrawn","No Results Available","COVID-19","Biological: UC-MSCs|Other: Placebo","Size of lesion area by chest imaging|Blood oxygen saturation|Rate of mortality within 28-days|Sequential organ failure assessment|Side effects in the UC-MSCs treatment group|Electrocardiogram, the changes of ST-T interval mostly|Concentration of C-reactive protein C-reactive protein, immunoglobulin|CD4+ and CD8+ T cells count|Concentration of the blood cytokine (IL-1β, IL-6, IL-8,IL-10,TNF-α)|Concentration of the myocardial enzymes","Puren Hospital Affiliated to Wuhan University of Science and Technology|Wuhan Hamilton Bio-technology Co., Ltd","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Pr20200225","February 24, 2020","February 25, 2020","February 25, 2020","March 3, 2020",,"March 18, 2020","Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04293692"
97,"NCT04329507","Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)",,"Not yet recruiting","No Results Available","COVID-19|Respiratory Disease","Diagnostic Test: Breath test","To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.|Detection of markers of Covid-19 pneumonia in non-invasive breath samples.|Relationship of this biomarker signature to the presence of SARS-CoV-2 in nasal and throat swabs.|Subsequently, the signature's relationship to other biomarkers of SARS-CoV-2 infection which are currently being explored|In a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between SARS-CoV-2 positive patients and those that are negative until hospital discharge or undue participant burden .","NHS Lothian","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","282014","March 25, 2020","March 25, 2020","March 25, 2020","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04329507"
98,"NCT04333472","Piclidenoson for Treatment of COVID-19",,"Not yet recruiting","No Results Available","COVID-19|Coronavirus Infection","Drug: Piclidenoson","Duration of viral shedding in days|Time to clinical recovery (TTCR) in days|Treatment-emergent adverse events (AEs)|Requirement for non-invasive or mechanical ventilation|Length of hospital stay in days|Estimated PaO2/FiO2 ratio on day of discharge|All-cause mortality|Patients reaching undetectable COVID-19 virus levels in respiratory secretions|Duration of symptoms and signs of respiratory infection in days|Need for supportive respiratory management|Viral load|Treatment-emergent serious AEs (SAEs)|AEs leading to withdrawal|Treatment-emergent abnormalities in clinical laboratory parameters","Can-Fite BioPharma|Rabin Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAN-COR-1","April 6, 2020","June 6, 2020","July 6, 2020","April 3, 2020",,"April 3, 2020","Rabin Medical Center, Petah tikva, Israel",,"https://ClinicalTrials.gov/show/NCT04333472"
99,"NCT04338828","Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED","NO COV-ED","Not yet recruiting","No Results Available","COVID19","Drug: Nitric Oxide Gas|Other: Inhaled Supplemental Oxygen","Rates of return visits to the ED|Inpatient hospitalizations required|Rates of intubation|Rates of mortality","Massachusetts General Hospital|Department of Anesthesia, Critical Care and Pain Medicine (DACCPM), Massachusetts General Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","260","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2019P00XXXX","April 2020","April 2021","April 2022","April 8, 2020",,"April 8, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04338828"
100,"NCT04335305","Checkpoint Blockade in COVID-19 Pandemic","COPERNICO","Not yet recruiting","No Results Available","COVID-19|Pneumonia, Viral","Drug: Tocilizumab|Biological: Pembrolizumab (MK-3475)","Percentage of patients with normalization of SpO2 ≥96%|Proportion of patients with temperature < 37,5 °C armpit.|Proportion of patients discharged from the emergency department and classified as low risk|Change from baseline in organ failure parameters|Proportion of mortality rate|Analysis of the remission of respiratory symptoms|Evaluation of the radiological response|Time to first negative in SARS-CoV-2 RT-PCR test|Change from baseline of ALC (absolute lymphocyte count),white blood cell count and white blood cell differential count|Change from baseline of hemoglobin|Change from baseline of platelets|Change from baseline of activated partial thromboplastin time (aPTT)|Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)|Change from baseline of creatinine|Change from baseline of glucose|Change from baseline of total bilirubin|Change from baseline of albumin|Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)","MedSIR","All","18 Years and older   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MedOPP376","March 30, 2020","May 15, 2020","May 15, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335305"
101,"NCT04273321","Efficacy and Safety of Corticosteroids in COVID-19",,"Recruiting","No Results Available","COVID-19|Novel Coronavirus Pneumonia","Drug: Methylprednisolone","the incidence of treatment failure in 14 days|clinical cure incidence in 14 days|the duration of virus change to negative|mortality at day 30|ICU admission rate in 30 days","Beijing Chao Yang Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","400","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Methylprednisolone in COVID-19","February 14, 2020","May 1, 2020","May 30, 2020","February 18, 2020",,"April 1, 2020","Hubei province hospital of integrated Chinese & Western Medicine, Wuhan, Hubei, China|Yichang first people's Hospital, Yichang, Hubei, China|Beijing YouAn Hospital, Beijing, China|Renmin Hospital of Wuhan University, Wuhan, China|Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China|Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China|the first peopel hospital of Xiangyang, Xiangyang, China",,"https://ClinicalTrials.gov/show/NCT04273321"
102,"NCT04338360","Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19",,"Available","No Results Available","COVID19","Biological: COVID-19 convalescent plasma",,"Mayo Clinic","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Intermediate-size Population",,"20-003312",,,,"April 8, 2020",,"April 8, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States|Mayo Clinic Health System in Austin, Austin, Minnesota, United States|Mayo Clinic Health System in Cannon Falls, Cannon Falls, Minnesota, United States|Mayo Clinic Health System in Lake City, Lake City, Minnesota, United States|Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States|Mayo Clinic Health System in Owatonna, Owatonna, Minnesota, United States|Mayo Clinic Health System in Red Wing, Red Wing, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System - Franciscan Healthcare, La Crosse, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04338360"
103,"NCT04331665","Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19|Pneumonia","Drug: Ruxolitinib","Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more)|All cause mortality rate|Average duration of hospital stay|Number of occurrence of secondary infections","University Health Network, Toronto","All","12 Years and older   (Child, Adult, Older Adult)","Not Applicable","64","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U-DEPLOY: RUX-COVID|20-5315","April 6, 2020","October 30, 2020","January 31, 2021","April 2, 2020",,"April 3, 2020","Princess Margaret Cancer Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04331665"
104,"NCT04318444","Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)",,"Not yet recruiting","No Results Available","COVID-19|Corona Virus Infection","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of participants with symptomatic, lab-confirmed COVID-19.","Columbia University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","1600","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","AAAS9676","March 2020","March 2021","March 2022","March 24, 2020",,"March 25, 2020","Columbia University Irving Medical Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04318444"
105,"NCT04336774","CAPTION AI to Minimize Risk of COVID Exposure","CAPTION AI","Not yet recruiting","No Results Available","COVID-19","Device: Caption AI","Percent of patient echos that are not interpretable|Percent of patient echos that provide an automated (AI) LVEF (left ventricular ejection fraction)|Time to acquire images as measured by time stamps|Percent of agreement between AI calculate LVEF and LVEF read by physician","Duke University|Caption Health, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","500","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","pro00105212","April 2020","November 1, 2020","November 9, 2020","April 7, 2020",,"April 7, 2020","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04336774"
106,"NCT04318015","Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)","PHYDRA","Not yet recruiting","No Results Available","COVID-19|Severe Acute Respiratory Syndrome","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Symptomatic COVID-19 infection rate|Symptomatic non-COVID viral infection rate|Days of labor absenteeism|Rate of labor absenteeism|Rate of severe respiratory COVID-19 disease in healthcare personnel","National Institute of Respiratory Diseases, Mexico|Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 3","400","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ProfilaxisCOVID","April 1, 2020","December 31, 2020","March 31, 2021","March 23, 2020",,"March 23, 2020",,,"https://ClinicalTrials.gov/show/NCT04318015"
107,"NCT04323345","Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus",,"Not yet recruiting","No Results Available","COVID-19","Dietary Supplement: Natural Honey|Other: Standard Care","Rate of recovery from positive to negative swaps|Fever to normal temperature in days|Resolution of lung inflammation in CT or X ray|30 days mortality rate|Number of days till reaching negative swab results","Misr University for Science and Technology","All","5 Years to 75 Years   (Child, Adult, Older Adult)","Phase 3","1000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","MUST23032020","March 25, 2020","April 25, 2020","May 10, 2020","March 26, 2020",,"March 26, 2020","Mahmoud Tantawy, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT04323345"
108,"NCT04328272","Effectiveness of Hydroxychloroquine in Covid-19 Patients","Covid","Not yet recruiting","No Results Available","COVID19","Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets","National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers","Prof. Dr. Umar Farooq|Ayub Medical College, Abbottabad","All","18 Years to 50 Years   (Adult)","Phase 3","75","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","Ath/ct101/22/3","March 28, 2020","May 28, 2020","June 28, 2020","March 31, 2020",,"April 2, 2020","Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan",,"https://ClinicalTrials.gov/show/NCT04328272"
109,"NCT04327531","Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study",,"Active, not recruiting","No Results Available","COVID-19|Physician-Patient Relations","Behavioral: turkish physicians","Evaluation of covid-19 knowledge level of turkish physicians|what they think about the future","Kanuni Sultan Suleyman Training and Research Hospital","All","25 Years to 55 Years   (Adult)",,"200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","turkishcovid19","March 26, 2020","April 26, 2020","April 28, 2020","March 31, 2020",,"April 2, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04327531"
110,"NCT04335019","Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +","eChoVid","Not yet recruiting","No Results Available","2019-nCoV (COVID-19)|Interstitial Pneumonia","Other: Pulmonary ultrasound","Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity|Assessment of the agreement between a newly trained operator and an experienced operator of classification in one of the three stages of ultrasound gravity, by Cohen's kappa coefficient.|Estimate in patients who had a CT-scan on D0, the agreement in the evaluation of the severity of lung lesions via ultrasound vs. CT-scan, by Cohen's kappa coefficient|Measurement of the cumulative incidence of invasive mechanical ventilation and measurement of survival","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Other|Time Perspective: Prospective","APHP200390|2020-A00768-31","April 2020","April 2020","May 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335019"
111,"NCT04334291","International COVID19 Clinical Evaluation Registry,","HOPE COVID 19","Recruiting","No Results Available","COVID 19","Combination Product: Observational (registry)","Death|In hospital stay.|Heart failure|Renal failure|Respiratory Insufficiency.|Upper respiratory tract involvement|Pneumonia|Sepsis|Systemic inflammatory response Syndrome.|Clinically relevant bleeding|Other complications.","IVAN J NUÑEZ GIL|St Carlos Hospital, Madrid, Spain","All","Child, Adult, Older Adult",,"2500","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","20/241-E|EUPAS34399","March 23, 2020","May 1, 2020","May 5, 2020","April 6, 2020",,"April 6, 2020","Hospital Lclinico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04334291"
112,"NCT04333914","Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 (COVID-19) Infection","IMMUNONCOVID","Recruiting","No Results Available","SARS-CoV-2 (COVID-19) Infection|Advanced or Metastatic Hematological or Solid Tumor","Drug: Chloroquine analog (GNS651)|Drug: Nivolumab|Drug: Tocilizumab|Other: Standard of care","28-day survival rate|Time to clinical improvement|Clinical status|Mean change in clinical status from baseline to days|Overall survival|Length of stay in Intensive Care Unit|Duration of mechanical ventilation or high flow oxygen devices|Duration of hospitalization|Rate of throat swab negativation|Quantitative SARS-CoV-2 virus in throat swab and blood samples|Rate of secondary infection by other documented pathogens|Biological parameters|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Cost-Effectiveness Analyses (CEA)","Centre Leon Berard","All","18 Years and older   (Adult, Older Adult)","Phase 2","273","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ET20-076 - IMMUNONCOVID-20|2020-001373-70","April 2020","June 2020","August 2020","April 3, 2020",,"April 7, 2020","Centre Léon Bérard, Lyon, Rhône, France",,"https://ClinicalTrials.gov/show/NCT04333914"
113,"NCT04323644","Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)","CovidSurg","Not yet recruiting","No Results Available","COVID-19|Coronavirus|Surgery","Procedure: Surgery","30-day mortality|7-day mortality|30-day reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis","University of Birmingham","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","CS-20200324","March 31, 2020","September 30, 2020","September 30, 2020","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04323644"
114,"NCT04251767","Washed Microbiota Transplantation for Patients With 2019-nCoV Infection",,"Withdrawn","No Results Available","COVID-19 Complicated With Refractory Intestinal Infections","Other: washed microbiota transplantation|Other: placebo","Number of participants with improvement from severe type to common type","The Second Hospital of Nanjing Medical University","All","14 Years to 70 Years   (Child, Adult, Older Adult)","Not Applicable","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","WMT-YJ-202001","February 5, 2020","April 30, 2020","April 30, 2020","February 5, 2020",,"March 17, 2020","Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT04251767"
115,"NCT04330144","Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)",,"Not yet recruiting","No Results Available","Contact Person From COVID-19 Confirmed Patient","Drug: Hydroxychloroquine as post exposure prophylaxis|Other: Others(No intervention)","The rate of COVID-19","Gangnam Severance Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","2486","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","3-2020-0036","April 1, 2020","March 30, 2021","March 30, 2022","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330144"
116,"NCT04338958","Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation","RuxCoFlam","Not yet recruiting","No Results Available","Covid-19","Drug: Ruxolitinib 10 MG","overall response rate in reversal of hyperinflammation|efficacy of ruxolitinib + standard-of-care (SoC)","Prof. Dr. med. Andreas Hochhaus|University of Jena","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RuxCoFlam","May 1, 2020","January 31, 2021","August 31, 2021","April 8, 2020",,"April 8, 2020","University Hospital Jena, Jena, Germany",,"https://ClinicalTrials.gov/show/NCT04338958"
117,"NCT04299724","Safety and Immunity of Covid-19 aAPC Vaccine",,"Recruiting","No Results Available","Treat and Prevent Covid-19 Infection","Biological: Pathogen-specific aAPC","Frequency of vaccine events|Frequency of serious vaccine events|Proportion of subjects with positive T cell response|28-day mortality|Duration of mechanical ventilation if applicable|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Clinical improvement based on the 7-point scale if applicable|Lower Murray lung injury score if applicable","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","All","6 Months to 80 Years   (Child, Adult, Older Adult)","Phase 1","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-20002","February 15, 2020","July 31, 2023","December 31, 2024","March 9, 2020",,"March 9, 2020","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04299724"
118,"NCT04338126","Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients","TCInpatient","Not yet recruiting","No Results Available","COVID19","Drug: Tranexamic acid|Drug: Placebo oral tablet","Admission to Intensive Care Unit","University of Alabama at Birmingham","All","19 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TXACOVID2","April 15, 2020","October 15, 2020","December 15, 2020","April 8, 2020",,"April 8, 2020","University of Alabama at Birmingham, Birmingham, Alabama, United States",,"https://ClinicalTrials.gov/show/NCT04338126"
119,"NCT04298814","Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia",,"Not yet recruiting","No Results Available","COVID-19|Endotracheal Intubation","Other: severe covid-19 pneumonia with ET","Success rate of intubation|Infection rate of Anesthesiologist|Extubation time","Tongji Hospital","All","18 Years to 90 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","COVEI","March 7, 2020","May 30, 2020","July 30, 2020","March 6, 2020",,"March 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04298814"
120,"NCT04335097","Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation","HSC19","Not yet recruiting","No Results Available","COVID 19","Device: Biosensors","Stop home isolation|NEWS score|Clinic at hospitalization|Symptoms developed|Relative/peers evaluation of the patient|Serious of symptoms at admittance hospital","Lars Wik|University of Stavanger|Oslo University Hospital|Norwegian Telemedicine|Basque Country University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","214","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","127157","April 7, 2020","April 8, 2021","December 20, 2025","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335097"
121,"NCT04324190","DIgital Online SuPport for COVID-19 StrEss","DISPOSE","Not yet recruiting","No Results Available","COVID-19|Psychosocial Stress|Mental Health","Behavioral: Guided online support program|Behavioral: WHO recommendations (waiting condition)","Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score|Chronic stress items (9 items)|Generalized Anxiety Disorder Scale (GAD-7)|Patient Health Questionnaire (PHQ8)|Somatic Symptom Disorder (SSD-12)|Somatic Symptom Scale (SSS-8)|Allgemeine Selbstwirksamkeit Kurzskala (ASKU)|Screening Tool for Psychological Distress (STOP-D) - selected items","Gunther Meinlschmidt|Selfapy GmbH|International Psychoanalytic University Berlin","All","18 Years and older   (Adult, Older Adult)","Not Applicable","600","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","IPUB_2020_01","April 2020","June 2020","December 2021","March 27, 2020",,"April 7, 2020","Selfapy GmbH, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04324190"
122,"NCT04334850","Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia","MultiCov","Not yet recruiting","No Results Available","Covid19|Pneumonia","Procedure: Combined use of a respiratory broad panel multiplex PCR and procalcitonin|Other: Usual antibiotic treatment","Number of antibiotic free days|Mortality rates|Number of defined daily dose (DDD) per 100 patient-days of broad- and narrow-spectrum antibiotics.|Antibiotics duration at D28|Number of organ-failure free days (based on SOFA)|Incidence rates of bacterial super-infections|Incidence rates of colonization/infection with multidrug resistant bacteria and Clostridium difficile infections|ICU and hospital lengths of stay|Quality of life Quality of life","Assistance Publique - Hôpitaux de Paris|BioMérieux","All","18 Years and older   (Adult, Older Adult)","Not Applicable","194","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200392|2020-001324-33","April 2020","July 2020","August 2020","April 6, 2020",,"April 6, 2020","Intensive care department-Hospital Tenon, Paris, France",,"https://ClinicalTrials.gov/show/NCT04334850"
123,"NCT04335071","Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)","CORON-ACT","Not yet recruiting","No Results Available","SARS-CoV-2 Infection","Drug: Tocilizumab (TCZ)|Drug: Placebo","Number of patients with ICU admission|Number of patients with intubation|Number of patients with death|Illness severity|Number of patients with clinical improvement|Time to clinical improvement (days)|Duration of hospitalization (days)|Time to ICU admission (days)|Duration of ICU stay|Time to intubation|Duration of mechanical ventilation (days)","University Hospital Inselspital, Berne|Roche Pharma AG","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 2","100","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-00691|2020DR2044","April 2020","October 2020","October 2020","April 6, 2020",,"April 8, 2020","University Hospital Bern (Inselspital), Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|University Hospital Zurich, Zurich, Switzerland",,"https://ClinicalTrials.gov/show/NCT04335071"
124,"NCT04333693","Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study","Covid-VAS","Not yet recruiting","No Results Available","Vascular Surgical Procedures|COVID-19|Postoperative Complications","Procedure: Vascular surgery","30-days mortality|7-days mortality|30-days reoperation|Postoperative ICU admission|Postoperative respiratory failure|Postoperative acute respiratory distress syndrome (ARDS)|Postoperative sepsis","Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RIV-2020-1","April 1, 2020","October 1, 2020","November 1, 2020","April 3, 2020",,"April 3, 2020","Spanish Society for Angiology and Vascular Surgery, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04333693"
125,"NCT04276896","Immunity and Safety of Covid-19 Synthetic Minigene Vaccine",,"Recruiting","No Results Available","Pathogen Infection Covid-19 Infection","Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs","Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of vaccine/CTL Events|Frequency of Serious vaccine/CTL Events","Shenzhen Geno-Immune Medical Institute|Shenzhen Third People's Hospital|Shenzhen Second People's Hospital","All","6 Months to 80 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-20001","March 24, 2020","July 31, 2023","December 31, 2024","February 19, 2020",,"March 19, 2020","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China|Shenzhen Second People's Hospital, Shenzhen, Guangdong, China|Shenzhen Third People's Hospital, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04276896"
126,"NCT04326725","Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia",,"Recruiting","No Results Available","to Evaluate the Efficacy of Hydroxychloroquine Plus vitACD-Zinc as Prevention for COVID19 Infection","Drug: Plaquenil 200Mg Tablet","Protection against COVID-19","Istinye University","All","20 Years to 90 Years   (Adult, Older Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","2020-2/1","March 20, 2020","July 1, 2020","September 1, 2020","March 30, 2020",,"March 30, 2020","Istinye University Medical School, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04326725"
127,"NCT04328961","Hydroxychloroquine for COVID-19 PEP",,"Not yet recruiting","No Results Available","COVID-19|Corona Virus Infection|SARS (Severe Acute Respiratory Syndrome)","Drug: Hydroxychloroquine Sulfate|Drug: Ascorbic Acid","Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection|Rate of participant-reported adverse events|Incidence rates of COVID-19 through study completion","University of Washington|New York University|Bill and Melinda Gates Foundation","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","2000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","STUDY00009750","March 2020","September 30, 2020","October 31, 2020","April 1, 2020",,"April 1, 2020","NYU Langone Health, New York, New York, United States|University of Washington, Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04328961"
128,"NCT04333862","Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy","Covid-19","Recruiting","No Results Available","SARS-CoV-2",,"Fraction of healthcare workers infected with SARS-CoV-2|Fraction of healthcare workers with COVID-19|Number of patients infected in the hospital|Development of SARS-CoV2 specific antibody repertoire","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00563","March 19, 2020","June 30, 2020","December 31, 2021","April 3, 2020",,"April 3, 2020","Guido Beldi, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04333862"
129,"NCT04333953","COVID-19 in Patients With HIV",,"Recruiting","No Results Available","HIV/AIDS|COVID-19|SARS-CoV-2","Other: No intervention","Mortality|Frequency of patients requiring hospital admissions|Frequency of patients requiring ICU admissions|Frequency of respiratory support use|Frequency of kidney injury|Frequency of liver injury","University of Missouri-Columbia","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","262095","April 1, 2020","October 1, 2020","October 1, 2020","April 3, 2020",,"April 7, 2020","University of Missouri-Columbia, Columbia, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT04333953"
130,"NCT04323514","Use of Ascorbic Acid in Patients With COVID 19",,"Recruiting","No Results Available","Hospitalized Patients With Covid-19 Pneumonia","Dietary Supplement: Vitamin C","In-hospital mortality|PCR levels|Lactate clearance|Hospital stay|Symptoms|Positive swab|Tomography imaging","University of Palermo","All","Child, Adult, Older Adult","Not Applicable","500","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","3143","March 13, 2020","March 13, 2021","March 13, 2021","March 26, 2020",,"March 26, 2020","A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/14/NCT04323514/Prot_SAP_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04323514"
131,"NCT04322188","An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection","SISCO","Recruiting","No Results Available","Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection",,"Cohort A: reduction of the need of invasive ventilation or 30-day mortality|Cohort B: reduction of mortality|Cohort A Reduction of the need of time of ventilatory support|Cohort B Percentage of patients that undergo to tracheostomy|Cohort B Improvement of the lung function assessed by radiologic findings","A.O. Ospedale Papa Giovanni XXIII","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","v 0.9 16th March 2020","March 19, 2020","May 19, 2020","May 19, 2020","March 26, 2020",,"March 31, 2020","ASST - Papa Giovanni XXIII, Bergamo, Italy",,"https://ClinicalTrials.gov/show/NCT04322188"
132,"NCT04334252","Descriptive Study Regarding Pre-operative Screening During COVID 19 Pandemia",,"Not yet recruiting","No Results Available","COVID 19","Other: Questionnaire","Prevalence of symptoms|Prevalence of positive Sars CoV-2 PCR|Prevalence of positive radiological findings|Prediction of symptoms","Jessa Hospital","All","18 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","JessaH_COVID19_prescreening","April 17, 2020","December 20, 2022","December 20, 2023","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04334252"
133,"NCT04316299","Acute Kidney Injury in Patients Hospitalized With COVID-19",,"Completed","No Results Available","COVID-19|Acute Kidney Injury|Kidney Function",,"Rate of Acute Kidney Injury|Rate of Death|the length of hospital stay","Zhenhua Zen|Nanfang Hospital of Southern Medical University","All","18 Years and older   (Adult, Older Adult)",,"287","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","hkyy2020-005 AKI","February 26, 2020","February 28, 2020","March 8, 2020","March 20, 2020",,"March 30, 2020","Hankou Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04316299"
134,"NCT04318431","Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children","COVILLE","Not yet recruiting","No Results Available","Covid19","Diagnostic Test: Data collection and rhinopharyngeal swab","Proportion of asymptomatic children or children with mild respiratory symptoms|Confirmed Cov2-SARS cases by age|Confirmed Cov2-SARS cases by symptoms|Viral load|Other respiratory viruses","Centre Hospitalier Intercommunal Creteil|ACTIV","All","6 Months to 15 Years   (Child)","Not Applicable","600","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","COVILLE|2020-A00724-35","April 2020","June 2020","June 2020","March 24, 2020",,"March 26, 2020","Cabinet du Dr Belaroussi, Boulogne, France|Cabinet du Dr Derkx, Champigny-sur-Marne, France|Cabinet du Dr Coicadan, Chennevières-sur-Marne, France|Cabinet du Dr Corrard, Combs-la-Ville, France|53 Boulevard De La Liberté, Les Lilas, France|157 Avenue du Général Leclerc, Maisons-Alfort, France|Cabinet du Dr Bodin, Montgeron, France|Cabinet du Dr Deberdt, Nogent-sur-Marne, France|Cabinet du Dr Wollner, Nogent-sur-Marne, France|Cabinet du Dr D'acremont, Paris, France|Cabinet du Dr Romain, Paris, France|Cabinet du Dr Turberg-Romain, Paris, France|Cabinet du Dr Michot, Paris, France|Cabinet du Dr Cohen, Saint-Maur-des-Fossés, France|Cabinet de Pédiatrie des Docteurs Ravilly et Bessa, Villejuif, France|13 Villa Beauséjour, Vincennes, France",,"https://ClinicalTrials.gov/show/NCT04318431"
135,"NCT04336345","Outcomes of Patients With COVID-19 in the Intensive Care Unit","MexCOVID-19","Not yet recruiting","No Results Available","Coronavirus Infections|COVID-19|Viral Pneumonia Human Coronavirus",,"Hospital mortality|Length of stay in the intensive care unit","Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","All","18 Years and older   (Adult, Older Adult)",,"150","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","TEI-3336-20-20-1","April 1, 2020","April 30, 2020","May 30, 2020","April 7, 2020",,"April 7, 2020","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico|All centres from Mexico willing to contribute are Welcome., Mexico, Mexico",,"https://ClinicalTrials.gov/show/NCT04336345"
136,"NCT04336787","Physical Activity Level, Stress Level, Sleep Quality in Covid-19 Quarantine",,"Not yet recruiting","No Results Available","Covid-19|Coronavirus Infection","Other: Survey","International Physical Activity Questionnaire|Pittsburgh Sleep Quality Index|Perceived Stress Scale|Numerical Pain Rating Scale","Istanbul Kültür University|Istanbul University-Cerrahpasa","All","18 Years to 80 Years   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","FADP-2","April 10, 2020","May 10, 2020","June 10, 2020","April 7, 2020",,"April 7, 2020","Istanbul University - Cerrahpaşa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04336787"
137,"NCT04334460","Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects",,"Not yet recruiting","No Results Available","Sars-CoV2","Drug: BLD-2660","Antiviral Activity|Improvement of oxygenation|Safety & Tolerability: incidence of TEAEs and serious adverse events (SAEs)","Blade Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","B-2660-204","May 2020","August 2020","September 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04334460"
138,"NCT04320017","Joint Use of Electrocardiogram and Transthoracic Echocardiography in an Observational Study to Monitor Cardio-vascular Events in Patients Diagnosed With COVID-19","JOCOVID","Recruiting","No Results Available","COVID-19|Myocardial Injury|Myocarditis","Diagnostic Test: Electrocardiogram and transthoracic echocardiography","Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay|Description of cardiovascular outcomes in the cohort|Prognosis role of baseline cardio-vascular caracteristics on patients survival|Prediction of cardio-vascular events with baseline characteristics|Characterization of inflammation on cardio-vascular outcomes","Groupe Hospitalier Pitie-Salpetriere","All","16 Years and older   (Child, Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","CIC1421-20-05","March 20, 2020","May 20, 2020","May 20, 2020","March 24, 2020",,"March 24, 2020","Clinical Investigation Center Pitié-Salpêtrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04320017"
139,"NCT04336384","Impact of Covid-19 in Congenital Heart Disease","COVID-CHD","Recruiting","No Results Available","Congenital Heart Disease|Covid-19",,"Population characteristics|Clinical course|Cardiovascular complications|Other complications|Number of deaths","University Hospital, Montpellier|Pr. Jean-Benoît THAMBO, Bordeaux (président)|Dr. Céline GRUNENWALD GRONIER, Strasbourg|Dr. Sébastien HASCOET, Le Plessis-Robinson|Dr. Adeline BASQUIN, Rennes|Dr. Nicolas COMBES, Toulouse|Dr. Xavier IRIART, Bordeaux|Dr. Daniela LAUX, Paris|Dr. Magalie LADOUCEUR, Paris|Pr. BERTRAND LEOBON, Toulouse|Pr. Caroline OVAERT, Marseille|Dr. Karine WARIN-FRESSE, Nantes|Alexis BLANC, Montpellier","All","Child, Adult, Older Adult",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","RECHMPL20_0155","March 1, 2020","December 1, 2020","December 30, 2020","April 7, 2020",,"April 7, 2020","Uh Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04336384"
140,"NCT04313127","A Phase I Clinical Trial in 18-60 Adults","APICTH","Active, not recruiting","No Results Available","COVID-19","Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)","Safety indexes of adverse reactions|Safety indexes of adverse events|Safety indexes of SAE|Safety indexes of lab measures|Immunogencity indexes of GMT(ELISA)|Immunogencity indexes of GMT(pseudoviral neutralization test method)|Immunogencity indexes of seropositivity rates(ELISA)|Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method)|Immunogencity indexes of GMI(ELISA)|Immunogencity indexes of GMI(pseudoviral neutralization test method)|Immunogencity indexes of GMC(Ad5 vector)|Immunogencity indexes of GMI(Ad5 vector)|Immunogencity indexes of cellular immune","CanSino Biologics Inc.|Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China|Jiangsu Province Centers for Disease Control and Prevention|Hubei Provincial Center for Disease Control and Prevention|Tongji Hospital","All","18 Years to 60 Years   (Adult)","Phase 1","108","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","JSVCT088","March 16, 2020","December 30, 2020","December 20, 2022","March 18, 2020",,"March 31, 2020","Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04313127"
141,"NCT04331574","Renin-Angiotensin System Inhibitors and COVID-19","SARS-RAS","Recruiting","No Results Available","COVID-19|Hypertension|Cardiovascular Diseases",,"Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents|Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity","Societa Italiana dell'Ipertensione Arteriosa","All","18 Years to 120 Years   (Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","SARS-RAS","March 10, 2020","April 10, 2020","April 30, 2020","April 2, 2020",,"April 2, 2020","Spedali Civili di Brescia, Brescia, Italy",,"https://ClinicalTrials.gov/show/NCT04331574"
142,"NCT04333732","CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION","CROWN CORONA","Not yet recruiting","No Results Available","COVID 19","Drug: Low-dose chloroquine/hydroxychloroquine|Drug: Mid dose chloroquine or hydroxychloroquine|Drug: High does chloroquine or hydroxychloroquine|Drug: Placebo","Symptomatic COVID-19|Peak severity of COVID-19 over the study period","Washington University School of Medicine","All","18 Years and older   (Adult, Older Adult)","Phase 2","55000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","202004xxx","April 2020","February 2021","February 2021","April 3, 2020",,"April 3, 2020","Washington University School of Medicine, Saint Louis, Missouri, United States|Melbourne Medical School, Melbourne, Victoria, Australia|Population Health Resarch Institute, Hamilton, Ontario, Canada|University of Toronto, Toronto, Ontario, Canada|St James's Hospital, Dublin, Leinster, Ireland|Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa|University College London, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04333732"
143,"NCT04321265","Outcomes and Prognostic Factors in COVID-19","COVIP","Recruiting","No Results Available","COVID-19|Elderly Patients|Critical Illness|Survival|Old Age",,"Survival|Fragilty","Heinrich-Heine University, Duesseldorf","All","70 Years and older   (Older Adult)",,"4000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-004","March 19, 2020","September 2020","December 2020","March 25, 2020",,"April 8, 2020","Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark|Hôpitaux de Paris, Hôpital Saint-Antoine, service de réanimation médicale, Paris, France|INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France|Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France|Division of Cardiology, Pulmonary Disease and Vascular Medicine, Duesseldorf, Germany|Department of Anaestesia and Intensive Care, Haukeland University Hospital, Bergen, Norway|Department of Clinical Medecine,University of Bergen, Bergen, Norway",,"https://ClinicalTrials.gov/show/NCT04321265"
144,"NCT04327206","BCG Vaccination to Protect Healthcare Workers Against COVID-19","BRACE","Recruiting","No Results Available","Coronavirus Disease 2019 (COVID-19)|Febrile Respiratory Illness|Corona Virus Infection|COVID-19","Drug: BCG Vaccine","COVID-19 disease incidence|Severe COVID-19 disease incidence|COVID-19 incidence by 12 months|Severe COVID-19 incidence by 12 months|Time to first symptom of COVID-19|Episodes of COVID-19|Asymptomatic SARS-CoV-2 infection|Work absenteeism due to COVID-19|Bed confinement due to COVID-19|Symptom duration of COVID-19|SARS-CoV-2 pneumonia|Oxygen therapy with SARS-CoV-2|Critical care admissions with SARS-CoV-2|Critical care admission duration with SARS-CoV-2|Mechanical ventilation with SARS-CoV-2|Mechanical ventilation duration with SARS-CoV-2|Hospitalisation duration with COVID-19|Mortality with SARS-CoV-2|Febrile respiratory illness|Episodes of febrile respiratory illness|Work absenteeism due to febrile respiratory illness|Bed confinement due to febrile respiratory illness|Symptom duration of febrile respiratory illness|Pneumonia|Oxygen therapy|Critical care admissions|Mechanical ventilation|Mortality|Hospitalisation duration with febrile respiratory illness|Unplanned work absenteeism|Hospitalisation cost to treat COVID-19|Local and systemic adverse events to BCG vaccination in healthcare workers","Murdoch Childrens Research Institute|Royal Children's Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 3","4170","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","62586","March 30, 2020","October 30, 2020","March 30, 2022","March 31, 2020",,"April 7, 2020","Epworth Victoria Parade, Melbourne, Victoria, Australia|Royal Children's Hospital, Melbourne, Victoria, Australia|Epworth Richmond, Melbourne, Victoria, Australia|Epworth Eastern, Melbourne, Victoria, Australia|Monash Health- Monash Medical Centre, Melbourne, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Perth Children's Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia",,"https://ClinicalTrials.gov/show/NCT04327206"
145,"NCT04326790","The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention","GRECCO-19","Not yet recruiting","No Results Available","Corona Virus Disease 19 (Covid 19)","Drug: Colchicine|Drug: Standard treatment","CRP increase to 3 x upper limit of normal|Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&D committee|Maximal concentration of cardiac troponin","National and Kapodistrian University of Athens","All","18 Years and older   (Adult, Older Adult)","Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","906295542","April 6, 2020","August 31, 2020","September 30, 2020","March 30, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04326790"
146,"NCT04338698","Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT","PROTECT","Not yet recruiting","No Results Available","COVID 19","Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin","Laboratory Result|Clinical Outcome","Shehnoor Azhar|Federal Task Force on Science & Technology notified by Government of Pakistan|University of Health Sciences Lahore","All","18 Years and older   (Adult, Older Adult)","Phase 3","500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12(06)/2016-Coord","April 7, 2020","September 1, 2020","November 30, 2020","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04338698"
147,"NCT04338009","Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019","REPLACECOVID","Not yet recruiting","No Results Available","COVID-19","Other: Discontinuation of ARB/ACEI|Other: Continuation of ARB/ACEI","Hierarchical composite endpoint|All-Cause Death|Length of Hospital Stay|Length of ICU Stay, invasive mechanical ventilation or extracorporeal membrane oxygenation|AUC SOFA","University of Pennsylvania|Jordana B. Cohen, MD, MSCE|Thomas C. Hanff, MD, MPH|Vicente Corrales-Medina, MD, PhD|James Brian Byrd, MD|Roberto Viau Colindres","All","18 Years and older   (Adult, Older Adult)","Not Applicable","152","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","842810","March 31, 2020","December 31, 2020","December 31, 2020","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04338009"
148,"NCT04334265","Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019",,"Not yet recruiting","No Results Available","COVID-19","Drug: Anluohuaxian","Changes in high-resolution computer tomography of the lung|Change in 6-minute walking distance|Changes in compound physiological index|Changes in the scores of the St. George's Hospital Respiratory Questionnaire|Changes in modified British Medical Research Council Dyspnea Scale (mMRC) scores|Changes in vital capacity of the lung","Peking University First Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","750","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020 research 110","April 1, 2020","June 1, 2020","December 1, 2020","April 6, 2020",,"April 6, 2020","The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04334265"
149,"NCT04334148","Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine","HERO-HCQ","Not yet recruiting","No Results Available","COVID-19","Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of participants testing positive for COVID-19 infection|Number of participants with COVID-19 viral shedding|Safety as measured by number of adverse events","Duke University|Patient-Centered Outcomes Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","15000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Pro00105274","April 2020","July 2020","July 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04334148"
150,"NCT04333589","A Prospective Study on Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive",,"Not yet recruiting","No Results Available","COVID-19","Drug: Favipiravir","Viral nucleic acid test negative conversion rate|Clinical cure rate","Peking University First Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","210","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020 research 112","April 1, 2020","June 1, 2020","September 15, 2020","April 3, 2020",,"April 3, 2020","The Second People's Hospital of Fuyang, Fuyang, Anhui, China|Ezhou Hospital of Traditional Chinese Medicine, Ezhou, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China|Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04333589"
151,"NCT04330599","Longitudinal Population-based Observational Study of Coronavirus Disease in the UK Population","COVIDENCE","Not yet recruiting","No Results Available","COVID-19",,"Incidence of suspected, probable or confirmed COVID-19|Incidence of confirmed COVID-19|Incidence of COVID-19 requiring hospitalisation|Incidence of COVID-19 requiring ventilatory support|Incidence of fatal COVID-19|Symptom duration per COVID-19 episode|Symptom severity per COVID-19 episode|Incidence of seroconversion to SARS-CoV-2|Incidence of recurrent COVID-19|EQ-5D-3L health-related quality of life score|Health care costs associated with incident COVID-19|Impact of COVID-19 on participants' financial status|Incidence of physical complications of COVID-19|Impact of COVID-19 on participants' mental well-being","Queen Mary University of London|King's College London|London School of Hygiene and Tropical Medicine","All","16 Years and older   (Child, Adult, Older Adult)",,"12000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIDENCE","April 2, 2020","April 1, 2025","April 1, 2025","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330599"
152,"NCT04328480","The ECLA PHRI COLCOVID Trial","COLCOVID","Not yet recruiting","No Results Available","COVID-19","Drug: Colchicine|Other: Local standard of care","All-cause mortality|Composite outcome:composite of intubation for mechanical ventilation or death.","Estudios Clínicos Latino América|Population Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","2500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COLCOVID version1.2","March 2020","May 30, 2020","June 30, 2020","March 31, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04328480"
153,"NCT04311398","Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System",,"Not yet recruiting","No Results Available","COVID-19","Diagnostic Test: New QIAstat-Dx fully automatic multiple PCR detection platform","Sensitivity， spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform","Huashan Hospital","All","16 Years to 100 Years   (Child, Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","KY2020-COVID-19","March 14, 2020","June 1, 2020","December 1, 2020","March 17, 2020",,"March 17, 2020","Huashan Hospital of Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04311398"
154,"NCT04310228","Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019",,"Recruiting","No Results Available","COVID-19","Drug: Favipiravir Combined With Tocilizumab|Drug: Favipiravir|Drug: Tocilizumab","Clinical cure rate|Viral nucleic acid test negative conversion rate and days from positive to negative|Duration of fever|Lung imaging improvement time|Mortality rate because of Corona Virus Disease 2019|Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs|Mean in-hospital time","Peking University First Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020YFC0844100","March 8, 2020","May 2020","May 2020","March 17, 2020",,"March 17, 2020","Anhui Medical University Affiliated First Hospital, Hefei, Anhui, China|Guiqiang Wang, Beijing, Beijing, China|Peking University First Hospital, Beijing, Beijing, China|Cancer Hospital Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China|Ezhou Central Hospital, Wuhan, Hubei, China|Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China|Jinyintan Hospital of Wuhan, Wuhan, Hubei, China|Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China|West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China|Wuhan Pulmonary Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04310228"
155,"NCT04302519","Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells",,"Not yet recruiting","No Results Available","COVID-19","Biological: Dental pulp mesenchymal stem cells","Disppear time of ground-glass shadow in the lungs|Absorption of Lung shadow absorption by CT Scan-Chest|Changes of blood oxygen","CAR-T (Shanghai) Biotechnology Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Early Phase 1","24","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KT005HB001","March 5, 2020","June 30, 2021","July 30, 2021","March 10, 2020",,"March 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04302519"
156,"NCT04295551","Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)",,"Not yet recruiting","No Results Available","COVID-19","Drug: Lopinavir / ritonavir tablets combined with Xiyanping injection|Drug: Lopinavir/ritonavir treatment","Clinical recovery time","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QF-XYP1990-1","March 14, 2020","July 14, 2020","April 14, 2021","March 4, 2020",,"March 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04295551"
157,"NCT04325646","Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples","CORSER","Recruiting","No Results Available","SARS (Severe Acute Respiratory Syndrome)|COVID-19","Other: Human Biological samples","Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.|Percentage of asymptomatic forms in individuals with anti-SARS-CoV-2 antibodies","Institut Pasteur","All","5 Years and older   (Child, Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-007","March 13, 2020","February 28, 2021","February 28, 2023","March 27, 2020",,"March 31, 2020","CHU Amiens-Picardie, Amiens, France|CHU François Mitterand, Dijon, France|CHU Limoges, Limoges, France|Hôpital de la Croix Rousse, Lyon, France|Hôpitaux de Brabois, Nancy, France|CHR Orléans, Orléans, France|Institut Pasteur, Paris, France|CHU Poitiers, Poitiers, France|Hôpital Pontchaillou, Rennes, France|CHU Saint-Etienne, Saint-Étienne, France|CH de Tourcoing, Tourcoing, France|Hôpital Bretonneau, Tours, France",,"https://ClinicalTrials.gov/show/NCT04325646"
158,"NCT04292964","Prognostic Factors of Patients With COVID-19",,"Completed","No Results Available","SARS-CoV-2|Outcome, Fatal",,"all-cause mortality|Severe state","Chongqing Medical University","All","18 Years and older   (Adult, Older Adult)",,"201","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-02-2","March 1, 2020","March 13, 2020","March 13, 2020","March 3, 2020",,"March 17, 2020","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04292964"
159,"NCT04331054","Protective Role of Inhaled Steroids for Covid-19 Infection","INHASCO","Not yet recruiting","No Results Available","Covid-19 Infection|Hospitalization in Respiratory Disease Department","Drug: 2: Usual practice + SYMBICORT RAPIHALER|Other: 1: Usual practice","Time (in days) to clinical improvement within 30 days after randomization|Mortality rate at D30|Time (in days) from randomization to death|Number of days alive outside ICU within 30 days|Number of days alive free of invasive or non-invasive ventilation within 30 days|Number of days alive with oxygen therapy within 30 days|Maximal oxygen rate within 30 days|Difference between PaO2/FiO2 ratio at randomization and at Day 7 (or at the time of stopping oxygen therapy or discharge if occurs before Day 7)|Number of days alive outside hospital within 30 days|Use of antibiotics for respiratory (proved or suspected) infection within 30 days|Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)|Safety outcomes included events that occurred during treatment, serious adverse events, and premature discontinuation of treatment.","Assistance Publique - Hôpitaux de Paris","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","436","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P 200394|2020-001306-35","April 2020","July 2020","July 2020","April 2, 2020",,"April 2, 2020","Hôpital Bichat - Service de Pneumologie, Paris, France",,"https://ClinicalTrials.gov/show/NCT04331054"
160,"NCT04337346","Evaluation of Covid 19 Anxiety in Endometriosis Patients",,"Active, not recruiting","No Results Available","Endometriosis|Covid19",,"Covid 19 Anxiety levels in Endometriosis Patients","Kanuni Sultan Suleyman Training and Research Hospital","Female","18 Years to 45 Years   (Adult)",,"80","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","endocovid19","April 5, 2020","April 20, 2020","April 25, 2020","April 7, 2020",,"April 7, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04337346"
161,"NCT04337294","Evaluation of Blood Results of Covid 19 Positive Pregnants",,"Active, not recruiting","No Results Available","Covid19|Pregnancy Related","Biological: Evaluation of blood results of covid 19 positive pregnant patients","Examination of changes in blood values of covid 19 positive pregnant patients","Kanuni Sultan Suleyman Training and Research Hospital","Female","18 Years to 45 Years   (Adult)",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","covid19pregnancies","March 21, 2020","May 20, 2020","May 22, 2020","April 7, 2020",,"April 7, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04337294"
162,"NCT04335786","Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease",,"Not yet recruiting","No Results Available","Respiratory Distress Syndrome, Adult|SARS-CoV-2","Drug: Valsartan (Diovan)|Drug: Placebo oral tablet","first occurrence of intensive care unit admission, mechanical ventilation or death|Death|Mechanical ventilation|Intensive care unit admission|Occurrence of acute kidney injury","Radboud University","All","18 Years and older   (Adult, Older Adult)","Phase 4","651","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NL73547.091.20|2020-001320-34","April 2020","July 2020","August 2021","April 6, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04335786"
163,"NCT04337866","Evaluation of the Effects of Ozone Therapy on Covid 19 Positive Patients",,"Active, not recruiting","No Results Available","Covid19|Ozene","Other: ozone therapy group (covid positive)","The effects of ozone therapy given in addition to the treatment they received in covid 19 positive patients (hydroxychloroquine + azithromycin)","Kanuni Sultan Suleyman Training and Research Hospital","Female","18 Years to 45 Years   (Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ozonecovid19","April 1, 2020","May 28, 2020","May 30, 2020","April 8, 2020",,"April 8, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04337866"
164,"NCT04337320","Evaluation of Postnatal Outcomes of Covid 19 Positive Mothers Newborns",,"Active, not recruiting","No Results Available","Covid19|Newborn Morbidity","Other: newborns from covid 19 positive mothers","Evaluation of apgar status of newborns from covid 19 positive mothers","Kanuni Sultan Suleyman Training and Research Hospital","All","up to 15 Minutes   (Child)",,"70","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","covid19pregnancynewborn","April 1, 2020","June 15, 2020","June 20, 2020","April 7, 2020",,"April 7, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04337320"
165,"NCT04335552","Phase 2 Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",,"Not yet recruiting","No Results Available","SARS-CoV-2","Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin","World Health Organization (WHO) ordinal scale measured at 14 days after enrollment|Rates of death during the index hospitalization|Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline|Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization|WHO ordinal scale measured at 28 days after enrollment|Hospital length of stay in days for the index hospitalization|Rates of all-cause study medication discontinuation|Rates of severe adverse events","Duke University","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","500","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PRO00105339","April 2020","August 1, 2020","August 1, 2020","April 6, 2020",,"April 6, 2020","Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04335552"
166,"NCT04278963","Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19",,"Active, not recruiting","No Results Available","CoVID-19|Chinese Medicine","Drug: YinHu QingWen Decoction|Drug: YinHu QingWen Decoction(low dose)|Other: Chinese medicine treatment|Other: standard western medicine treatment","Mean clinical recovery time (hours)|Time to CoVID-19 RT-PCR negative in upper respiratory tract specimen|Change (reduction) in CoVID-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Frequency of respiratory progression|Severe case incidence|Proportion of re-hospitalization or admission to ICU|All-cause mortality|Frequency of serious adverse events","China Academy of Chinese Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","YHQW-V3.0","February 27, 2020","January 2021","January 2021","February 20, 2020",,"March 17, 2020","Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China|Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04278963"
167,"NCT04303507","Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting","COPCOV","Not yet recruiting","No Results Available","COVID19|Coronavirus|Acute Respiratory Illnesses","Drug: Chloroquine or Hydroxychloroquine|Drug: Placebo","Number of symptomatic COVID-19 infections|Symptoms severity of COVID-19|Number of asymptomatic cases of COVID-19|Number of symptomatic acute respiratory illnesses|Severity of symptomatic acute respiratory illnesses","University of Oxford","All","16 Years and older   (Child, Adult, Older Adult)","Not Applicable","40000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","VIR20001","April 2020","April 2021","April 2021","March 11, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04303507"
168,"NCT04328012","COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2","COVIDMED","Recruiting","No Results Available","SARS-CoV-2 Infection","Drug: lopinavir/ritonavir|Drug: Hydroxychloroquine Sulfate|Drug: Losartan|Drug: Placebos","National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)|Hospital length of stay (LOS)|Intensive care unit level LOS|Mechanical ventilation|survival","Bassett Healthcare","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","4000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","1581969","April 6, 2020","January 1, 2021","April 1, 2021","March 31, 2020",,"April 8, 2020","Bassett Medical Center, Cooperstown, New York, United States",,"https://ClinicalTrials.gov/show/NCT04328012"
169,"NCT04272710","Prognositc Factors in COVID-19 Patients Complicated With Hypertension",,"Withdrawn","No Results Available","2019-nCoV",,"Occupancy rate in the intensive care unit (ICU)|Mechanical Ventilation|Death|All cause mortality|Time from onset of symptoms to main outcome and its components|Time to Clinical Recovery","Chongqing Medical University","All","18 Years to 100 Years   (Adult, Older Adult)",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","2020-02","January 25, 2020","March 31, 2020","April 30, 2020","February 17, 2020",,"March 17, 2020","The First Affiliated Hospital of Chongqing Medical University, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT04272710"
170,"NCT04273763","Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)",,"Enrolling by invitation","No Results Available","Novel Coronavirus Pneumonia|2019-nCoV","Drug: Bromhexine Hydrochloride Tablets|Drug: Arbidol Hydrochloride Granules|Drug: Recombinant Human Interferon α2b Spray","Time to clinical recovery after treatment|Rate of aggravation|Clinical remission rate|Dynamic changes of oxygenation index|Time to cure|rate to cure|Time to defervescence|Time to cough remission|Time to dyspnea remission|Days of supplemental oxygenation|Rate of patients with requring supplemental oxygen|Rate of patients with mechanical ventilation|Time of negative COVID-19 nucleic acid results|Rate of negative COVID-19 nucleic acid results|Rate of ICU admission|28-day mortality","Second Affiliated Hospital of Wenzhou Medical University|WanBangDe Pharmaceutical Group Co.,Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019NCP1.0","February 16, 2020","April 15, 2020","April 30, 2020","February 18, 2020",,"March 23, 2020","The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT04273763"
171,"NCT04303299","Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID19 : A Randomized Control Trial","THDMS-COVID19","Not yet recruiting","No Results Available","Coronavirus Infections|COVID19","Drug: Oral","SARS-CoV-2 eradication time|Number of patient with Death|Number of patient with Recovery adjusted by initial severity in each arm|Number of day With ventilator dependent adjusted by initial severity in each arm|Number of patient developed Acute Respiratory Distress Syndrome After treatment","Rajavithi Hospital","All","16 Years to 100 Years   (Child, Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TH-DMS-COVID19 study","March 15, 2020","October 31, 2020","November 30, 2020","March 11, 2020",,"March 25, 2020","Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand",,"https://ClinicalTrials.gov/show/NCT04303299"
172,"NCT04331613","Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS",,"Recruiting","No Results Available","COVID-19|Acute Respiratory Distress Syndrome|Virus; Pneumonia|Acute Lung Injury","Biological: CAStem","Adverse reaction (AE) and severe adverse reaction (SAE)|Changes of lung imaging examinations|Time to SARS-CoV-2 RT-PCR negative|Duration of fever (Celsius)|Changes of blood oxygen (%)|Rate of all-cause mortality within 28 days|Lymphocyte count (*10^9/L)|Alanine aminotransferase (U/L)|Creatinine (umol/L)|Creatine kinase (U/L)|C-reactive protein (mg/L)|Procalcitonin (ng/L)|Lactate (mmol/L)|IL-1beta (pg/mL)|IL-2 (pg/mL)|IL-6 (pg/mL)|IL-8 (pg/mL)","Chinese Academy of Sciences|Beijing YouAn Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ChineseASZQ-006","January 27, 2020","December 2020","December 2020","April 2, 2020",,"April 2, 2020","Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China, China",,"https://ClinicalTrials.gov/show/NCT04331613"
173,"NCT04338568","Screening COVID by Point-of-care Lung Ultrasound: a Validation Study","SCOUT","Not yet recruiting","No Results Available","COVID-19 Pneumonia|Lung Ultrasound","Diagnostic Test: Lung ultrasound","Accuracy of the diagnosis of interstitial syndrome by lung ultrasound|Inter-observer variability","Hasselt University|Ziekenhuis Oost-Limburg","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","CTU2020032","April 13, 2020","April 30, 2020","April 30, 2020","April 8, 2020",,"April 8, 2020","Ziekenhuis Oost Limburg, Genk, Limburg, Belgium",,"https://ClinicalTrials.gov/show/NCT04338568"
174,"NCT04310865","Yinhu Qingwen Granula for the Treatment of Severe CoVID-19",,"Not yet recruiting","No Results Available","COVID-19|Severe Pneumonia|Chinese Medicine","Drug: Yinhu Qingwen Granula|Drug: Yin Hu Qing Wen Granula(low does)|Other: standard medical treatment","changes in the ratio of PaO2 to FiO2 from baseline|PaO2|blood oxygen saturation (SpO2)|clinical status rating on the 7-point ordinal scale|Time to Clinical Improvement (TTCI)|Duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use|Duration (hours) of invasive mechanical ventilation use|Duration (hours) of extracorporeal membrane oxygenation (ECMO) use|Duration (days) of Oxygen use|The proportion of the patients reporting 2019-nCoV RT-PCR negativity at Day 10 after treatment|The counts/percentage of Lymphocyte|Time to hospital discharge with clinical recovery from the randomisation|The incidence of critical status conversion in 30 days|All-cause mortality within 30 days|Frequency of severe adverse drug events","Zhong Wang|Wuhan Leishenshan Hospital|The First Affiliated Hospital of Dalian Medical University|Tanshan People's Hospital|North China University of Science and Technology Affiliated Hospital|Jizhong Energy Fengfeng Group Hospital|China Academy of Chinese Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","116","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","YHQW-Severe-V2.0","March 20, 2020","March 30, 2021","June 30, 2021","March 17, 2020",,"March 17, 2020","Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital, Wuhan, Hubei, China|Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital, Wuhan, Hubei, China|Zhongnan Hospital of Wuhan University/Tanshan People's Hospital, Wuhan, Hubei, China|Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04310865"
175,"NCT04324021","Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.",,"Recruiting","No Results Available","SARS-CoV-2","Biological: Emapalumab|Biological: Anakinra","Treatment success|Time to mechanical ventilation|Change from baseline in Modified Early Warning system score|Change from baseline in resting peripheral capillary oxygen saturation (SpO2)|Change from baseline in partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2)|Change of pH in hemogasanalysis from baseline|Change of carbon dioxide tension (pCO2) in hemogasanalysis from baseline|Change of oxygen tension (pO2) in hemogasanalysis from baseline|Change of potassium in hemogasanalysis from baseline|Change of sodium in hemogasanalysis from baseline|Change of chloride in hemogasanalysis from baseline|Change of lactic acid in hemogasanalysis from baseline|Change of hemoglobin in hemogasanalysis from baseline|Change from baseline in oxygen supplementation|Change of findings of high-resolution computed tomography (CT) scan of the chest|Change from baseline in Ferritin|Change from baseline in lactate dehydrogenase (LDH)|Change from baseline in D-dimers|Change from baseline in White Blood Cells with differential counts|Change from baseline in Red Blood Counts|Change from baseline in Hemoglobin|Change from baseline in Platelet count|Change from baseline in Fibrinogen|Change from baseline in Complement factors C3/C4|Change from baseline in Prothrombin time|Change from baseline in Cardiac troponin|Change from baseline in aspartate aminotransferase (AST)|Change from baseline in alanine aminotransferase (ALT)|Change from baseline in total bilirubin levels|Change from baseline in C-Reactive Protein|Change from baseline in Creatinine|Overall survival|Time to hospital discharge","Swedish Orphan Biovitrum","All","30 Years to 79 Years   (Adult, Older Adult)","Phase 2|Phase 3","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Sobi.IMMUNO-101|2020-001167-93","April 2020","July 2020","September 2020","March 27, 2020",,"April 6, 2020","ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica, Brescia, Italy|Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza, Milano, Italy|Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia, Parma, Italy|Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04324021"
176,"NCT04319445","Mindfulness During COVID-19",,"Recruiting","No Results Available","Migraine Disorders|Stress|Anxiety","Behavioral: Mindfulness session(s)","Helpfulness of the session|Platform effectiveness|Change in Anxiety Level|Change in Stress Level|Value of the session|Satisfaction with the session|Percentage of participants that showed interest in a future session|Percentage of participants that would recommend this session to a family member|Percentage of participants by session frequency preference","Wake Forest University Health Sciences","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","IRB00064587","March 22, 2020","December 2020","December 2020","March 24, 2020",,"April 8, 2020","Wake Forest Health Sciences, Winston-Salem, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04319445"
177,"NCT04319731","A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure",,"Not yet recruiting","No Results Available","SARS CoV-2 Infection","Biological: Human Amniotic Fluid","Ventilator Free Days|Duration of supplemental oxygen use|All cause mortality|Systemic inflammation","University of Utah","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","131618","March 20, 2020","March 20, 2021","March 20, 2021","March 24, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04319731"
178,"NCT04334967","Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care",,"Enrolling by invitation","No Results Available","COVID-19|Corona Virus Infection|SARS-CoV-2|2019-nCoV|2019 Novel Coronavirus","Drug: Hydroxychloroquine|Dietary Supplement: Vitamin C","Total Hospitalization|Total Mechanical Ventilation|Fever intensity measure|Shortness of breath measure|Changes in daytime cough measure|Changes in nighttime cough measure|Total mortality","Providence Health & Services|Center for Outcomes Research and Education|Providence Cancer Center, Earle A. Chiles Research Institute","All","45 Years and older   (Adult, Older Adult)","Phase 4","1250","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2020000186","March 30, 2020","September 30, 2021","September 30, 2023","April 6, 2020",,"April 6, 2020","Portland Providence Medical Center, Portland, Oregon, United States",,"https://ClinicalTrials.gov/show/NCT04334967"
179,"NCT04321928","Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary","PROACTIVE-19","Not yet recruiting","No Results Available","SARS-CoV-2|Coronavirus|COVID-19|2019-nCoV|2019nCoV","Behavioral: Personalized health education|Behavioral: General health education","Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases|The number of general practitioner visits|The number of emergency, hospital admission and intensive care admission|Length of hospitalization and intensive care unit stay|Organ dysfunction|Lifestyle changes|The cost of care","University of Pecs","All","60 Years and older   (Adult, Older Adult)","Not Applicable","7576","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention","IV/2428- 2 /2020/EKU","April 1, 2020","April 21, 2021","August 21, 2021","March 25, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04321928"
180,"NCT04336215","Rutgers COVID-19 Cohort Study",,"Recruiting","No Results Available","Coronavirus|SARS-CoV-2","Other: Non-Interventional","Prevalence|Incidence","Rutgers, The State University of New Jersey","All","20 Years and older   (Adult, Older Adult)",,"750","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020000679","March 28, 2020","September 1, 2020","October 21, 2021","April 7, 2020",,"April 7, 2020","Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -, New Brunswick, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Clinical Research Unit Rutgers New Jersey Medical School, Newark, New Jersey, United States|Rutgers School of Dental Medicine, Newark, New Jersey, United States|University Hospital, Newark, New Jersey, United States|Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey, United States|RUCDR Infinite Biologics, Piscataway, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT04336215"
181,"NCT04298060","DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)","STOP-Flu","Not yet recruiting","No Results Available","Influenza Infection|SAD-RV Infection and COVID-19","Drug: DAS181|Drug: Placebo","Percent of subjects who have returned to room air|Percent change of subjects return to baseline oxygen requirement","Ansun Biopharma, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 2","280","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","DAS181-2-07","April 2020","March 2021","September 2022","March 6, 2020",,"April 2, 2020","Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04298060"
182,"NCT04270383","Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children",,"Not yet recruiting","No Results Available","2019-nCoV",,"The cure rate of 2019-nCoV.|The improvement rate of 2019-nCoV.|The incidence of long-term adverse outcomes.|Duration of fever|Duration of respiratory symptoms|Duration of hospitalization|Number of participant(s) need intensive care|Number of participant(s) with acute respiratory distress syndrome|Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.|Number of participant(s) who died during the trial","Beijing Children's Hospital|Capital Institute of Pediatrics, China|The First Affiliated Hospital of Anhui Medical University|China-Japan Friendship Hospital|The First Affiliated Hospital of Xiamen University|Guangzhou Women and Children's Medical Center|Shenzhen Children's Hospital|First Affiliated Hospital of Guangxi Medical University|The Affiliated Hospital Of Guizhou Medical University|Hainan People's Hospital|Children's Hospital of Hebei Province|Wuhan Women and Children's Medical Center|Changchun Children's Hospital|Children’s Hospital of Nanjing Medical University|Jiangxi Province Children's Hospital|Shengjing Hospital|Shanxi Provincial Maternity and Children's Hospital|Xian Children's Hospital|Children's Hospital of Chongqing Medical University|Tianjin Children's Hospital|Tianjin Medical University Second Hospital|Kunming Children's Hospital|Second Affiliated Hospital of Wenzhou Medical University","All","up to 18 Years   (Child, Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","BCH Lung 012","February 15, 2020","December 31, 2020","December 31, 2020","February 17, 2020",,"February 17, 2020","Beijing Children's Hospital,, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04270383"
183,"NCT04332991","Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease","ORCHID","Recruiting","No Results Available","Coronavirus|Acute Respiratory Infection|SARS-CoV Infection","Drug: Hydroxychloroquine|Drug: Placebo","COVID Ordinal Outcomes Scale on Day 15|all-location, all-cause mortality assessed on day 15|all-location, all-cause mortality assessed on day 29|COVID Ordinal Outcomes Scale on Study Day 3|COVID Ordinal Outcomes Scale on Study Day 8|COVID Ordinal Outcomes Scale on Study Day 29|Number of patients dead or with receipt of ECMO between enrollment and Day 28|Oxygen-free days through Day 28|Ventilator-free days through Day 28|Vasopressor-free days through Day 28|ICU-free days to Day 28|Hospital-free days to Day 28","Massachusetts General Hospital|National Heart, Lung, and Blood Institute (NHLBI)","All","18 Years and older   (Adult, Older Adult)","Phase 3","510","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PETAL 05 Orchid","April 2, 2020","April 2021","July 2021","April 3, 2020",,"April 7, 2020","University of Arizona, Tucson, Arizona, United States|UCSF Fresno, Fresno, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|UCSF Medical Center, San Francisco, California, United States|Stanford University, Stanford, California, United States|Medical Center of Aurora, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|Denver Health Medical Center, Denver, Colorado, United States|St. Joseph Hospital, Denver, Colorado, United States|University of Florida, Gainesville, Florida, United States|University of Kentucky, Lexington, Kentucky, United States|University Medical Center, New Orleans, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|St. Vincent's Hospital, Worcester, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States|Henry Ford Medical Center, Detroit, Michigan, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Montefiore Medical Center-Weiler, Bronx, New York, United States|Montefiore Medical Center-Moses, Bronx, New York, United States|Mt. Sinai Hospital, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Penn State Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, Houston, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|University of Utah Hospital, Salt Lake City, Utah, United States|University of Virginia Health System, Charlottesville, Virginia, United States|VCU Medical Center, Richmond, Virginia, United States|Harborview Medical Center, Seattle, Washington, United States|Swedish Hospital First Hill, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04332991"
184,"NCT04334954","SARS-COV2 Pandemic Serosurvey and Blood Sampling",,"Recruiting","No Results Available","SARS-COV2 Virus",,"Number of people with detectable antibodies to SARS-COV2","National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC)","All","18 Years and older   (Adult, Older Adult)",,"1000","NIH","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","200083|20-I-0083","April 13, 2020","March 31, 2022","March 31, 2022","April 6, 2020",,"April 8, 2020","National Institutes of Health Clinical Center, Bethesda, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT04334954"
185,"NCT04320511","Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2",,"Not yet recruiting","No Results Available","SARS-COV2|Severe Acute Respiratory Syndrome|COVID-19","Device: CT-V","Predictive association between CT-V, PBM score and disease progression","William Beaumont Hospitals","All","18 Years and older   (Adult, Older Adult)",,"25","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-087","April 2020","March 2021","March 2022","March 25, 2020",,"March 31, 2020","Beaumont Health, Royal Oak, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT04320511"
186,"NCT04324528","Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation","CYCOV","Recruiting","No Results Available","Coronavirus|COVID-19|SARS-CoV Infection|Respiratory Failure|Cytokine Storm","Device: vv-ECMO + cytokine adsorption (Cytosorb adsorber)|Device: vv-ECMO only (no cytokine adsorption)","interleukin-6 (IL-6) level after 72 hours|30-day-survival|vasopressor dosage|fluid balance|lactate","Dr. Alexander Supady|University Hospital Freiburg","All","18 Years to 100 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CYCOV","March 27, 2020","September 26, 2020","November 26, 2020","March 27, 2020",,"March 31, 2020","University Clinic Freiburg, Freiburg, Germany",,"https://ClinicalTrials.gov/show/NCT04324528"
187,"NCT04323878","Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.","EC-COVID-PCS","Not yet recruiting","No Results Available","Early CPAP Ventilation in COVID-19 Patients",,"Death or need of intubation|30-day mortality","Mario Negri Institute for Pharmacological Research","All","18 Years and older   (Adult, Older Adult)",,"3000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EC-COVID-PCS-Fenice","April 6, 2020","October 5, 2020","November 9, 2020","March 27, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04323878"
188,"NCT04285190","The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Disease 2019|Novel Coronavirus Pneumonia","Drug: T89","The time to oxygen saturation recovery to normal level (≥97%)|The proportion of patients with normal level of oxygen saturation(≥97%)|The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, etc.|The time to the myocardial enzyme spectrum recovery to normal after treatment|The proportion of the patients with normal myocardial enzyme spectrum after treatment|The time to the electrocardiogram recovery to normal level after treatment|The proportion of the patients with normal electrocardiogram after treatment|The time to the hemodynamics recovery to normal after treatment|The proportion of the patients with normal hemodynamics after treatment|The time to exacerbation or remission of the disease after treatment;|The proportion of the patients with exacerbation or remission of disease after treatment|The proportion of patients who need other treatment (e.g. heparin, anticoagulants) due to microcirculation disorders|The all-cause mortality rate|The proportion of patients with acidosis|The total duration of the patients in-hospital|The total duration of oxygen inhalation during treatment|The oxygen flow rate during treatment|The oxygen concentration during treatment","Tasly Pharmaceuticals, Inc.","All","18 Years to 85 Years   (Adult, Older Adult)","Not Applicable","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T89-NCP-01","February 26, 2020","June 15, 2020","September 15, 2020","February 26, 2020",,"February 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04285190"
189,"NCT04324606","A Study of a Candidate COVID-19 Vaccine (COV001)",,"Not yet recruiting","No Results Available","Coronavirus","Biological: ChAdOx1 nCoV-19|Biological: MenACWY Placebo","Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases|Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs)|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests|Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19|Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays|Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19","University of Oxford","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","510","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","COV001","April 2020","May 2021","May 2021","March 27, 2020",,"April 6, 2020","NIHR WTCRF, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom|Imperial College Healthcare NHS Trust, London, United Kingdom|CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04324606"
190,"NCT04323800","Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19","CSSC-001","Not yet recruiting","No Results Available","Coronavirus|Convalescence","Biological: Anti- SARS-CoV-2 Plasma|Biological: SARS-CoV-2 non-immune Plasma","Cumulative incidence of composite outcome of disease severity|Anti-SARS-CoV-2 titers|Rates of SARS-CoV-2 PCR positivity|Duration of SARS-CoV-2 PCR positivity|Peak quantity levels of SARS-CoV-2 RNA|Cumulative incidence of disease severity","Johns Hopkins University","All","18 Years and older   (Adult, Older Adult)","Phase 2","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","IRB00245634","May 1, 2020","December 31, 2022","January 2023","March 27, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04323800"
191,"NCT04325412","Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY","CAPACITY-COVID","Recruiting","No Results Available","COVID-19; Cardiovascular Diseases",,"The incidence of cardiovascular complications in patients with COVID-19","UMC Utrecht","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-161/C","March 23, 2020","March 23, 2021","June 23, 2021","March 27, 2020",,"March 27, 2020","University Medical Center Utrecht, Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT04325412"
192,"NCT04337281","Evaluation of the Effect of High-dose Vitamin C Use in Covid 19 Positive Pregnants",,"Active, not recruiting","No Results Available","Covid19|Pregnancy Related|Vitamin C Deficiency","Drug: High dose vitamin C","evaluation of the change of peripheral blood values in pregnant women receiving high doses of vitamin C","Kanuni Sultan Suleyman Training and Research Hospital","Female","18 Years to 45 Years   (Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Highdosevitcincovid19","April 1, 2020","May 28, 2020","May 30, 2020","April 7, 2020",,"April 7, 2020","Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04337281"
193,"NCT04321096","The Impact of Camostat Mesilate on COVID-19 Infection","CamoCO-19","Recruiting","No Results Available","Corona Virus Infection","Drug: Camostat Mesilate|Drug: Placebo oral tablet","Days to clinical improvement from study enrolment|Safety evaluation, as measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs)|Clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30|Day 30 mortality|Change in NEW(2) score from baseline to day 30|Admission to ICU|Use of invasive mechanical ventilation or ECMO|Duration of supplemental oxygen (days)|Days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30","University of Aarhus","All","18 Years to 110 Years   (Adult, Older Adult)","Phase 1|Phase 2","180","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2020-001200-42","March 31, 2020","December 31, 2020","May 1, 2021","March 25, 2020",,"April 6, 2020","Department of Infectious Diseases, Aalborg, Denmark|Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark|Herning Regional Hospital, Herning, Denmark|Northzealands hospital - Hillerød, Hillerød, Denmark|Horsens Regional Hospital, Horsens, Denmark|Bispebjerg hospital, København, Denmark|Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark|Randers Regional Hospital, Randers, Denmark|Silkeborg Hospital, Silkeborg, Denmark",,"https://ClinicalTrials.gov/show/NCT04321096"
194,"NCT04332380","Convalescent Plasma for Patients With COVID-19: A Pilot Study","CP-COVID-19","Not yet recruiting","No Results Available","Coronavirus|Coronavirus Infection","Drug: Plasma","Change in Viral Load|Change in Immunoglobulin M COVID-19 antibodies Titers|Change in Immunoglobulin G COVID-19 antibodies Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality","Universidad del Rosario|CES University|Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud|Fundación Universitaria de Ciencias de la Salud","All","18 Years to 60 Years   (Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABN011-1","April 1, 2020","August 31, 2020","December 31, 2020","April 2, 2020",,"April 2, 2020","Universidad del Rosario, Bogota, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04332380"
195,"NCT04332666","Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial","ATCO","Not yet recruiting","No Results Available","Coronavirus|Respiratory Failure|Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere|SARS-CoV-2","Drug: Angiotensin 1-7|Drug: Placebos","ventilator free days|ICU free days|Hospital length of stay|Time to wean from mechanical ventilation|PaO2/FiO2 changes during drug administration|Deep vein thrombosis incidence|Changes in inflammatory markers|RAS effectors levels|Radiological findings","Erasme University Hospital|Fonds Erasme pour la Recherche Médicale","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","P2020/201","March 31, 2020","May 30, 2020","June 15, 2020","April 3, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04332666"
196,"NCT04268537","Immunoregulatory Therapy for 2019-nCoV",,"Not yet recruiting","No Results Available","2019 nCoV, PD-1","Drug: PD-1 blocking antibody+standard treatment|Drug: Thymosin+standard treatment|Other: standard treatment","lung injury score|absolute lymphocyte counts|serum level of CRP, PCT and IL-6|SOFA score|all cause mortality rate|ventilation free days|ICU free days","Southeast University, China","All","18 Years and older   (Adult, Older Adult)","Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2020YFC0841300-03","February 10, 2020","April 30, 2020","October 31, 2020","February 13, 2020",,"February 13, 2020",,,"https://ClinicalTrials.gov/show/NCT04268537"
197,"NCT04330495","Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection",,"Not yet recruiting","No Results Available","COVID 19|Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors","Drug: Experimental group|Drug: Control group","Incidence rate of new COVID-19 cases in both arms|Prevalence of COVID-19 cases in both arms|Mortality rate secondary to COVID-19 cases in both groups|Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups|Adverse events","Instituto de Investigación Marqués de Valdecilla","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","EnCOVID-HidroxiCLOROQUINA","April 6, 2020","November 6, 2020","November 6, 2020","April 1, 2020",,"April 1, 2020",,,"https://ClinicalTrials.gov/show/NCT04330495"
198,"NCT04334928","Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS)","EPICOS","Active, not recruiting","No Results Available","Coronavirus Infection","Drug: Emtricitabine/tenofovir disoproxil|Drug: Hydroxychloroquine|Drug: Placebo: Emtricitabine/tenofovir disoproxil Placebo|Drug: Placebo: Hydroxychloroquine","Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)|Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)|Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days","Plan Nacional sobre el Sida (PNS)|Effice Servicios Para la Investigacion S.L.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","4000","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","PrEP COVID-19","April 1, 2020","June 30, 2020","July 31, 2020","April 6, 2020",,"April 7, 2020","Hospital Universitario Ramón y Cajal, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04334928"
199,"NCT04332835","Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study","CP-COVID-19","Not yet recruiting","No Results Available","Coronavirus|Coronavirus Infection","Drug: Plasma|Drug: Hydroxychloroquine|Drug: Azithromycin","Change in Viral Load|Change in Immunoglobulin M COVID-19 Titers|Change in Immunoglobulin G COVID-19 Titers|Intensive Care Unit Admission|Length of Intensive Care Unit stay|Length of hospital stay (days)|Requirement of mechanical ventilation|Duration (days) of mechanical ventilation|Clinical status assessed according to the World Health Organization guideline|Mortality","Universidad del Rosario|Fundación Universitaria de Ciencias de la Salud|CES University|Instituto Distrital de Ciencia Biotecnología e Innovacion en Salud","All","18 Years to 60 Years   (Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ABN011-2","April 1, 2020","August 31, 2020","December 31, 2020","April 3, 2020",,"April 3, 2020","Universidad del Rosario, Bogota, Cundinamarca, Colombia",,"https://ClinicalTrials.gov/show/NCT04332835"
200,"NCT04306705","Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19","TACOS","Recruiting","No Results Available","Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab","Drug: Tocilizumab|Other: Standard of care|Procedure: Continuous renal replacement therapy","Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14|Duration of hospitalization|Proportion of Participants With Normalization of Fever Through Day 14|Change from baseline in white blood cell and differential count|Time to first negative in 2019 novel Corona virus RT-PCR test|All-cause mortality|Change from baseline in hsCRP|Change from baseline in cytokines IL-1β, IL-10, sIL-2R, IL-6, IL-8 and TNF-α|Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells","Tongji Hospital|Hubei Xinhua Hospital|Wuhan No.1 Hospital|Wuhan central hospital","All","18 Years to 80 Years   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","WHTJCOVID-19","February 20, 2020","May 30, 2020","June 20, 2020","March 13, 2020",,"March 17, 2020","Tongji Hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04306705"
201,"NCT04334876","Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers","COVID-Antibody","Not yet recruiting","No Results Available","SARS-CoV-2","Diagnostic Test: SARS-CoV-2 IgG Antibody Testing Kit","Validation of SARS-CoV-2 IgG Antibody Test|Incidence of Seroconversion|Identify Candidacy","Indiana University","All","18 Years and older   (Adult, Older Adult)",,"340","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","2003973826","April 1, 2020","November 1, 2020","January 1, 2021","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04334876"
202,"NCT04304690","Sars-CoV2 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","SEROCOV","Recruiting","No Results Available","Sars-CoV2","Other: blood sample","Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff|Identification of risk factors for seroconversion|Quantify the proportion of asymptomatic infections among staff who have seroconverted|"" Describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome ""","Assistance Publique - Hôpitaux de Paris","All","Child, Adult, Older Adult","Not Applicable","1000","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","APHP200310","March 16, 2020","July 16, 2020","October 16, 2020","March 11, 2020",,"March 19, 2020","Hopital Pitié Salpetrière, Paris, France",,"https://ClinicalTrials.gov/show/NCT04304690"
203,"NCT04337424","Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2","EasyCoV","Not yet recruiting","No Results Available","SARS-CoV-2","Diagnostic Test: Sampling salivary","Specific detection of SARS-CoV-2 specific RNA|Analytical sensitivity of the LAMP test.|The correlation between the measurement of the assayed viral load (CT value) by the standard method and by the LAMP developed by SYS2DIAG / SKILLCELL.|Evaluation of the use of saliva samples compared to nasopharyngeal samples","University Hospital, Montpellier|SkillCell|Sys2Diag (CNRS-Alcediag UMR9005)","All","18 Years to 90 Years   (Adult, Older Adult)",,"180","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","RECHMPL20_0170","April 7, 2020","April 17, 2020","April 17, 2020","April 7, 2020",,"April 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04337424"
204,"NCT04320472","Acute Encephalopathy in Critically Ill Patients With SARS-Cov-2 Infection","NeuroCOVID19","Recruiting","No Results Available","COVID-19|Encephalopathy|Critically Ill","Other: Follow up","prevalence|Favorable outcome","Ictal Group","All","18 Years and older   (Adult, Older Adult)",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Neuro-COVID-19","March 23, 2020","December 2020","December 2020","March 25, 2020",,"April 1, 2020","Centre Hospitalier de Versailles, Le Chesnay, France",,"https://ClinicalTrials.gov/show/NCT04320472"
205,"NCT04312100","Sequential Oxygen Therapy Strategy for Patients With COVID-19","SOTSPC","Recruiting","No Results Available","Coronavirus Disease-2019","Other: oxygen treatment","Incidence of respiratory failure|28 day mortality rate","Henan Provincial People's Hospital","All","18 Years to 75 Years   (Adult, Older Adult)",,"30","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","SOT-C","February 1, 2020","October 2020","February 2021","March 18, 2020",,"March 18, 2020","Henan Provincial People's Hospital, Zhengzhou, Henan, China",,"https://ClinicalTrials.gov/show/NCT04312100"
206,"NCT04252664","Mild/Moderate 2019-nCoV Remdesivir RCT",,"Recruiting","No Results Available","2019-nCoV","Drug: Remdesivir|Drug: Remdesivir placebo","Time to Clinical recoveryTime to Clinical Recovery (TTCR)|All cause mortality|Frequency of respiratory progression|Time to defervescence (in those with fever at enrolment)|Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)|Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)|Frequency of requirement for supplemental oxygen or non-invasive ventilation|Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen|Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.|Frequency of requirement for mechanical ventilation|Frequency of serious adverse events","Capital Medical University|Chinese Academy of Medical Sciences","All","18 Years and older   (Adult, Older Adult)","Phase 3","308","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAP-China remdesivir 1","February 12, 2020","April 10, 2020","April 27, 2020","February 5, 2020",,"February 24, 2020","Jin Yin-tan hospital, Wu Han, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04252664"
207,"NCT04323839","COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)","PRIORITY","Recruiting","No Results Available","Pregnancy|Coronavirus|COVID-19","Other: Pregnant women under investigation for Coronavirus or diagnosed with COVID-19|Other: Postpartum women under investigation for Coronavirus or diagnosed with COVID-19","Clinical presentation|Disease prognosis outcomes|Pregnancy outcomes|Obstetric outcomes|Neonatal outcomes|Modes of transmission of COVID-19","University of California, San Francisco|University of California, Los Angeles","Female","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-30410","March 20, 2020","March 31, 2024","March 31, 2024","March 27, 2020",,"April 7, 2020","University of California, San Francisco, San Francisco, California, United States",,"https://ClinicalTrials.gov/show/NCT04323839"
208,"NCT04312009","Losartan for Patients With COVID-19 Requiring Hospitalization",,"Not yet recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Losartan|Other: Placebo","Sequential Organ Failure Assessment (SOFA) Respiratory Score|28-Day Mortality|90-Day Mortality|Respiratory Failure Requiring Mechanical Ventilation|Number of 28-Day Ventilator-Free Days|Length of Hospital Stay|ICU Admission|ICU Length of Stay|Acute Kidney Injury|Hypotension Requiring Vasopressors|Sequential Organ Failure Assessment (SOFA) Total Score|Severity Assessment|Incidence of Respiratory Failure|Oxygen Saturation / Fractional Inhaled Oxygen (F/S)","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SURG-2020-28675","April 2, 2020","April 1, 2021","April 1, 2021","March 17, 2020",,"April 3, 2020","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04312009"
209,"NCT04313946","Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays","AI-COVID-Xr","Recruiting","No Results Available","COVID-19|Pneumonia, Viral|Influenza With Pneumonia|Flu Symptom|Flu Like Illness|Pneumonia, Interstitial|Pneumonia, Ventilator-Associated|Pneumonia Atypical","Diagnostic Test: Scanning Chest X-rays and performing AI algorithms on images","COVID-19 positive X-Rays|COVID-19 negative X-Rays","Professor Adrian Covic|Falcon Trading Iasi|Grigore T. Popa University of Medicine and Pharmacy","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Ecologic or Community|Time Perspective: Prospective","0110","March 18, 2020","August 16, 2020","August 18, 2020","March 18, 2020",,"April 2, 2020","U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale; Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute Università degli Studi di Trieste, Cremona, Italy|University of Medicine and Pharmacy Gr T Popa, Iaşi, Romania|Department of Cardiology at Chelsea and Westminster NHS hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04313946"
210,"NCT04315948","Trial of Treatments for COVID-19 in Hospitalized Adults","DisCoVeRy","Recruiting","No Results Available","Corona Virus Infection","Drug: Remdesivir|Drug: Lopinavir/ritonavir|Drug: Interferon Beta-1A|Drug: Hydroxychloroquine|Other: Standard of care","Percentage of subjects reporting each severity rating on a 7-point ordinal scale|Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale|The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.|Number of oxygenation free days in the first 28 days|Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.|Ventilator free days in the first 28 days|Incidence of new mechanical ventilation use during the trial.|Hospitalization|Mortality|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)|Changes from baseline in blood white cell count|Changes from baseline in haemoglobin|Changes from baseline in platelets|Changes from baseline in creatinine|Changes from baseline in blood electrolytes (including kaliemia)|Changes from baseline in prothrombine time|Changes from baseline in international normalized ratio (INR)|Changes from baseline in glucose|Changes from baseline in total bilirubin|Changes from baseline in alanine aminotransferase (ALT)|Changes from baseline in aspartate aminotransferase (AST)","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years and older   (Adult, Older Adult)","Phase 3","3100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C20-15","March 22, 2020","March 2023","March 2023","March 20, 2020",,"March 25, 2020","CHRU Lille, Lille, France|CHU Nantes, Nantes, France|APHP - Bichat Claude Bernard, Paris, France",,"https://ClinicalTrials.gov/show/NCT04315948"
211,"NCT04311177","Losartan for Patients With COVID-19 Not Requiring Hospitalization",,"Not yet recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Losartan|Other: Placebo","Hospital Admission|Change in PROMIS Dyspnea Functional Limitations|Change in PROMIS Dyspnea Severity|Fever Incidence Day 3|Fever Incidence Day 5|Fever Incidence Day 7|Fever Incidence Day 10|Severity of Symptoms upon Hospital Admission","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 2","516","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","SURG-2020-28683","April 2, 2020","April 1, 2021","April 1, 2021","March 17, 2020",,"April 3, 2020","Hennepin County Medical Center, Minneapolis, Minnesota, United States|M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04311177"
212,"NCT04335032","EPA-FFA to Treat Hospitalised Patients With SARS-CoV-2",,"Not yet recruiting","No Results Available","SARS-CoV-2","Drug: Eicosapentaenoic acid gastro-resistant capsules","Efficacy of EPA-FFA|Increase in oxygen saturation|PaO2/FiO2 >300mmHg increase|Reduction of IL-6|Mortality rate reduction|Reduction in ICU stays|Reducing hospitalisation days|reduction in need for mechanical ventilation|Fever reduction","S.L.A. Pharma AG","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 3","150","Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EPA-COV-001","April 13, 2020","July 13, 2020","July 31, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335032"
213,"NCT04252118","Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus",,"Recruiting","No Results Available","2019 Novel Coronavirus Pneumonia","Biological: MSCs","Size of lesion area by chest radiograph or CT|Side effects in the MSCs treatment group|Improvement of Clinical symptoms including duration of fever and respiratory|Time of nucleic acid turning negative|Rate of mortality within 28-days|CD4+ and CD8+ T celll count|Alanine aminotransferase|C-reactive protein|Creatine kinase","Beijing 302 Hospital|Innovative Precision Medicine Group (IPM), Hangzhou, China.|Wuhan Huoshenshan Hospital, Wuhan, China|Tianjin Haihe Hospital|VCANBIO CELL & GENE ENGINEERING CORP.,LTD, China|Shenzhen Third People's Hospital|Fifth Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020003D","January 27, 2020","December 2020","December 2021","February 5, 2020",,"February 26, 2020","Beijing 302 Military Hospital of China, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04252118"
214,"NCT04337788","Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease","COVIDeHPAD","Not yet recruiting","No Results Available","Coronavirus Infection","Other: telehealth applications","Impact of Gerontological telemonitoring on healthcare management for older adults living in Nursing Homes with symptoms of confirmed or probable COVID-19 disease (Death within 30 days).","University Hospital, Limoges","All","75 Years and older   (Older Adult)","Not Applicable","200","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","87RI20_0013","April 2020","July 2020","September 2020","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04337788"
215,"NCT04261426","The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia",,"Not yet recruiting","No Results Available","2019-nCoV","Drug: Intravenous Immunoglobulin|Other: Standard care","Clinical improvement based on the 7-point scale|Lower Murray lung injury score|28-day mortality|Duration of mechanical ventilation|Duration of hospitalization|Proportion of patients with negative RT-PCR results|Proportion of patients in each category of the 7-point scale|Proportion of patients with normalized inflammation factors|Frequency of Adverse Drug Events|Frequency of Serious Adverse Drug Events","Peking Union Medical College Hospital|Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IVIG-001","February 10, 2020","April 30, 2020","June 30, 2020","February 7, 2020",,"February 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04261426"
216,"NCT04273646","Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Novel Coronavirus Severe Pneumonia",,"Not yet recruiting","No Results Available","2019 Novel Coronavirus Pneumonia|COVID-19","Biological: UC-MSCs|Drug: Placebo","Pneumonia severity index|Oxygenation index (PaO2/FiO2)|Side effects in the UC-MSCs treatment group|28-days survival|Sequential organ failure assessment|C-reactive protein|Procalcitonin|Lymphocyte count|CD3+, CD4+ and CD8+ T celll count|CD4+/CD8+ratio","Wuhan Union Hospital, China|Wuhan Hamilton Bio-technology Co., Ltd, China.","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","48","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","202001","February 16, 2020","June 30, 2020","February 15, 2022","February 18, 2020",,"February 21, 2020","Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04273646"
217,"NCT04332016","COVID-19 Biological Samples Collection","COLCOV19-BX","Recruiting","No Results Available","Infection Viral","Other: biological samples collection","COVID-19 desease description","University Hospital, Bordeaux","All","up to 100 Years   (Child, Adult, Older Adult)",,"2000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CHUBX 2020/11","April 2, 2020","March 2023","March 2023","April 2, 2020",,"April 3, 2020","Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France",,"https://ClinicalTrials.gov/show/NCT04332016"
218,"NCT04255017","A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",,"Recruiting","No Results Available","2019-nCoV","Drug: Abidol hydrochloride|Drug: Oseltamivir|Drug: Lopinavir/ritonavir","Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery|Rate of undetectable viral RNA","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","400","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TJ20200128","February 1, 2020","June 1, 2020","July 1, 2020","February 5, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04255017"
219,"NCT04254874","A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",,"Recruiting","No Results Available","2019-nCoV","Drug: Abidol hydrochloride|Drug: Abidol Hydrochloride combined with Interferon atomization","Rate of disease remission|Time for lung recovery|Rate of no fever|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery|Rate of undetectable viral RNA","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TJ20200131","February 1, 2020","June 1, 2020","July 1, 2020","February 5, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04254874"
220,"NCT04275414","Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia","BEST-CP","Recruiting","No Results Available","Coronavirus Infections","Drug: Bevacizumab Injection","Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio|Degree of dyspnea (Liker scale)|Degree of dyspnea (VAS)|The area of lung lesions on Chest CT|The degree of lung exudation on Chest CT|SpO2|PaO2|CRP|hs-CRP|All-cause mortality","Qilu Hospital of Shandong University|Renmin Hospital of Wuhan University|Moriggia-Pelascini Gravedona Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QLEmer20200214","February 15, 2020","April 2020","May 2020","February 19, 2020",,"April 3, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China|Qilu Hospital of Shandong University, Jinan, Shandong, China|Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy",,"https://ClinicalTrials.gov/show/NCT04275414"
221,"NCT04316949","Predictors of Respiratory Failure in SARS-Cov-2 Infection",,"Recruiting","No Results Available","SARS-CoV-2 Pneumonia",,"Respiratory failure|Occurence of bacterial superinfection","University of Bologna","All","18 Years to 99 Years   (Adult, Older Adult)",,"350","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","PREDI-CO","March 20, 2020","April 30, 2020","May 31, 2020","March 20, 2020",,"April 7, 2020","University of Bologna - Department of Medical and Surgical Sciences, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT04316949"
222,"NCT04323761","Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection",,"Available","No Results Available","SARS-CoV2 Infection","Drug: Remdesivir",,"Gilead Sciences","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Treatment IND/Protocol",,"GS-US-540-5821",,,,"March 27, 2020",,"April 6, 2020","Huntington Hospital, Pasadena, California, United States|California Pacific Medical Center, San Francisco, California, United States|Regional Medical Center, San Jose, California, United States|Piedmont Fayette Hospital, Fayetteville, Georgia, United States|Ochsner Medical Center, New Orleans, Louisiana, United States|Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Holy Name Medical Center, Teaneck, New Jersey, United States|Maimonides Medical Center, Brooklyn, New York, United States|New York Presbyterian Hospital, Flushing, New York, United States|Mount Sinai South Nassau, Oceanside, New York, United States",,"https://ClinicalTrials.gov/show/NCT04323761"
223,"NCT04261270","A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",,"Recruiting","No Results Available","2019-nCoV Pneumonia","Drug: ASC09F+Oseltamivir|Drug: Ritonavir+Oseltamivir|Drug: Oseltamivir","Rate of comprehensive adverse outcome|Time of clinical remission|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no need for oxygen inhalation|Rate of undetectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery","Tongji Hospital","All","18 Years to 55 Years   (Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ASC09F-CTP-TJ-01","February 1, 2020","May 1, 2020","July 1, 2020","February 7, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04261270"
224,"NCT04332042","TOFAcitinib in SARS-CoV2 Pneumonia",,"Not yet recruiting","No Results Available","SARS-COv2 Related Interstitial Pneumonia","Drug: Tofacitinib","need of mechanical ventilation|need of admission in intensive care unit|death|rate of adverse events","Università Politecnica delle Marche","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOFACoV","April 10, 2020","June 20, 2020","July 10, 2020","April 2, 2020",,"April 2, 2020","Ospedali Riuniti di Ancona, Ancona, Marche, Italy",,"https://ClinicalTrials.gov/show/NCT04332042"
225,"NCT04311697","Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress","COVID-AIV","Not yet recruiting","No Results Available","Acute Respiratory Distress Syndrome|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Corona Virus Infection","Drug: Aviptadil by intravenous infusion + maximal intensive care|Drug: Normal Saline Infusion + Maximal intensive care","Mortality|PaO2:FiO2 ratio|TNF alpha|Multi-system organ failure free days","NeuroRx, Inc.|Relief Therapeutics Holding SA|Target Health Inc.|Lavin Consulting, LLC","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","120","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","COVID-AIV","April 2020","August 2020","September 2020","March 17, 2020",,"April 7, 2020","Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States|Robert I Grossman School of Medicine / NYU Langone Medical Center, New York, New York, United States|Rambam Health Care Campus, Haifa, Israel",,"https://ClinicalTrials.gov/show/NCT04311697"
226,"NCT04316728","Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19",,"Not yet recruiting","No Results Available","Coronavirus Infections","Device: VivaDiag™ COVID-19 lgM/IgG Rapid Test","Number of patients with constant negative results|Number of patients with positive test with a positive PCR for COVID-19|Overall Number of patients positive for COVID-19|Overall Number of patients negative for COVID-19|Number of patients with contrasting results|Reliability of the test|Positive HCW|Number of Chronic Patients","Centro Studi Internazionali, Italy|VivaChek Laboratories, Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","VivaDiag-2020","March 2020","September 2020","November 2020","March 20, 2020",,"March 20, 2020","Unità' Complesse di cure primarie (UCCP), ASP Catanzaro, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04316728"
227,"NCT04327349","Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial",,"Enrolling by invitation","No Results Available","Coronavirus Infections","Biological: Convalescent Plasma","Mortality changes in day 10|Mortality changes in day 30|Changes of C-reactive protein|Changes of Interleukin 6|Changes of tumor necrosis factor-α|Changes of PaO2/FiO2 Ratio|Changes of CD3|Changes of CD4|Changes of CD8|Changes of CD4/CD8 ratio|Changes of lymphocyte count|Changes of leukocyte count|Changes of alanine transaminase (ALT)|Changes of aspartate transaminase (AST)|Changes of alkaline phosphatase (ALP)|Changes of lactate dehydrogenase (LDH)|Changes of creatine phosphokinase (CPK)|Changes of Creatine kinase-MB (CK-MB)|Changes of Specific IgG|Radiological findings|Number of days ventilated|Length of hospitalization","Mazandaran University of Medical Sciences","All","30 Years to 70 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IR.MAZUMS.REC.1399.7330|IRCT20181104041551N1","March 28, 2020","May 20, 2020","September 30, 2020","March 31, 2020",,"March 31, 2020","Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04327349"
228,"NCT04328129","Household Transmission Investigation Study for COVID-19 in French Guiana","EPI-COVID-19","Recruiting","No Results Available","Coronavirus Infections|Severe Acute Respiratory Syndrome|SARS-CoV Infection","Procedure: Human biological samples","Evaluation of the extent of the virus transmission within households|Characterization of the secondary cases","Institut Pasteur|Institut Pasteur de la Guyane|Centre Hospitalier Andrée Rosemon de Cayenne","All","Child, Adult, Older Adult","Not Applicable","450","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Screening","2020-009","March 23, 2020","March 23, 2022","March 23, 2022","March 31, 2020",,"March 31, 2020","Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana|Institut Pasteur de la Guyane, Cayenne, French Guiana",,"https://ClinicalTrials.gov/show/NCT04328129"
229,"NCT04329195","ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic","ACORES-2","Not yet recruiting","No Results Available","History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection","Drug: 1: discontinuation of RAS blocker therapy|Drug: 2: continuation of RAS blocker therapy","Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)|Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28|Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.|Number of days alive free of oxygen.|Number of days alive outside hospital until day28|Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28|Number of days alive free of ICU admission until day28|Rate of all-cause mortality at day 28|Rate of cardiovascular death at day 28|Number of days alive free of acute kidney injury until hospital discharge","Assistance Publique - Hôpitaux de Paris|Groupe Hospitalier Pitié-Salpêtrière","All","18 Years and older   (Adult, Older Adult)","Phase 3","554","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200409","April 2020","May 2020","May 2020","April 1, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04329195"
230,"NCT04263402","The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia",,"Recruiting","No Results Available","2019-nCoV Severe Pneumonia","Drug: Methylprednisolone","Rate of disease remission|Rate and time of entering the critical stage|Rate of normal tempreture|Rate of respiratory symptom remission|Rate of lung imaging recovery|Rate of laboratory indicator recovery|Rate of undetectable viral RNA","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TJ20200201","February 1, 2020","June 1, 2020","July 1, 2020","February 10, 2020",,"March 17, 2020","Department and Institute of Infectious Disease, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04263402"
231,"NCT04331106","Survey of the Anxiety Associated With the SARS-CoV-2 Pandemic","CORA","Recruiting","No Results Available","Anxiety Related to the SARS-CoV-2 Pandemic","Diagnostic Test: Online Questionnaire","Characteristics of SARS-CoV-2-related anxiety|SARS-CoV-2-related anxiety symptoms|Self-efficacy and coping with SARS-CoV-2|Consequences of SARS-CoV-2 in the last three weeks.|General Illness Attitude|Media reporting|Ultra-brief screening scale for anxiety and depression|Change in characteristics of SARS-CoV-2-related anxiety|Change in SARS-CoV-2-related anxiety symptoms","Charite University, Berlin, Germany","All","18 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EA1/071/20","March 27, 2020","September 2020","September 2021","April 2, 2020",,"April 7, 2020","Charité-Universitätsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germany",,"https://ClinicalTrials.gov/show/NCT04331106"
232,"NCT02735707","Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","REMAP-CAP","Recruiting","No Results Available","Community-acquired Pneumonia, Influenza, COVID-19","Drug: Fixed-duration Hydrocortisone|Drug: Shock-dependent hydrocortisone|Drug: Ceftriaxone|Drug: Moxifloxacin or Levofloxacin|Drug: Piperacillin-tazobactam|Drug: Ceftaroline|Drug: Amoxicillin-clavulanate|Drug: Macrolide administered for 3-5 days|Drug: Macrolide administered for up to 14 days|Drug: Five-days oseltamivir|Drug: Ten-days oseltamivir|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine + lopinavir/ritonavir|Drug: Interferon-β1a|Drug: Anakinra","All-cause mortality|Days alive and outside of ICU|ICU Mortality|ICU length of stay|Hospital length of stay|Ventilator free days|Organ failure free days|Health-related Quality of life assessment|Proportion of intubated patients who receive a tracheostomy|Destination at time of hospital discharge|Readmission to the index ICU during the index hospitalization","MJM Bonten|Berry Consultants|Australian and New Zealand Intensive Care Research Centre|Medical Research Institute of New Zealand|Unity Health|UMC Utrecht","All","18 Years and older   (Adult, Older Adult)","Phase 4","6800","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","U1111-1189-1653|2015-002340-14|602525|16/631|APP1101719|158584","April 11, 2016","December 2021","June 2022","April 13, 2016",,"March 30, 2020","Wollongong Hospital, Sidney, New South Wales, Australia|St Vincent's Hospital Sydney, Sydney, New South Wales, Australia|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Nepean Hospital, Sydney, New South Wales, Australia|Royal Darwin Hospital,, Darwin, Northern Territory, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Logan Hospital, Brisbane, Queensland, Australia|Toowoomba Hospital, Toowoomba, Queensland, Australia|The Queen Elizabeth Hospital, Adelaide, South Australia, Australia|Bendigo Hospital, Bendigo, Victoria, Australia|University Hosptial Geelong, Geelong, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia|St John of God Hospital Midland, Perth, Western Australia, Australia|Fiona Stanley Hospital, Perth, Western Australia, Australia|St John of God Hospital Murdoch, Perth, Western Australia, Australia|AZ Sint-Jan, Brugge, Belgium|CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium|Universitair Ziekenhuis Antwerp, Edegem, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|St. Joseph's Healthcare Hamilton, Hamilton, Canada|Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada|St. Michael's Hospital Unity Health Toronto, Toronto, Canada|General County Hospital Požega, Požega, Croatia|University Hospital Centre Zagreb, Zagreb, Croatia|University Hospital for Infectious Diseases, Zagreb, Croatia|Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany|Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Köln, Cologne, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitätsklinikum Jena, Jena, Germany|Universitätsklinikum Leipzig, Leipzig, Germany|Universitäts Klinikum Tübingen, Tübingen, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Jósa András County Hospital, Nyíregyháza, Hungary|Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary|Almási Balogh Pál Kórház, Ózd, Hungary|Beaumont Hospital, Dublin, Ireland|St. Vincent's University Hospital, Dublin, Ireland|University Hospital Galway, Galway, Ireland|Meander Medisch Centrum, Amersfoort, Netherlands|Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|University Medical Center Groningen, Groningen, Netherlands|Leiden University Medical Center, Leiden, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Radboud University Medical Center, Nijmegen, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands|North Shore Hospital, Auckland, New Zealand|CVICU, Auckland City Hospital, Auckland, New Zealand|DCCM, Auckland City Hospital, Auckland, New Zealand|Middlemore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Waikato Hospital, Hamilton, New Zealand|Rotorua Hospital, Rotorua, New Zealand|Tauranga Hospital, Tauranga, New Zealand|Wellington Regional Hospital, Wellington, New Zealand|Whangarei Hospital, Whangarei, New Zealand|Centro Hospitalar do Medio Tejo, Abrantes, Portugal|Hospital Lusíadas Lisbon, Lisboa, Portugal|Clinical Hospital of Infectious and Tropical Diseases ""Dr. Victor Babes"", Bucharest, Romania|Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain|Hospital Universitario Reina Sofia, Córdoba, Spain|Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom|Southmead Hospital, Bristol, United Kingdom|University Hospital Coventry, Coventry, United Kingdom|Darlington Memorial Hospital, Darlington, United Kingdom|University Hospital of North Durham, Durham, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom|The James Cook University Hospital, Middlesbrough, United Kingdom|Milton Keynes University Hospital, Milton Keynes, United Kingdom|Northampton General Hospital, Northampton, United Kingdom|Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Poole Hospital NHS Foundation Trust, Poole, United Kingdom|Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom|Royal Berkshire Hospital, Reading, United Kingdom|University Hospital of North Tees, Stockton-on-Tees, United Kingdom|Royal Cornwall Hospital, Truro, United Kingdom|Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom|York Hospital, York, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02735707"
233,"NCT04327505","Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19","COVID-19-HBO","Not yet recruiting","No Results Available","Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)|Cytokine Storm|Infection Viral","Drug: Hyperbaric oxygen","PO2/FiO2 (Safety)|PO2/FiO2 (Efficacy)|Early Warning Score (NEWS) (Safety)|Early Warning Score (NEWS) (Efficacy)|Immunological response (Efficacy)|Mechanical ventilation (Efficacy)|SAE|Serious ADR|AE|Oxygen dose|Pulmonary CT (low-dose CT)|Chest X-ray|Chest ultrasound|Secondary infections|Mortality|ICU free days|ICU mortality|Hospital mortality|Micro RNA plasma (Biomarker)|MicroRNA/RNA PBMC (Explanatory)|Immunological response (Explanatory)|Viral load","Karolinska University Hospital|Karolinska Institutet|University of California, San Diego|Blekinge County Council Hospital","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2|Phase 3","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","K-2020-2611|2020-001349-37|4-1199/2020","April 25, 2020","October 31, 2021","December 31, 2022","March 31, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04327505"
234,"NCT04256395","Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19","COVID-19","Recruiting","No Results Available","Susceptibility to Viral and Mycobacterial Infection","Other: mobile internet survey on self-test","positive number diagnosed by national guideline in the evaluated population|distribution map of evaluated people|Effect of medical guidance by designated feedback questionnaire|mental scale of relief the mental anxiety and avoid unnecessary outpatient","Beijing Tsinghua Chang Gung Hospital|Institute for precision medicine of Tsinghua University|Institute for artificial intelligent of Tsinghua University|Chinese Medical Doctor Association|Institute for network behavior of Tsinghua University|school of clinical medicine of Tsinghua University","All","Child, Adult, Older Adult",,"300000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","RWS-BTCH-002","February 1, 2020","July 31, 2020","July 31, 2020","February 5, 2020",,"February 20, 2020","Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04256395"
235,"NCT04325919","Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong",,"Recruiting","No Results Available","Coronavirus Infections","Other: No intervention","Clinical|Virological|Microbiological","Chinese University of Hong Kong","All","18 Years and older   (Adult, Older Adult)",,"170","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","COVID-19 study 2020.076","February 24, 2020","February 28, 2021","June 17, 2021","March 30, 2020",,"March 30, 2020","Prince of Wales Hospital, Sha Tin, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04325919"
236,"NCT04324866","Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy",,"Not yet recruiting","No Results Available","Coronavirus Infection","Diagnostic Test: Nasopharyngeal swab","Point prevalence of COVID-19 infection|Incidence of COVID-19 infection|Percentage of subjects presenting fever or respiratory symptoms|Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments|Evaluate the relationship between COVID-19 infection and comorbid medical conditions","Universita di Verona|Azienda Ospedaliera Universitaria Integrata Verona","All","18 Years to 75 Years   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Gisondi 4","April 1, 2020","November 2020","December 2020","March 27, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04324866"
237,"NCT04305457","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19","NoCovid","Recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Drug: Nitric Oxide","Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation|Mortality|Time to clinical recovery","Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","18 Years and older   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NOgas mildCOVID-19","March 21, 2020","April 1, 2021","April 1, 2022","March 12, 2020",,"April 3, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04305457"
238,"NCT04324463","Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial","ACT COVID19","Not yet recruiting","No Results Available","Coronavirus|Severe Acute Respiratory Syndrome","Drug: Azithromycin|Drug: Chloroquine","Outpatients: Hospital Admission or Death|Inpatients: Invasive mechanical ventilation or mortality","Population Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHRI.ACT.COVID19","April 1, 2020","September 30, 2020","December 31, 2020","March 27, 2020",,"March 27, 2020","Hamilton Health Sciences, Hamilton, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04324463"
239,"NCT04320277","Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.","BARI-COVID","Recruiting","No Results Available","Pharmacological Action","Drug: Baricitinib","The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.|The percentage of patients achieving the remission; CRP, IL-6 and TNFα values at baseline and during the treatment course; the number of AEs.","Hospital of Prato","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HPrato-3","March 16, 2020","April 30, 2020","April 30, 2020","March 24, 2020",,"March 24, 2020","Fabrizio Cantini, Prato, Tuscany, Italy",,"https://ClinicalTrials.gov/show/NCT04320277"
240,"NCT04327570","In-depth Immunological Investigation of COVID-19.","COntAGIouS","Not yet recruiting","No Results Available","Coronavirus Infections","Other: Patient sampling","Clinical Features|Immune host response at systemic level|Immune host response at local level|Host genetic variation|Comparison severe and non-severe COVID-19 hospitalised patients|Correlation of findings with outcome|Correlation of immune profiling - microbiome","Universitaire Ziekenhuizen Leuven","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Other|Time Perspective: Prospective","COntAGIouS","March 27, 2020","September 30, 2020","September 30, 2020","March 31, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04327570"
241,"NCT04333368","Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS","STROMA-CoV2","Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome Coronavirus 2|Severe Acute Respiratory Distress Syndrome","Biological: Umbilical cord Wharton's jelly-derived human|Other: NaCl 0.9%","Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group|Lung injury score|Oxygenation index|In-hospital mortality|Mortality|Ventilator-free days|Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 > 200 (out of a prone positioning session)|Cumulative use of sedatives|Cumulative duration of use of sedatives|Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)|Cumulative use of neuromuscular blocking agents (other than used for intubation)|ICU-acquired weakness and delirium|Treatment-induced toxicity rate and adverse events up to day 28|Quality of life at one year (EQ5D-3L quality of life questionnaire)|Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level|Anti-HLA antibodies plasmatic dosage","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","APHP200395|2020-001287-28","April 1, 2020","June 30, 2020","May 31, 2021","April 3, 2020",,"April 3, 2020","Hôpital Pitié-Salpêtrière - APHP, Paris, France|Hôpital Européen Georges Pompidou - APHP, Paris, France",,"https://ClinicalTrials.gov/show/NCT04333368"
242,"NCT04325867","Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19","eCardioCovid19","Recruiting","No Results Available","Angina Pectoris|Acute Coronary Syndrome|Coronary Syndrome|Coronary Artery Disease|Angioplasty|Stent Restenosis|Hypertension|Heart Failure, Systolic|Depression, Anxiety|Covid-19|Isolation, Social","Other: Tele-medicine platform","Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients|Number of patients included in this platform|Number of consultations/sessions given","Professor Adrian Covic|Medical Sciences Academy - Romania|Victor Babes Clinical Hospital of Infectious Diseases - Bucharest|Grigore T. Popa University of Medicine and Pharmacy","All","Child, Adult, Older Adult","Not Applicable","200","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","GTP0032","March 31, 2020","October 1, 2020","October 1, 2020","March 30, 2020",,"April 1, 2020","Medical Sciences Academy, Bucharest, Romania|University of Medicine and Pharmacy Gr T Popa, Iasi, Romania",,"https://ClinicalTrials.gov/show/NCT04325867"
243,"NCT04323787","Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID19 Registry","VIRUS","Recruiting","No Results Available","Coronavirus","Other: observational","ICU and hospital mortality of COVID-19 patients|30 days mortality","Mayo Clinic","All","Child, Adult, Older Adult",,"50000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","20-002610","March 30, 2020","April 30, 2021","April 30, 2021","March 27, 2020",,"April 3, 2020","Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic in Florida, Jacksonville, Florida, United States|Society of Critical Care Medicine (150+ sites), Chicago, Illinois, United States|Rahul Kashyap, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04323787"
244,"NCT04338100","Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients","POCUSCO","Not yet recruiting","No Results Available","COVID|Coronavirus Infection","Procedure: Follow-up at 14 days","Risk of unfavourable outcome at D14|Risk of unfavourable outcome over time|Risk-stratification threshold values|Adding value of POCUS score to previous risk-stratification clinical rules|POCUS score and patient clinical status at D14|POCUS and CT scan correlation|POCUS versus CT scan risk-stratification performances|POCUS score evolution performances","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)",,"300","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2020-A00782-37","April 6, 2020","December 29, 2020","January 29, 2021","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04338100"
245,"NCT04327401","COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III","CODEX","Not yet recruiting","No Results Available","Coronavirus Infection|Pneumonia, Viral|Acute Respiratory Distress Syndrome","Drug: Dexamethasone","Ventilator-free days|Evaluation of the clinical status|All-cause mortality|Mechanical ventilation duration|Sequential Organ Failure Assessment (SOFA) Score","Luiz F. L. Reis, Ph.D.|Hospital Israelita Albert Einstein|Hospital do Coracao|Brazilian Research In Intensive Care Network|Ache Laboratorios Farmaceuticos S.A.|Hospital Sirio-Libanes","All","18 Years and older   (Adult, Older Adult)","Phase 3","290","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","codex_v1.1","April 1, 2020","August 30, 2020","August 30, 2020","March 31, 2020",,"April 1, 2020","Hospital Ana Nery, Salvador, Bahia, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Esoírito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Eurolatino Natal Pesquisas Médicas Ltda, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP - HCFMRP, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Santa Casa de Misericórdia, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04327401"
246,"NCT04329533","Effects of Using Mobile App on Perceived Stress During Coronavirus (""COVID 19"") Pandemic",,"Not yet recruiting","No Results Available","Perceived Stress|Anxiety|Sleep Disturbance","Other: ""Calm"" is a mindfulness meditation mobile app","Perceived Stress Scale|Hospital Anxiety and Depression Scale|PROMIS Sleep Disturbance Short Form Survey|Adherence|Participant Satisfaction|Coronavirus Questionnaire","University of Arizona","Female","18 Years to 99 Years   (Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","Pending UA IRB Approval","April 1, 2020","June 30, 2020","July 30, 2020","April 1, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04329533"
247,"NCT04280705","Adaptive COVID-19 Treatment Trial (ACTT)",,"Recruiting","No Results Available","Corona Virus Infection","Other: Placebo|Drug: Remdesivir","Percentage of subjects reporting each severity rating on an 8-point ordinal scale|Change from baseline in alanine transaminase (ALT)|Change from baseline in aspartate transaminase (AST)|Change from baseline in creatinine|Change from baseline in glucose|Change from baseline in hemoglobin|Change from baseline in platelets|Change from baseline in prothrombin time (PT)|Change from baseline in total bilirubin|Change from baseline in white blood cell count with differential|Change in National Early Warning Score (NEWS) from baseline|Clinical status using ordinal scale|Cumulative incidence of Grade 3 and 4 adverse events (AEs)|Cumulative incidence of serious adverse events (SAEs)|Discontinuation or temporary suspension of infusions|Duration of hospitalization|Duration of new non-invasive ventilation or high flow oxygen use|Duration of new oxygen use|Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Incidence of new non-invasive ventilation or high flow oxygen use|Incidence of new oxygen use|Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use|Mean change in the ordinal scale|Number of non-invasive ventilation/high flow oxygen free days|Number of oxygenation free days|Subject 14-day mortality|Subject 28-day mortality|Time to an improvement of one category using an ordinal scale|Time to an improvement of two categories using an ordinal scale|Time to discharge or to a National Early Warning Score (NEWS) of </= 2 and maintained for 24 hours, whichever occurs first|Ventilator/extracorporeal membrane oxygenation (ECMO) free days","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","440","NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20-0006","February 21, 2020","April 1, 2023","April 1, 2023","February 21, 2020",,"April 6, 2020","University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States|University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States|University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States|University of California Irvine Medical Center - Infectious Disease, Orange, California, United States|VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States|Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States|University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States|Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States|University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States|Cedars Sinai Medical Center, West Hollywood, California, United States|Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States|Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States|University of Florida Health Sciences Center, College of Public Health- Epidemiology, Gainesville, Florida, United States|Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States|University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States|Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States|University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States|Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States|National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States|Walter Reed Army Institute of Research - Clinical Trials Center, Silver Spring, Maryland, United States|Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States|University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States|University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States|Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States|University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States|Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States|New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States|University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States|Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States|Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States|Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States|University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States|Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States|University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States|University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States|Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States|EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States|The University of Washington - Virology Research Clinic, Seattle, Washington, United States|Providence Sacred Heart Medical Center, Spokane, Washington, United States|Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States|University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark|Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany|Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany|National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan|Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of|Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of|Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico|National Centre for Infectious Diseases (NCID), Singapore, Singapore|Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom|Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04280705"
248,"NCT04279197","Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu",,"Recruiting","No Results Available","Pulmonary Fibrosis Due to 2019-nCoV","Drug: N-acetylcysteine+ Fuzheng Huayu Tablet|Drug: N-acetylcysteine+Placebo","High-resolution computed tomography (HRCT) score|Lung function including FVC, FVC as a percentage of projected value and DLco|Times of acute exacerbation|Six-minute walk distance|Dyspnea Scores|Composite physiological index","ShuGuang Hospital|Hubei Hospital of Traditional Chinese Medicine|Jingmen No.1 People’s Hospital|Tongji Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","136","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Fzhy-ncp-2","February 15, 2020","December 2022","December 2022","February 21, 2020",,"February 21, 2020","Shuguang Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04279197"
249,"NCT04284046","CT Scores Predict Mortality in 2019-nCoV Pneumonia",,"Completed","No Results Available","CT Scores Predict Mortality in 2019-nCoV Pneumonia","Other: CT score","7-day mortality","Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","All","Child, Adult, Older Adult",,"39","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","CT2019-nCoV","January 31, 2020","February 18, 2020","February 18, 2020","February 25, 2020",,"February 25, 2020","Wuhan third hospital, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04284046"
250,"NCT04321174","COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir","CORIPREV-LR","Not yet recruiting","No Results Available","Coronavirus Infections|Post-exposure Prophylaxis","Drug: Lopinavir/ritonavir","Microbiologic evidence of infection|Adverse events|Symptomatic COVID-19 disease|Seropositivity|Days of hospitalization attributable to COVID-19 disease|Respiratory failure requiring ventilatory support attributable to COVID-19 disease|Mortality|Short-term psychological impact of exposure to COVID-19 disease|Long-term psychological impact of exposure to COVID-19 disease|Health-related quality of life","Darrell Tan|St. Michael's Hospital, Toronto","All","18 Months and older   (Child, Adult, Older Adult)","Phase 3","1220","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","CORIPREV-1","March 30, 2020","March 31, 2021","March 31, 2022","March 25, 2020",,"March 25, 2020","Sunnybrook Hospital, Toronto, Ontario, Canada|St. Michael's Hospital, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT04321174"
251,"NCT04318314","COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2","COVID19-HCW","Recruiting","No Results Available","Health Care Worker Patient Transmission|Coronavirus|Coronavirus Infections|Immunological Abnormality","Diagnostic Test: COPAN swabbing and blood sample collection","Seroconversion to SARS-CoV-2 positivity","University College, London|St. Bartholomew's Hospital|Royal Free Hospital NHS Foundation Trust|UCLH","All","18 Years and older   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","130852","March 18, 2020","December 31, 2020","December 31, 2021","March 23, 2020",,"March 26, 2020","Barts Heart Center, London, United Kingdom|Royal Free London NHS Foundation Trust, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04318314"
252,"NCT04322487","Simple, Safe, Same: Lung Ultrasound for COVID-19","LUSCOVID19","Not yet recruiting","No Results Available","Coronavirus|Epidemic Disease|Pneumonia, Viral","Diagnostic Test: Lung ultrasound","Lung ultrasound grading system for COVID-19 pneumonia","Catholic University of the Sacred Heart|Valle del Serchio General Hospital, Lucca, Italy|University of Trento, Trento, Italy|Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy|Bresciamed, Brescia, Italy|118 USL Nordovest Toscana, Lucca, Italy|General Hospital, Voghera, Italy|Lodi General Hospital, Lodi, Italy","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","0013226/20","April 1, 2020","December 31, 2020","January 15, 2021","March 26, 2020",,"March 27, 2020","Bresciamed, Brescia, Italy|Pulmonary Medicine Unit, Lodi General Hospital, Lodi, Italy|118 USL Nordovest Toscana, Lucca, Italy|Diagnostic and Interventional Ultrasound Unit, Valle del Serchio General Hospital, Lucca, Italy|Emergency Department, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy|Department of woman and child health and public health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Pulmonary Medicine Unit, Dept. Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy|Department of Information Engineering and Computer Science, Ultrasound Laboratory Trento, University of Trento, Trento, Italy|Emergency Medicine Unit, General Hospital, Voghera, Italy",,"https://ClinicalTrials.gov/show/NCT04322487"
253,"NCT04323592","Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome","MP-C19","Recruiting","No Results Available","Severe Acute Respiratory Syndrome (SARS) Pneumonia|Coronavirus Infections|ARDS, Human","Drug: Methylprednisolone|Other: standard care","Composite primary end-point|death|Admission to ICU|Endotracheal intubation (invasive mechanical ventilation)|reduction of C-reactive protein or CRP|Reduction of mechanical ventilation","University of Trieste","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2|Phase 3","104","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MP-19 023_2020","March 23, 2020","May 20, 2020","May 30, 2020","March 26, 2020",,"March 27, 2020","Marco Confalonieri, Trieste, TS, Italy","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04323592"
254,"NCT04335747","COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases",,"Not yet recruiting","No Results Available","Rheumatoid Arthritis|Psoriatic Arthritis|Axial Spondyloarthritis|Systemic Lupus Erythematosus|Giant Cell Arteritis","Other: COVID-19 infection","Disease activity|Immune modulating treatments|Biomarkers","Salome Kristensen|Aalborg University Hospital","All","18 Years and older   (Adult, Older Adult)",,"333","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20200401","April 8, 2020","August 1, 2021","September 1, 2021","April 6, 2020",,"April 7, 2020","Aalborg University Hospital, Aalborg, Denmark",,"https://ClinicalTrials.gov/show/NCT04335747"
255,"NCT04335188","COVID-19 Registry Rhineland-Palatinate (Germany)",,"Recruiting","No Results Available","COVID","Other: Prospective oberservational registry","Chest x-ray|Chest CT|Supportive care - ICU|Supportive care - oxygen therapy|Supportive care - ventilation|Medication|Therapeutic strategies|Lab parameters|Intra-hospital complications|Vital status at discharge","IHF GmbH - Institut für Herzinfarktforschung|Ministerium für Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-Pfalz","All","Child, Adult, Older Adult",,"4000","Other","Observational","Observational Model: Other|Time Perspective: Prospective","COVID-19 Registry","April 6, 2020","July 31, 2021","September 30, 2021","April 6, 2020",,"April 8, 2020","Klinikum der Stadt Ludwigshafen am Rhein GmbH, Klinik für Herzchirurgie, Ludwigshafen, RLP, Germany",,"https://ClinicalTrials.gov/show/NCT04335188"
256,"NCT04335773","COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology",,"Not yet recruiting","No Results Available","Pediatric Respiratory Diseases|COVID|Fatigue Post Viral",,"Risk Factors|Immunulogical mechanisms|Long term outcome","University Hospital, Akershus|St. Olavs Hospital|Helse Stavanger HF|Haukeland University Hospital|University Hospital of North Norway|Alesund Hospital|Norwegian Institute of Public Health|The University of New South Wales|University of Bristol|Sykehuset Ostfold|Nordlandssykehuset HF|Vestre Viken Hospital Trust|Helse Fonna|Levanger Hospital|Oslo University Hospital|Sykehuset Innlandet HF","All","up to 18 Years   (Child, Adult)",,"350","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20/03794","April 1, 2020","December 31, 2030","December 31, 2030","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335773"
257,"NCT04334629","LIBA Trial in COVID-19","LIBA","Not yet recruiting","No Results Available","Coronavirus|Respiratory Distress Syndrome|SARS-CoV Infection","Drug: Ibuprofen","Disease progression|Time to mechanical ventilation|Overall survival|Reduction in proportion of patients who require ventilation|Reduction in length of Critical Care stay|Reduction in length of Hospital stay|Modulation of serum pro- and anti-inflammatory cytokines|Reduction in duration of ventilation|Increase in ventilator-free days","King's College London|Guy's & St Thomas NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 4","230","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","282009","April 6, 2020","August 5, 2020","November 5, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04334629"
258,"NCT04330300","Coronavirus ACEi/ARB Investigation","CORONACION","Recruiting","No Results Available","Hypertension|COVID-19","Drug: Thiazide or Thiazide-like diuretics|Drug: Calcium Channel Blockers|Drug: ACE inhibitor|Drug: Angiotensin receptor blocker","Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)|Number of Covid-19 positive participants who die|Number of Covid-19 positive participants who require intubation in intensive care unit (ICU)|Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV)|Number of SARS-CoV-2 positive participants|Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization|24 hour mean systolic BP (mmHg) on ambulatory BP monitoring","National University of Ireland, Galway, Ireland","All","60 Years and older   (Adult, Older Adult)","Phase 4","2414","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","C.A. 2348","March 30, 2020","January 31, 2021","March 1, 2021","April 1, 2020",,"April 2, 2020","University Hospital Galway, Galway, Ireland",,"https://ClinicalTrials.gov/show/NCT04330300"
259,"NCT04338945","Impact of COVID-19 Emergency on Italian Surgical Residents",,"Enrolling by invitation","No Results Available","COVID","Behavioral: COVID-surgRES questionaire","Measure of the impact of COVID Emergency on surgical specialist training programs|Measure of impact of COVID Emergency on wellness of residents","Ospedale Policlinico San Martino","All","18 Years and older   (Adult, Older Adult)",,"1200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-surgRES-Italy","March 15, 2020","April 15, 2020","May 1, 2020","April 8, 2020",,"April 8, 2020","Ospedale Policlinico San Martino, Genova, Italy",,"https://ClinicalTrials.gov/show/NCT04338945"
260,"NCT04322565","Colchicine Efficacy in COVID-19 Pneumonia",,"Not yet recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral","Drug: Colchicine","Clinical improvement|Hospital discharge|Death|Clinical status|Mechanical venhtilation|Hospitalization|Time from death|Negativization COVID 19|Fever","Lucio Manenti|Azienda Ospedaliero-Universitaria di Parma","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COLCOVID01","April 1, 2020","May 30, 2020","June 30, 2020","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04322565"
261,"NCT04264858","Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients",,"Not yet recruiting","No Results Available","2019-nCoV|Immunoglobulin of Cured Patients","Drug: Immunoglobulin of cured patients|Drug: γ-Globulin","Time to Clinical Improvement (TTCI)|Clinical status assessed by the ordinal scale|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days]|Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days]|Dynamic changes of 2019-nCoV antibody titer in blood|Length of hospital stay (days)|All cause mortality","Wuhan Union Hospital, China","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WuhanUH-2019 nCoV-Ig","March 17, 2020","April 30, 2020","May 31, 2020","February 11, 2020",,"March 17, 2020","Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04264858"
262,"NCT04321811","Behavior, Environment And Treatments for Covid-19","BEAT19","Recruiting","No Results Available","Coronavirus","Other: Observation of patients with known, suspected, or at risk for COVID-19 infection","Define Natural Symptom Course|Time to Hospitalization|Time to Symptomatic Recovery","xCures|Genetic Alliance|LunaDNA|Cancer Commons|REDCap Cloud","All","18 Years and older   (Adult, Older Adult)",,"100000","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","XC-PCOR-COVID19","March 21, 2020","March 20, 2021","March 20, 2022","March 25, 2020",,"April 2, 2020","BEAT19.org, San Francisco, California, United States","""Study Protocol and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT04321811/Prot_ICF_000.pdf","https://ClinicalTrials.gov/show/NCT04321811"
263,"NCT04337502","Clinical and Radiomic Model of COVID-19",,"Completed","No Results Available","Coronavirus|Machine Learning","Diagnostic Test: Machine learning model","Predictive performance","Maastricht University|The Central Hospital of Wuhan","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","UM_2020_GY_COVID-19","December 23, 2019","January 20, 2020","March 3, 2020","April 7, 2020",,"April 7, 2020","The central hospital of Wuhan, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04337502"
264,"NCT04326452","Treating COVID-19 With a Bidirectional Oxygenation Valve",,"Recruiting","No Results Available","Coronavirus Infection","Device: bidirectional oxygenation mouthpiece","Pulse oximetry level|Respiratory rate|Heart rate|Blood pressure|Systemic carbon dioxide","TMC HealthCare|PEEP Medical, LLC","All","18 Years and older   (Adult, Older Adult)","Not Applicable","15","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID19PEEP2020|GO2 PEEP Study","March 27, 2020","May 1, 2020","June 1, 2020","March 30, 2020",,"April 1, 2020","TMC HealthCare, Tucson, Arizona, United States|Stanford University, Stanford, California, United States|Emory Saint Joseph's Hospital, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT04326452"
265,"NCT04335162","Cardiovascular Complications and COVID-19 (CovCardioVasc)","CovCardioVasc","Recruiting","No Results Available","COVID|Acute Coronary Syndrome|Myocardial Infarction|Myocarditis|Venous Thromboembolism|Deep Vein Thrombosis|Pulmonary Embolism",,"Determine the incidence of cardiomyopathies and venous thromboembolism|Mortality|Duration of mechanical ventilation|shock at day 28|length of stay in the intensive care unit","Centre Hospitalier Universitaire de Nice","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20reamedcovid19","February 28, 2020","August 28, 2020","August 28, 2020","April 6, 2020",,"April 6, 2020","CHU de Nice, Nice, France|Hôpitaux Universitaires Paris Centre - Hôpital Cochin, Paris, France",,"https://ClinicalTrials.gov/show/NCT04335162"
266,"NCT04312243","NO Prevention of COVID-19 for Healthcare Providers","NOpreventCOVID","Not yet recruiting","No Results Available","Coronavirus Infections|Healthcare Associated Infection","Drug: Inhaled nitric oxide gas","COVID-19 diagnosis|Positive SARS-CoV-2 rt-PCR test","Massachusetts General Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","470","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","NOpreCOVID-19","April 2, 2020","March 20, 2021","March 20, 2022","March 18, 2020",,"April 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04312243"
267,"NCT04321616","The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2",,"Not yet recruiting","No Results Available","SARS-CoV Infection|COVID 19|Acute Respiratory Distress Syndrome ARDS","Drug: Hydroxychloroquine|Drug: Remdesivir|Other: (Standard of Care) SoC","In-hospital mortality|Occurrence and duration of mechanical ventilation|Occurrence and duration of intensive care unit (ICU) treatment|Duration of hospital admittance|28 Day mortality|Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen|Occurrence of co-infections|Occurrence of organ dysfunction","Oslo University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","700","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","118684","March 26, 2020","August 2020","November 2020","March 25, 2020",,"April 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04321616"
268,"NCT04335279","Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program","SPIN-CHAT","Not yet recruiting","No Results Available","Scleroderma|Scleroderma, Systemic|Systemic Sclerosis","Other: SPIN-CHAT Program","Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0|Depression symptoms: Patient Health Questionnaire (PHQ-8)|Stress: Perceived Stress Scale (PSS)|Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)|Boredom: Multidimensional State Boredom Scale (MSBS-8)|Physical activity: International Physical Activity Questionnaire - modified for the elderly (IPAQ-E)|Frequency of social interactions|Adverse Effects","Lady Davis Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","162","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","SPIN-CHAT-001","April 15, 2020","June 3, 2020","June 3, 2020","April 6, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04335279"
269,"NCT04337047","Assessment of Distress in Crisis Situations During COVID-19",,"Enrolling by invitation","No Results Available","Stress, Psychological","Other: questionnaire assesment","quantify and qualify distress over a large population in times of pandemic crisis.|qualify demographic data vs distress over a large population in times of pandemic crisis.","Wefight","All","18 Years and older   (Adult, Older Adult)",,"2000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","WefightDistress20","March 31, 2020","April 30, 2020","May 31, 2020","April 7, 2020",,"April 7, 2020","Wefight, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT04337047"
270,"NCT04337008","Renin Angiotesnin System - CoronaVirus","SRA-COV","Recruiting","No Results Available","COVID 19","Other: blood draw","overactivity of the renin / aldosterone system","Assistance Publique Hopitaux De Marseille","All","18 Years and older   (Adult, Older Adult)","Not Applicable","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2020-16|2020-A00795-34","April 3, 2020","June 3, 2020","July 31, 2020","April 7, 2020",,"April 7, 2020","ASSISTANCE PUBLIQUE HÖPITAUX de MARSEILLE, Marseille, France",,"https://ClinicalTrials.gov/show/NCT04337008"
271,"NCT04331886","An Observational Study of Patients With Coronavirus Disease 2019","COVID-19","Not yet recruiting","No Results Available","COVID-19|Coronavirus",,"Natural history of COVID-19: Characteristics of COVID-19|Natural history of COVID-19: Participant demographics|Natural history of COVID-19: Treatment use|Time point of clinical response","Target PharmaSolutions, Inc.","All","Child, Adult, Older Adult",,"5000","Industry","Observational","Observational Model: Cohort|Time Perspective: Other","TARGET-COVID-19","April 2020","March 2021","March 2021","April 2, 2020",,"April 2, 2020",,,"https://ClinicalTrials.gov/show/NCT04331886"
272,"NCT04306055","Blood Donor Recruitment During Epidemic of COVID-19",,"Not yet recruiting","No Results Available","Blood Donation","Other: Questionnaire with precaution information|Other: Experimental: Questionnaire without precaution information","Differences of attitude about blood donation towards different questionnaires|Rates of blood donation during 3 weeks","Guangzhou Blood Center","All","18 Years to 60 Years   (Adult)","Not Applicable","1500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research","Blood donor recruitment","March 12, 2020","March 19, 2020","April 9, 2020","March 12, 2020",,"March 12, 2020",,,"https://ClinicalTrials.gov/show/NCT04306055"
273,"NCT04293887","Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients",,"Not yet recruiting","No Results Available","COVID-19|Recombinant Human Interferon α1β","Drug: Recombinant human interferon α1β","The incidence of side effects|Time from patient enrollment to clinical remission|Proportion of patients with normal body|Proportion of patients without dyspnea|Proportion of patients without cough|Proportion|The negative conversion rate of new coronavirus nucleic acid|Frequency of serious adverse drug events.","Tongji Hospital","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","328","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Zhaojp","March 1, 2020","May 30, 2020","June 30, 2020","March 3, 2020",,"March 3, 2020",,,"https://ClinicalTrials.gov/show/NCT04293887"
274,"NCT04329546","Understanding COVID",,"Recruiting","No Results Available","SARS-CoV-2 Viral Kinetics and Host Immune Responses","Other: NA (no intervention)","Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days|Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis","University Hospital, Geneva|University of Geneva, Switzerland","All","Child, Adult, Older Adult",,"250","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00516","March 27, 2020","January 31, 2022","March 31, 2022","April 1, 2020",,"April 1, 2020","University Hospitals of Geneva, Geneva, Switzerland",,"https://ClinicalTrials.gov/show/NCT04329546"
275,"NCT04320732","Risk Factors for Community- and Workplace Transmission of COVID-19",,"Recruiting","No Results Available","Coronavirus","Behavioral: Observation of behavior and COVID-19 infection will be conducted.","Rate of COVID-19 infection","Oslo University Hospital|Age Labs AS","All","18 Years and older   (Adult, Older Adult)",,"50000","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","REK-124170","March 27, 2020","March 27, 2022","March 20, 2030","March 25, 2020",,"March 31, 2020","Oslo University Hospital, Oslo, Norway",,"https://ClinicalTrials.gov/show/NCT04320732"
276,"NCT04333654","Hydroxychloroquine in Outpatient Adults With COVID-19",,"Recruiting","No Results Available","Coronavirus Infection","Drug: Hydroxychloroquine SAR321068|Drug: Placebo","Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)|Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)|Change from baseline to Day 5 in nasopharyngeal SARS-CoV-2 viral load|Number of participants by PCR result status (positive or negative)|Number of participants with COVID-19 symptoms by severity|Time to resolution of COVID-19 Symptoms|Time to resolution of fever|Percentage of participants with resolution of fever|Percentage of participants hospitalized|Number of participants with Adverse Events","Sanofi","All","18 Years and older   (Adult, Older Adult)","Phase 1","210","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16855|2020-001269-35|U1111-1249-6168","March 31, 2020","May 2020","May 2020","April 3, 2020",,"April 3, 2020","Investigational site number 8401001, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04333654"
277,"NCT04337489","Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)","REMOTE-COVID","Not yet recruiting","No Results Available","Coronavirus","Device: SensiumVitals wearable sensor","Deterioration resulting in healthcare review|Hospitalisation|Participant anxiety|Participant depression","Imperial College London|CW+ Charity","All","18 Years to 95 Years   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REMOTE-COVID","April 1, 2020","April 1, 2021","April 1, 2021","April 7, 2020",,"April 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04337489"
278,"NCT04296643","Medical Masks vs N95 Respirators for COVID-19",,"Not yet recruiting","No Results Available","Coronavirus|N95|Medical Mask","Device: Medical Mask|Device: N95 respirator","RT-PCR confirmed COVID-19 infection|Acute respiratory illness|Absenteeism|Lower respiratory infection|Pneumonia|ICU admission|Mechanical ventilation|Death","McMaster University|Vancouver Coastal Health|University of Alberta|Dalhousie University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","576","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","20006014","April 1, 2020","December 1, 2020","January 1, 2021","March 5, 2020",,"March 5, 2020",,,"https://ClinicalTrials.gov/show/NCT04296643"
279,"NCT04319016","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy","COVID-preg","Recruiting","No Results Available","Infection Viral","Other: pregnant women with laboratory-confirmed 2019-n-CoV","Maternal and perinatal outcomes","Federico II University","Female","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Other","145/20","January 1, 2020","April 30, 2020","May 1, 2020","March 24, 2020",,"April 1, 2020","Gabriele Saccone, Napoli, Italy",,"https://ClinicalTrials.gov/show/NCT04319016"
280,"NCT04302688","Accurate Classification System for Patients With COVID-19 Pneumonitis",,"Completed","No Results Available","Pneumonitis",,"survival status","Renmin Hospital of Wuhan University","All","Child, Adult, Older Adult",,"669","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","COVID-19 WU1","December 10, 2019","February 10, 2020","March 4, 2020","March 10, 2020",,"March 10, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04302688"
281,"NCT04333849","Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19","TOVID-49","Recruiting","No Results Available","Coronavirus",,"Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).|proportion of elderly people with loss of functional independence to communicate with their relatives.|level of satisfaction of patients who have benefited from a telephone call.|level of satisfaction of patients who have benefited from a videophone call.|satisfaction level of older people according to the means of communication used.|impact of age on the preferred means of communication.","University Hospital, Angers","All","70 Years and older   (Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020/29","March 27, 2020","September 2020","September 2020","April 3, 2020",,"April 8, 2020","Angers University Hospital, Angers, France",,"https://ClinicalTrials.gov/show/NCT04333849"
282,"NCT04279899","The Investigation of the Neonates With or With Risk of COVID-19",,"Recruiting","No Results Available","Neonatal Infection|Perinatal Problems|Infectious Disease",,"The death of newborns with COVID-19|The SARS-CoV-2 infection of neonates born to mothers with COVID-19|The Chinese standardized Denver Developmental Screening Test (DDST) in neonates with or with risk of COVID-19|The small for gestational age newborns in the neonates born to mothers with COVID-19|The preterm delivery of neonates born to mothers with COVID-19|The disease severity of neonates with COVID-19","Children's Hospital of Fudan University","All","up to 28 Days   (Child)",,"100","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","CHFudanU_NNICU14","February 1, 2020","November 30, 2020","December 31, 2020","February 21, 2020",,"February 21, 2020","Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China|Children Hospital of Fudan University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04279899"
283,"NCT04290871","Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.","NOSARSCOVID","Withdrawn","No Results Available","Coronavirus|SARS (Severe Acute Respiratory Syndrome)","Drug: Nitric Oxide Gas","SARS-free patients at 14 days|Survival at 28 days|Survival at 90 days|SARS-free days at 28 days|SARS -free days at 90 days|Renal Replacement Therapy|Liver Failure|Mechanical Support of Circulation|PaO2/FiO2 ratio in ambient air","Xijing Hospital|Massachusetts General Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","NO-SARS-COVID-19","March 23, 2020","March 1, 2021","March 1, 2022","March 2, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04290871"
284,"NCT04337151","Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment",,"Recruiting","No Results Available","MAGEC Rod","Device: MAGEC Spine Rod|Diagnostic Test: Titanium blood test","Titanium level","Royal National Orthopaedic Hospital NHS Trust","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","RNOH MAGEC","April 2020","January 2021","March 2021","April 7, 2020",,"April 7, 2020","Royal National Orthopaedic Hospital, Stanmore, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04337151"
285,"NCT04320238","Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff",,"Recruiting","No Results Available","2019 Novel Coronavirus Infection","Drug: recombinant human interferon Alpha-1b|Drug: thymosin alpha 1","new-onset COVID-19|Number of Participants with coronavirus related symptoms|Number of Participants with adverse effect","Shanghai Jiao Tong University School of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","2944","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","Interferon_prophylaxis","January 21, 2020","May 2020","June 2020","March 24, 2020",,"March 31, 2020","Taihe Hospital, Shiyan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04320238"
286,"NCT04316884","Mechanisms for Organ Dysfunction in Covid-19","UMODCOVID19","Recruiting","No Results Available","COVID-19|Organ Dysfunction Syndrome Sepsis|Organ Dysfunction Syndrome, Multiple|Septic Shock|Acute Kidney Injury|Acute Respiratory Distress Syndrome",,"Acute Kidney Injury|ARDS|30 day mortality|1 year mortality|Chronic Kidney Disease|SOFA-score","Uppsala University","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","EPN 2017/043 Covid19","March 12, 2020","December 31, 2020","December 31, 2021","March 20, 2020",,"March 20, 2020","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT04316884"
287,"NCT04328454","Clinical Characteristics and Prognostic Factors of Patients With COVID-19",,"Recruiting","No Results Available","Coronavirus","Other: retrospective analysis","Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation","Shanghai 10th People's Hospital|Chibi People's Hospital, Hubei Province","All","18 Years and older   (Adult, Older Adult)",,"120","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","HBCBH-IEC-2020-101","January 30, 2020","April 2, 2020","April 15, 2020","March 31, 2020",,"March 31, 2020","Shanghai 10th People's Hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04328454"
288,"NCT03808922","Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study",,"Recruiting","No Results Available","Lower Respiratory Tract Infection|Parainfluenza|Immunocompromised|COVID-19","Drug: DAS181|Drug: Placebo|Drug: DAS181 COVID-19|Drug: DAS181 OL","Percent of subjects who Return to Room Air (RTRA) (main study)|Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)|All-cause mortality rate (main study)|Time (in days) to RTRA (main study)|Percent of subjects who achieve clinical stability (main study)|Percent of subjects discharged (without mortality and hospice) (main study)|Time (in days) to first hospital discharge (without hospice) (main study)|Total number of inpatient days (main study)|Baseline SAD-RV infection-related mortality rate (main study)|Change in pulmonary function (FEV1% predicted) (main study)|Time to improved COVID19 clinical status (Sub-study)|Time to RTRA|Time to Clinical stability|Time to SARS-CoV-2 RNA in the respiratory specimens being undetectable|Time to Clinical deterioration|Time to Discharge from hospital (without readmission before Day 28).|Time to Death (all causes)","Ansun Biopharma, Inc.","All","Child, Adult, Older Adult","Phase 3","250","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","DAS181-3-01|2018-004318-16","May 23, 2019","April 30, 2021","December 28, 2021","January 18, 2019",,"April 2, 2020","City of Hope cancer Center, Duarte, California, United States|UCLA, Los Angeles, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Medical Center, Fairway, Kansas, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Cook Children's, Fort Worth, Texas, United States|MD Anderson, Houston, Texas, United States|VCU Health System, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Westmead Hospital, Sydney, New South Wales, Australia|The Wesley Hospital, Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Seoul National University Bundang Hospital, Seongnam-si, Guenoggi-do, Korea, Republic of|Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of|Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of|Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of|National Taiwan University Hospital, Zhongzheng Dist., Taipei City, Taiwan",,"https://ClinicalTrials.gov/show/NCT03808922"
289,"NCT04327388","Sarilumab COVID-19",,"Recruiting","No Results Available","Corona Virus Infection","Drug: Sarilumab SAR153191|Drug: Placebo","Phase 2: Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner|Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale|Phase 2: The time to improvement in oxygenation|Phase 2: Mean change in 7-point ordinal scale from baseline to Day 15|Phase 2: Clinical status using the 7-point ordinal scale at Day 15|Phase 2: Time to improvement of two categories from admission using the 7-point ordinal scale|Phase 2 and 3 : Time to resolution of fever|Phase 2 and 3 : Time to improvement in oxygenation|Phase 2 and 3: Time to resolution of fever and improvement in oxygenation|Phase 2 and 3:Time to change in NEWS2 from baseline|Phase 2 and 3: Time to NEWS2 of <2 and maintained for 24 hours|Phase 2 and 3: Mean change from baseline to days 3, 5, 8, 11, 15, and 29 in NEWS2|Phase 2 and 3:Days with fever|Phase 2 and 3: Alive off supplemental oxygen at day 29|Phase 2 and 3: Days of resting respiratory rate >24 breaths/min|Phase 2 and 3:Days of hypoxemia|Phase 2 and 3: Days of supplemental oxygen use|Phase 2 and 3: Time to saturation ≥94% on room air|Phase 2 and 3: Ventilator free days in the first 28 days (to day 29)|Phase 2 and 3: The number of patients with Initiation of mechanical ventilation, non-invasive ventilation, or use of high flow nasal cannula|Phase 2 and 3: Proportion of patients requiring rescue medication during the 28-day period|Phase 2 and 3: The number of patients transferred to the ICU or the need to transfer to the ICU (if the ICU is not available)|Phase 2 and 3: Days of hospitalization among survivors|Phase 2 and 3: Incidence of death|Phase 3: Mean change in the 7-point ordinal scale from baseline to days 3, 5, 8, 11, 15, and 29 (or until discharge)|Phase 3: Clinical status using the 7-point ordinal scale at days 3, 5, 8, 11,15, and 29|Phase 3: Time to improvement of two categories from admission using the 7-point ordinal scale|Phase 2 and 3: Incidence of serious adverse events|Phase 2 and 3: The incidence of major or opportunistic bacterial or fungal infections|Phase 2 and 3: The incidence of major or opportunistic bacterial or fungal infections in patients with grade 4 neutropenia|Phase 2 and 3: The incidence of hypersensitivity reactions, infusion reactions, gastrointestinal perforation|The number of patients with clinically significant laboratory abnormalities","Sanofi|Regeneron Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","EFC16844|U1111-1249-6021","March 29, 2020","July 2020","June 2021","March 31, 2020",,"April 8, 2020","Investigational Site Number 1240001, Montreal, Canada|Investigational Site Number 2500001, Bordeaux Cedex, France|Investigational Site Number 2500003, Strasbourg, France|Investigational Site Number 7240003, Barcelona, Spain|Investigational Site Number 7240004, Barcelona, Spain|Investigational Site Number 7240002, Madrid, Spain|Investigational Site Number 7240005, Madrid, Spain|Investigational Site Number 7240001, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04327388"
290,"NCT04325906","Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS",,"Not yet recruiting","No Results Available","Prone Positioning|High Flow Nasal Cannula|Acute Respiratory Distress Syndrome|Corona Virus Infection","Device: high flow nasal cannula (HFNC)|Procedure: Prone positioning (PP)","Treatment failure|Intubation rate|Efficacy of PP","Rush University Medical Center|Medical College of Wisconsin","All","18 Years and older   (Adult, Older Adult)","Not Applicable","346","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-19-HFNC+PP","April 6, 2020","May 31, 2020","June 30, 2020","March 30, 2020",,"April 3, 2020","Rush University Medical Center, Chicago, Illinois, United States|Medical College of Wisconsin, Wauwatosa, Wisconsin, United States",,"https://ClinicalTrials.gov/show/NCT04325906"
291,"NCT04325893","Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease","HYCOVID","Recruiting","No Results Available","Coronavirus","Drug: Hydroxychloroquine|Drug: Placebo","Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.|Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14|Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.|Number of all-cause mortality at day 14|Number of all-cause mortality at day 28|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5|Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10|The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.|Number of all-cause mortality at day 28 in patients aged 75 and older|Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older|Rate of severe adverse events at day 28|Number of all-cause mortality at day 14 in patients aged 75 and older","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)","Phase 3","1300","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","49RC20_0071","April 2020","September 2020","September 2020","March 30, 2020",,"April 8, 2020","CH Agen, Agen, France|CHU Amiens, Amiens, France|CHU Angers, Angers, France|APHP Avicenne, Bobigny, France|CHU Brest, Brest, France|CHU Caen, Caen, France|CH Cherbroug, Cherbourg, France|CH Cholet, Cholet, France|CH Colmar, Colmar, France|APHP Henri Mondor, Créteil, France|CHU Dijon, Dijon, France|CHD Vendée, La Roche-sur-Yon, France|CH Laval, Laval, France|CH Le Mans, Le Mans, France|CHU Limoges, Limoges, France|CH Lorient, Lorient, France|CH Melun, Melun, France|CHU Nantes, Nantes, France|Hôpital Privé du Confluent, Nantes, France|CH Niort, Niort, France|CHR Orléans, Orléans, France|APHP Saint-Antoine, Paris, France|La Pitié-Salpétrière, Paris, France|CHU Poitiers, Poitiers, France|CH Pointoise, Pontoise, France|CH Quimper, Quimper, France|CH Saint-Brieuc, Saint-Brieuc, France|CH Saint-Nazaire, Saint-Nazaire, France|CHU Saint-Etienne, Saint-Étienne, France|CHU Toulouse, Toulouse, France|CH Tourcoing, Tourcoing, France|CHU Tours, Tours, France|CH Valenciennes, Valenciennes, France|Clinique Tessier Valenciennes, Valenciennes, France|CH Vannes, Vannes, France|CH Versailles, Versailles, France|CH Princesse Grace, Monaco, Monaco",,"https://ClinicalTrials.gov/show/NCT04325893"
292,"NCT04338906","Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19","CLOCC","Not yet recruiting","No Results Available","COVID","Drug: Camostat Mesilate|Drug: Placebo|Drug: Hydroxychloroquine","Not hospitalized|Time to improvement of 2 categories from admission on a 7-point ordinal scale|Proportion of participants in each group with normalization of fever|Proportion of participants in each group with oxygen saturation > 94% on room air for >24h|Time to fever normalization (if febrile at baseline)|Time to first negative SARS-CoV-2 PCR in NP swap (if pos. at baseline)|Time to first negative SARS-CoV-2 PCR in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)|Duration of oxygen therapy|Proportion of participants in each group with need for mechanical ventilation|Duration of hospitalization|All cause mortality","Heinrich-Heine University, Duesseldorf|Universitätsklinikum Hamburg-Eppendorf|University Hospital, Frankfurt|St. Georg Hospital Leipzig, Germany|Hospital Schwabing Munich, Germany|Missioklinik, Wuerzburg, Germany","All","18 Years and older   (Adult, Older Adult)","Phase 4","334","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CLOCC-2020","June 1, 2020","June 1, 2021","December 31, 2021","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04338906"
293,"NCT04292340","Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19",,"Recruiting","No Results Available","Coronavirus",,"The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|Numbers of participants with different Clinical outcomes|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0","Shanghai Public Health Clinical Center","All","Child, Adult, Older Adult",,"15","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","Anti-SARS-CoV-2","February 1, 2020","July 31, 2020","December 31, 2020","March 3, 2020",,"March 3, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04292340"
294,"NCT04326114","Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19",,"Not yet recruiting","No Results Available","Disease, Infectious|Respiratory Disease|Safety Issues|Effectiveness","Device: Inspiratory training device|Device: Expiratory training device","COVID-19 disease diagnosis|COVID-19 disease symptoms severity|Adverse effects","Universidad Complutense de Madrid","All","18 Years and older   (Adult, Older Adult)","Not Applicable","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","Covid_ISCIII 20/265-E_BS","April 26, 2020","September 26, 2020","October 12, 2020","March 30, 2020",,"March 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04326114"
295,"NCT04325048","Clinical Evaluation of Cordio Application in Adult COVID19 Virus Positive Patients",,"Not yet recruiting","No Results Available","Coronavirus Infection","Device: Cordio App","Voice anaysis","Cordio Medical","All","18 Years and older   (Adult, Older Adult)",,"5000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","COV001","April 2020","June 2021","September 2021","March 27, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04325048"
296,"NCT04324047","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients","CORIMUNO-19","Recruiting","No Results Available","Corona Virus Infection",,"Survival|WHO progression scale COVID 19","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","APHP200375|2020-001246-18","March 27, 2020","March 27, 2021","December 31, 2021","March 27, 2020",,"April 1, 2020","Kremlin Bictre APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|Hegp Aphp, Paris, Ile De France, France",,"https://ClinicalTrials.gov/show/NCT04324047"
297,"NCT04315870","Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.","I-COVID","Recruiting","No Results Available","Infection Viral","Other: pregnant women with laboratory-confirmed 2019-n-CoV","Maternal and perinatal outcomes","Federico II University","Female","18 Years to 50 Years   (Adult)",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Other","5/20","January 1, 2020","April 20, 2020","April 30, 2020","March 20, 2020",,"March 20, 2020","University of Naples Federico II, Napoli, Italy",,"https://ClinicalTrials.gov/show/NCT04315870"
298,"NCT04337918","Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection","NOCOVID","Not yet recruiting","No Results Available","Corona Virus Infection","Drug: NORS (Nitric Oxide Releasing Solution)","Prevention Primary Endpoint|Treatment Sub Study Primary Endpoint|Prevention Secondary Endpoint|Treatment Sub Study Secondary Endpoint","Sanotize Research and Development corp.|The Emmes Company, LLC","All","19 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention","COVID-CTP-01","April 6, 2020","July 31, 2020","September 30, 2020","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04337918"
299,"NCT04326036","Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection","GARM-COVID19","Enrolling by invitation","No Results Available","Pulmonary Alveolar Proteinosis|COPD|Idiopathic Pulmonary Fibrosis|Viral Pneumonia|Coronavirus Infection|Interstitial Lung Disease","Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)|Device: Centricyte 1000|Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution|Drug: Liberase Enzyme (Roche)|Drug: Sterile Normal Saline for Intravenous Use","Incidence of Treatment-Emergent Adverse Events|Pulmonary Function Analysis|Digital Oximetry","Healeon Medical Inc|Robert W. Alexander, MD","All","18 Years to 90 Years   (Adult, Older Adult)","Early Phase 1","10","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GARM COVID19","March 25, 2020","November 1, 2021","December 31, 2021","March 30, 2020",,"March 31, 2020","Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States",,"https://ClinicalTrials.gov/show/NCT04326036"
300,"NCT04322396","Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19","ProPAC-COVID","Not yet recruiting","No Results Available","Virus Diseases|Infection Viral","Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet","Number of days alive and discharged from hospital within 14 days|Categorization of hospitalization status|Admitted to intensive care unit, if admitted to ICU then length of stay|Have used Non-invasive ventilation (NIV) during hospitalization|Mortality|Length of hospitalization|Days alive and discharged from hospital|Number of readmissions (all causes)|Number of days using non-invasive ventilation (NIV)|Change in patient's oxygen partial pressure|Change in patient's carbondioxid partial pressure|Level of pH in blood|Time for no oxygen supplement (or regular oxygen supplement ""LTOT"")","Chronic Obstructive Pulmonary Disease Trial Network, Denmark","All","Child, Adult, Older Adult","Phase 4","226","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KronLungesyg_COVID_19_protokol","April 1, 2020","October 31, 2020","March 31, 2021","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04322396"
301,"NCT04274322","Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool",,"Active, not recruiting","No Results Available","Critically Ill|Coronavirus Infections","Other: Nutrition support","28-day all cause mortality|All cause infection|The rate of complications|Length of ICU stay|Duration of mechanical ventilation","Peking University Third Hospital|School of Pharmaceutical Sciences, Peking University, Beijing, China|Department of Medicine, Queen's University, Kingston, Ontario, Canada","All","18 Years and older   (Adult, Older Adult)",,"117","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COV_NUTRIC","February 19, 2020","April 4, 2020","July 2020","February 18, 2020",,"April 8, 2020","Peking University Third Hospital, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04274322"
302,"NCT04324073","Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI","CORIMUNO-SARI","Recruiting","No Results Available","Corona Virus Infection","Drug: Sarilumab","Survival without needs of ventilator utilization at day 14.|WHO progression scale <=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14|WHO progression scale <=7 at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-2","March 27, 2020","March 27, 2021","December 31, 2021","March 27, 2020",,"April 1, 2020","Kremlin Bicetre hospital APHP, Le Kremlin-Bicêtre, Ile De France, France|Cochin Aphp, Paris, Ile De France, France|HEGP, Paris, Ile De France, France|NECKER Hospital, Paris, France",,"https://ClinicalTrials.gov/show/NCT04324073"
303,"NCT04321278","Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)",,"Recruiting","No Results Available","Coronavirus Infections|Pneumonia, Viral","Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine","Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death","Hospital Israelita Albert Einstein|EMS|Hospital do Coracao|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|Cristália Produtos Químicos Farmacêuticos Ltda.","All","18 Years and older   (Adult, Older Adult)","Phase 3","440","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","30155020.5.1001.0071","March 28, 2020","August 30, 2020","August 30, 2020","March 25, 2020",,"April 1, 2020","Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil|Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil|Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Universitário Onofre Lopes, Natal, Rio Grande Do Norte, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|AMICO Saude LTDA, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil|Santa Casa de Misericórdia, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT04321278"
304,"NCT04260594","Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus",,"Not yet recruiting","No Results Available","2019-nCoV","Drug: Arbidol|Other: basic treatment","Virus negative conversion rate in the first week|Virus negative conversion rate|Antipyretic rate|Symptom relief time|Finger oxygen improvement rate|Disease progression rate|Mortality rate|Incidence of severe adverse reactions|Change curve of peripheral blood lymphocyte count","Jieming QU|Ruijin Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","380","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Abdrcspc202001","February 7, 2020","July 1, 2020","December 30, 2020","February 7, 2020",,"February 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04260594"
305,"NCT04314232","Mechanisms to Morbidity and Mortality for Covid-19","COVID MECH","Not yet recruiting","No Results Available","Coronavirus|SARS",,"Change in viral expression in association to organspecific biomarkers","University Hospital, Akershus","All","18 Years and older   (Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","117589","March 23, 2020","December 31, 2021","December 31, 2021","March 19, 2020",,"March 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04314232"
306,"NCT04330261","Clinical Characteristics and Outcomes of Pediatric COVID-19","PERN-COVID-19","Recruiting","No Results Available","COVID-19|SARS-CoV-2 Infection|Pediatric ALL|Pneumonia, Viral|Pandemic Response","Other: Exposure (not intervention) - SARS-CoV-2 infection","Clinical characteristics of children with SARS-CoV-2|Factors associated with severe COVID-19 outcomes|Health care resource utilization for COVID-19 patient management|Sensitivity and specificity of COVID-19 case screening policies","University of Calgary","All","up to 18 Years   (Child, Adult)",,"12500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","REB18-0107_MOD9","March 18, 2020","March 17, 2021","March 17, 2022","April 1, 2020",,"April 1, 2020","University of Calgary/Alberta Children's Hospital, Calgary, Alberta, Canada",,"https://ClinicalTrials.gov/show/NCT04330261"
307,"NCT04336748","HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers",,"Not yet recruiting","No Results Available","Sars-CoV2|Infection Viral|Healthcare Worker|Prophylaxis","Drug: Hydroxychloroquine","Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR|Viral load during SARS-CoV-2 infection|Seroconversion during the study period|Incidence of any acute respiratory infection|Days of sick leave","Medical University of Vienna","All","18 Years and older   (Adult, Older Adult)","Phase 3","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","HCQ prophylaxis for COVID19","April 2020","July 2020","August 2020","April 7, 2020",,"April 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04336748"
308,"NCT04326426","ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection",,"Not yet recruiting","No Results Available","Coronavirus Infection","Drug: Tradipitant|Drug: Placebo","Proportion of participants with normalization of fever and oxygen saturation by day 14|Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)|Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples|In-hospital mortality|Mean change in NEWS2 score from baseline|Understand the effect of genetics for treatment response through whole genome sequence of the participant and the COVID-19 virus|Reduction from baseline of NRS for cough","Vanda Pharmaceuticals","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 3","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","VLY-686-3501","April 1, 2020","August 1, 2020","August 31, 2020","March 30, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04326426"
309,"NCT04327180","PREdiction of DIagnosed Covid-19 infecTion in IUC Patients","PREDICT","Recruiting","No Results Available","Infection Viral|Coronavirus|ARDS|Pneumonia",,"Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU|Coinfections|Respiratory dysfunction requiring mechanical ventilation|Sequential Organ Failure Assessment (SOFA) Score|SAPS II score|Disseminated Intravascular Coagulation (DIC) score|Number of days on vasopressive amines|Occurrence of an event of venous or arterial thromboembolic disease|Number of days with extra renal treatment (ERA)|Number of patients alive after ICU stay less than 28 days will be tracked|Short Form 36|Hospital anxiety and depression scale (HADS)|Impact of Event Scale - revised (IES-R)|Post-traumatic stress disorder Checklist version DSM-5 (PSL-5)|Modified Medical Research Council (MMRC) Dyspnea Scale|Correlation between number of patient deaths and all predictors for Covid-19 including anamnestic, clinical, biological, radiological parameters|Viral clearance","University Hospital, Lille","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_20|2020-A00763-36","March 30, 2020","September 2021","September 2021","March 30, 2020",,"April 6, 2020","Hôpital Roger Salengro, ICU, CHU Lille, Lille, France",,"https://ClinicalTrials.gov/show/NCT04327180"
310,"NCT04291729","Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of Novel Coronavirus Infection",,"Completed","No Results Available","2019-nCoV Pneumonia","Drug: Ganovo+ritonavir+/-Interferon nebulization","Rate of composite adverse outcomes|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requiring supplemental oxygen|Rate of undetectable New coronavirus pathogen nucleic acid|Rate of mechanical ventilation|Rate of ICU admission|Rate of serious adverse event","The Ninth Hospital of Nanchang|Ascletis Pharmaceuticals Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","11","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASC-CTP-NC-01","February 17, 2020","March 19, 2020","March 19, 2020","March 2, 2020",,"March 24, 2020","The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China",,"https://ClinicalTrials.gov/show/NCT04291729"
311,"NCT04334434","Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)",,"Not yet recruiting","No Results Available","Telerehabilitation","Other: Telerehabilitation","Physical Activity Scale for the Elderly|Nottingham Health Profile|Loneliness Scale for the Elderly","Kubra Koce, MSc PT|Istanbul University-Cerrahpasa","All","65 Years and older   (Older Adult)","Not Applicable","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","002","April 1, 2020","June 1, 2020","July 31, 2020","April 6, 2020",,"April 7, 2020",,,"https://ClinicalTrials.gov/show/NCT04334434"
312,"NCT04290858","Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection","NoCovid","Withdrawn","No Results Available","Coronavirus Infections|Pneumonia, Viral|Dyspnea","Drug: Nitric Oxide","Reduction in the incidence of intubation and mechanical ventilation|Mortality|Negative conversion of COVID-19 RT-PCR from upper respiratory tract|Time to clinical recovery","Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID19 NOgas mild","March 1, 2020","March 1, 2021","February 1, 2022","March 2, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04290858"
313,"NCT04257656","Severe 2019-nCoV Remdesivir RCT",,"Recruiting","No Results Available","2019-nCov|Remdesivir","Drug: Remdesivir|Drug: Remdesivir placebo","Time to Clinical Improvement (TTCI) [Censored at Day 28]|Clinical status|Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.|All cause mortality|Duration (days) of mechanical ventilation|Duration (days) of extracorporeal membrane oxygenation|Duration (days) of supplemental oxygenation|Length of hospital stay (days)|Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens|Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.|Frequency of serious adverse drug events","Capital Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 3","453","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAP-China remdesivir 2","February 6, 2020","April 3, 2020","May 1, 2020","February 6, 2020",,"February 24, 2020","Bin Cao, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04257656"
314,"NCT04288713","Eculizumab (Soliris) in Covid-19 Infected Patients","SOLID-C19","Available","No Results Available","Coronavirus","Drug: Eculizumab",,"Hudson Medical","All","18 Years and older   (Adult, Older Adult)",,,"Other","Expanded Access:Individual Patients|Treatment IND/Protocol",,"COVID19",,,,"February 28, 2020",,"March 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04288713"
315,"NCT04318366","COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor","COVID-BioB","Recruiting","No Results Available","Coronavirus Infections","Other: Observational Study","Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response","Università Vita-Salute San Raffaele","All","18 Years and older   (Adult, Older Adult)",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-BioB/OSR","March 19, 2020","March 19, 2022","March 19, 2022","March 24, 2020",,"March 31, 2020","Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -, Milan, Lombardy, Italy|Department of Internal Medicine - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy|Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Nephrology Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute, Milan, Lombardy, Italy|Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy|Università Vita-Salute San Raffaele, Milano, Mi, Italy",,"https://ClinicalTrials.gov/show/NCT04318366"
316,"NCT04320953","Non-contact Endoscopy at Covid-19 Outbreak",,"Completed","No Results Available","Gastrointestinal Disease|Infectious Disease","Device: Non-contact MCE system","Technical success|Clinical success|Adverse events","Changhai Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","1","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","ncMCE1","March 16, 2020","March 16, 2020","March 16, 2020","March 25, 2020",,"March 25, 2020","Changhai Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04320953"
317,"NCT04338802","Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19",,"Not yet recruiting","No Results Available","COVID-19|Nintedanib|Safety|Effect of Drugs","Drug: Nintedanib 150 MG|Other: Placebo","Changes in forced vital capacity (FVC)|Changes in carbon monoxide dispersion (DLco%)|Changes in the six-minute walk test (6MWT)|Changes in High resolution CT score","Huilan Zhang|Tongji Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","96","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","huilanz Zhang","April 2, 2020","May 4, 2020","August 1, 2020","April 8, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04338802"
318,"NCT04308187","Influence of the COvid-19 Epidemic on STRESS","COVISTRESS","Not yet recruiting","No Results Available","Stress, Psychological",,"Stress|Perception and knowledge of the epidemic|Feeling of information on the part of companies / establishments / governments|Means of protection|Feelings of fear generated and its impact on feelings of stigmatization towards ethnic groups or categories of patients|Sociodemographic factors and lifestyle habits","University Hospital, Clermont-Ferrand|Faculty of Medicine, Clermont-Ferrand, France|UMR CNRS 6024 LaPSCo, Clermont-Ferrand, France|Wittyfit, Paris, France","All","Child, Adult, Older Adult",,"50000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2020 COVISTRESS","March 11, 2020","March 2022","March 2022","March 13, 2020",,"March 13, 2020","University Hospital, Clermont-Ferrand, Clermont-Ferrand, France",,"https://ClinicalTrials.gov/show/NCT04308187"
319,"NCT04306393","Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19","NOSARSCOVID","Recruiting","No Results Available","SARS (Severe Acute Respiratory Syndrome)|Coronavirus","Drug: Nitric Oxide Gas","Change of arterial oxygenation at 48 hours from enrollment|Time to reach normoxemia during the first 28 days after enrollment|Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment|Survival at 28 days from enrollment|Survival at 90 days from enrollment","Massachusetts General Hospital|Xijing Hospital|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Niguarda Hospital","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","NO-SARS-COVID-19","March 21, 2020","March 21, 2021","March 21, 2022","March 12, 2020",,"April 7, 2020","University of Alabama, Birmingham, Alabama, United States|Louisiana State University Health Shreveport, Shreveport, Louisiana, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT04306393"
320,"NCT04322344","Escin in Patients With Covid-19 Infection","add-on-COV2","Recruiting","No Results Available","Coronavirus Infections","Drug: Escin|Drug: standard therapy","Mortality rate|Clinical status evaluated in agreement with guidelines|The differences in oxygen intake methods|Time of hospitalization (days)|Time of hospitalization in intensive care units|Pulmonary function","University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico ""Mater Domini""","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2|Phase 3","120","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Supportive Care","covid-19 add-on therapy","March 23, 2020","June 30, 2020","August 30, 2020","March 26, 2020",,"March 27, 2020","Luca Gallelli, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04322344"
321,"NCT04322773","Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","TOCIVID","Recruiting","No Results Available","Corona Virus Disease","Drug: RoActemra iv|Drug: RoActemra sc|Drug: Kevzara sc|Other: Standard medical care","Time to independence from supplementary oxygen therapy|Number of deaths|Days out of hospital and alive|Ventilator free days alive and out of hospital|C-reactive protein (CRP) level|Number of participants with serious adverse events","Marius Henriksen|Lars Erik Kristensen|Frederiksberg University Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APPI2-CV-2020-01","April 5, 2020","June 1, 2021","June 1, 2021","March 26, 2020",,"April 7, 2020","Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark|Hillerød Hospital, Hillerød, Denmark",,"https://ClinicalTrials.gov/show/NCT04322773"
322,"NCT04324684","Prognostic Factors Keeping Track for Covid19 Pneumonia","NIKE_C19","Recruiting","No Results Available","Pneumonia, Viral|Hypertension|Diabetes Mellitus|Obesity|Cardiovascular Diseases|Obstructive Lung Disease",,"rate of recovery|time to improvement|efficacy of treatments|organ failure","Catholic University of the Sacred Heart","All","18 Years to 100 Years   (Adult, Older Adult)",,"198","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","20202503","March 31, 2020","May 5, 2020","May 30, 2020","March 27, 2020",,"April 8, 2020","Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04324684"
323,"NCT04337983","Hemodynamic Characteristics of Patients With SARS-CoV-2","PiCCOVID","Not yet recruiting","No Results Available","Coronavirus|SARS-CoV-2|COVID-19|Acute Respiratory Distress Syndrome|Shock|Acute Circulatory Failure|Left Ventricular Dysfunction|Fluid Overload","Device: Transpulmonary thermodilution|Device: Echocardiography","Body temperature|Blood pressure|Pulse (heart rate)|Respiratory rate|Data provided by transpulmonary thermodilution-CI|Data provided by transpulmonary thermodilution-GEDV|Data provided by transpulmonary thermodilution-EVLW|Data provided by transpulmonary thermodilution-PVPI|Incidence of abnormal laboratory test results|Incidence of new-onset or reversible systolic left ventricular dysfunction|Changes of extravascular lung water measured by transpulmonary thermodilution|Changes of pulmonary vascular permeability index measured by transpulmonary thermodilution|Correlation between the hemodynamic characteristics and 90-day mortality","Bicetre Hospital","All","Child, Adult, Older Adult",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-A00793-36","April 15, 2020","October 2020","April 2021","April 8, 2020",,"April 8, 2020","Bicetre Hospital, Paris, Val-de-Marne, France",,"https://ClinicalTrials.gov/show/NCT04337983"
324,"NCT04336761","Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France","INCOVPED","Not yet recruiting","No Results Available","Coronavirus|COVID|Infection Viral","Diagnostic Test: nasopharyngeal swab","Prevalence of positivity of COVID-19 virus measured by rt-PCR|Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients|Respiratory signs of children tested within 28 day|Percentage of children hospitalized tested within 28 day|Contact frequency|Prevalence of positivity of other respiratory viruses measured by rt-PCR","University Hospital, Lille","All","up to 18 Years   (Child, Adult)",,"914","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020_21|2020-A00811-38","April 2020","December 2020","December 2020","April 7, 2020",,"April 7, 2020","CH Louis MOURIER, Colombes, France|Hôpital Mère Enfant CHU, Nantes, France|Hôpitaux Pédiatriques de Nice CHU-Lenval, Nice, France|Hôpital des enfants - CHU, Toulouse, France|CHU de Tours, Tours, France",,"https://ClinicalTrials.gov/show/NCT04336761"
325,"NCT04322786","The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?",,"Active, not recruiting","No Results Available","Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom","Drug: ACE inhibitor","Incidence of influenza","University College, London","All","18 Years and older   (Adult, Older Adult)",,"1302508","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ISAC17_205R","January 1, 1998","May 31, 2016","March 31, 2020","March 26, 2020",,"March 26, 2020",,,"https://ClinicalTrials.gov/show/NCT04322786"
326,"NCT04338672","The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients",,"Not yet recruiting","No Results Available","Emergency Service, Hospital|General Surgery","Other: COVID-19 Pandemic","Rates of emergency visits needing surgical consult|The ratio of severe presentations to non-severe presentations|The impact of age on ED attendance rates|Differences in ED surgical visits (in terms of capacity and severity) of surgical patients depending on the presentation and the co morbidity","Sheba Medical Center","All","18 Years and older   (Adult, Older Adult)",,"1000000","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","SMC-20-7078-YZ-CTIL","April 5, 2020","April 1, 2021","April 1, 2022","April 8, 2020",,"April 8, 2020","Sheba Medical Center, Ramat Gan, Israel",,"https://ClinicalTrials.gov/show/NCT04338672"
327,"NCT04327479","Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection",,"Recruiting","No Results Available","Cardiovascular Diseases|Cardiovascular Risk Factor|SARS","Diagnostic Test: Assessment of cardiovascular diseases and cardiovascular risk factors","All-cause mortality|30-day mortality|Major adverse cardiovascular events","University Hospital, Essen","All","18 Years and older   (Adult, Older Adult)",,"6000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","20-9213-BO","March 26, 2020","March 25, 2026","March 25, 2026","March 31, 2020",,"March 31, 2020","University Hospital Essen, Essen, NRW, Germany",,"https://ClinicalTrials.gov/show/NCT04327479"
328,"NCT04322123","Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 Virus","Coalition-I","Recruiting","No Results Available","Coronavirus Infections","Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin","Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Presence of virus at day 10 in subset of 180 patients","Hospital do Coracao|Hospital Israelita Albert Einstein|Hospital Sirio-Libanes|Brazilian Research In Intensive Care Network|EMS","All","18 Years and older   (Adult, Older Adult)","Phase 3","630","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Brazil COVID Coalition I Trial","April 6, 2020","August 30, 2020","August 30, 2020","March 26, 2020",,"April 7, 2020","Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vitória Da Conquista, BA, Brazil|Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil|Hospital de Brasília, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil|Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil|Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil|Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São José, Criciuma, SC, Brazil|Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil|Hospital Nereu Ramos, Florianópolis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil|Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil|Hospital Albert Einstein, São Paulo, SP, Brazil|Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil|Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil|Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil|Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil|Hospital Sírio-Libanês, São Paulo, SP, Brazil|Hospital SEPACO, São Paulo, S, Brazil",,"https://ClinicalTrials.gov/show/NCT04322123"
329,"NCT04305574","Social Media Use During COVID-19",,"Recruiting","No Results Available","Coronavirus|Depression|Anxiety|Stress","Behavioral: Use of social media during COVID-19","Assessment of COVID-19 situation|Depression, Anxiety and Stress Scale|Familiarity and trust in COVID-related rumours|Availability heuristic","Jean Liu|Yale-NUS College","All","21 Years and older   (Adult, Older Adult)",,"5000","Other","Observational","Observational Model: Cohort|Time Perspective: Cross-Sectional","2020-CERC-001","March 8, 2020","May 31, 2020","May 31, 2020","March 12, 2020",,"March 17, 2020","Yale-NUS College, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT04305574"
330,"NCT04326387","Evaluation of Novel Diagnostic Tests for 2019-nCOV","COVIDx","Not yet recruiting","No Results Available","Acute Disease|Coronavirus|Respiratory Viral Infection","Diagnostic Test: SAMBA II (Diagnostic for the Real World)|Diagnostic Test: Public Health England Gold Standard|Diagnostic Test: Cambridge Validated Viral Detection Method|Diagnostic Test: Radiological Detection","SAMBA COVID-19 POC PCR Test|Patient acceptability|Immune Response Positivity","CCTU- Cancer Theme|Cambridge University Hospitals NHS Foundation Trust","All","16 Years and older   (Child, Adult, Older Adult)",,"200","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIDx","April 8, 2020","April 7, 2021","October 7, 2021","March 30, 2020",,"March 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04326387"
331,"NCT04279795","Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations",,"Recruiting","No Results Available","Coronavirus",,"Positive rate of 2019 Novel Coronavirus RNA|Survival rate","Third Affiliated Hospital, Sun Yat-Sen University","All","Child, Adult, Older Adult",,"20","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","PL11","January 20, 2020","January 31, 2021","February 28, 2021","February 21, 2020",,"February 21, 2020","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04279795"
332,"NCT04279782","Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection",,"Recruiting","No Results Available","Coronavirus","Other: Comprehensive treatment","Survival rate|Chest computed tomography|Recovery Time|Depression evaluation","Third Affiliated Hospital, Sun Yat-Sen University","All","Child, Adult, Older Adult",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","XWX3","January 20, 2020","January 31, 2021","February 28, 2021","February 21, 2020",,"February 24, 2020","The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04279782"
333,"NCT04292327","Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus","2019-nCoV","Active, not recruiting","No Results Available","Pneumonia Caused by Human Coronavirus",,"Mortality|The time interval of Nucleic acid detection become negative","Fujian Provincial Hospital","All","18 Years to 75 Years   (Adult, Older Adult)",,"400","Other","Observational","Observational Model: Other|Time Perspective: Retrospective","KY-2020-24.01","January 1, 2020","April 30, 2020","July 31, 2020","March 3, 2020",,"March 3, 2020","Fujian Provincial Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT04292327"
334,"NCT04269525","Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia",,"Recruiting","No Results Available","Pneumonia, Viral|Pneumonia, Ventilator-Associated","Biological: UC-MSCs","Oxygenation index|28 day mortality|Hospital stay|2019-nCoV nucleic acid test|Improvement of lung imaging examinations|White blood cell count|Lymphocyte count|Lymphocyte percentage|Procalcitonin|interleukin(IL)-2|IL-4|IL-6|IL-8|IL-10|tumor necrosis factor(TNF)-α|γ-interferon(IFN)","ZhiYong Peng|Tuohua Biological Technology Co. Ltd|Zhongnan Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2020002","February 6, 2020","April 30, 2020","September 30, 2020","February 13, 2020",,"February 17, 2020","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04269525"
335,"NCT04261907","Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection",,"Not yet recruiting","No Results Available","2019-nCoV","Drug: ASC09/ritonavir group|Drug: lopinavir/ritonavir group","The incidence of composite adverse outcome|Time to recovery|Rate of no fever|Rate of no cough|Rate of no dyspnea|Rate of no requring supplemental oxygen|Rate of undectable viral RNA|Rate of mechanical ventilation|Rate of ICU admission|Time and rate of laboratory indicators related to disease improvement to return to normal","First Affiliated Hospital of Zhejiang University|Ascletis Pharmaceuticals Co., Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","160","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ASC09F-CTP-ZY-01","February 7, 2020","May 31, 2020","June 30, 2020","February 10, 2020",,"February 10, 2020",,,"https://ClinicalTrials.gov/show/NCT04261907"
336,"NCT04325672","Convalescent Plasma to Limit Coronavirus Associated Complications",,"Withdrawn","No Results Available","Coronavirus","Biological: Convalescent Plasma","RNA in SARS-CoV-2|ICU Admissions|Hospital Mortality|Hospital Length of Stay (LOS)|Type of respiratory support|Duration of respiratory support","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","20-002864","April 1, 2020","December 31, 2022","December 31, 2022","March 27, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04325672"
337,"NCT04326075","Early CPAP in COVID Patients With Respiratory Failure.","EC-COVID-RCT","Not yet recruiting","No Results Available","CPAP Ventilation|COVID-19|Emergency Departments","Device: CPAP treatment","Death or need of intubation|30-day mortality","Mario Negri Institute for Pharmacological Research","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","900","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EC-COVID-RCT-Fenice","April 6, 2020","October 5, 2020","November 9, 2020","March 30, 2020",,"March 31, 2020",,,"https://ClinicalTrials.gov/show/NCT04326075"
338,"NCT04337190","Impact of Angiotensin II Type 2 Receptor Agonists Treatment in Patients With COVID 19 (COVID-ARA2)","COVID-ARA2","Recruiting","No Results Available","COVID|Acute Respiratory Distress Syndrome","Biological: blood sampling","ACE2 level change over time|ACE2 activity over time|Mortality at day 28|ARDS severity|Duration of mechanical ventilation|Need for prone positionning|Need for extracorporeal membran oxygenation|Use of paralytic agents|Need for renal replacement therapy|Need for vasoactive drugs (norepinephrine, dobutamine,epinephrine)|Sequential Organ Failure Assessment (SOFA) score|Number of session(s) of prone positionning|Duration of extracorporeal membran oxygenation treatment|Type of vasoactive drugs|Duration of vasoactive treatment","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVID-ARA2","April 3, 2020","October 6, 2020","December 6, 2020","April 7, 2020",,"April 7, 2020","University Hospital Angers, Angers, France",,"https://ClinicalTrials.gov/show/NCT04337190"
339,"NCT04061382","Sero-epidemiological Survey of England in 2019/2020","STORY","Recruiting","No Results Available","Serogroup C Meningococcal Meningitis|Diphtheria|COVID-19","Procedure: venepuncture","Feasibility of developing a UK based sero-epidemiological programme in 0-24 year olds|Feasibility of developing a UK based sero epidemiological survey in 0-24 year olds|Recruitment rate|Cost|To assess, in relevant age groups, immunity against infections and vaccine preventable diseases|Sera collection","University of Oxford","All","up to 24 Years   (Child, Adult)",,"2300","Other","Observational","Observational Model: Other|Time Perspective: Prospective","ID 263097","October 15, 2019","April 30, 2020","November 30, 2020","August 19, 2019",,"March 24, 2020","Centre for Clinical Vaccinology & Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04061382"
340,"NCT04264533","Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia",,"Recruiting","No Results Available","Vitamin C|Pneumonia, Viral|Pneumonia, Ventilator-Associated","Drug: VC|Drug: Sterile Water for Injection","Ventilation-free days|28-days mortality|ICU length of stay|Demand for first aid measuments|Vasopressor days|Respiratory indexes|Ventilator parameters|APACHE II scores|SOFA scores","ZhiYong Peng|Zhongnan Hospital","All","18 Years and older   (Adult, Older Adult)","Phase 2","140","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","2020001","February 14, 2020","September 30, 2020","September 30, 2020","February 11, 2020",,"March 10, 2020","Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04264533"
341,"NCT04302766","Expanded Access Remdesivir (RDV; GS-5734™)",,"Available","No Results Available","Coronavirus Disease 2019","Drug: Remdesivir",,"U.S. Army Medical Research and Development Command","All","Child, Adult, Older Adult",,,"U.S. Fed","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"S-20-01",,,,"March 10, 2020",,"March 20, 2020",,,"https://ClinicalTrials.gov/show/NCT04302766"
342,"NCT04338841","HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection","HOME-CoV","Not yet recruiting","No Results Available","Coronavirus Infection","Other: HOME-CoV rule implementation","the composite rate of adverse outcomes|The rate of hospitalization","University Hospital, Angers","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4000","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-A00831-38","April 13, 2020","June 1, 2020","June 1, 2020","April 8, 2020",,"April 8, 2020","Clinique Universitaire Saint-Luc, Bruxelles, Belgium|CHU de Liège, Liege, Belgium|Ch Argenteuil, Argenteuil, France|CHU Brest, Brest, France|CH Cholet, Cholet, France|CHU Clermont Ferrand, Clermont Ferrand, France|Ch Colmar, Colmar, France|CH Alpes Lemant, Contamine-sur-Arve, France|CHU Dijon, Dijon, France|CH Le Mans, Le Mans, France|CH Libourne, Libourne, France|CH Limoges, Limoges, France|Ch Longjumeau, Longjumeau, France|Hospices Civils de Lyon (University Hospital of Lyon), Lyon, France|Chu Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|CH Niort, Niort, France|Hopital Paris Saint Joseph, Paris, France|Hopital Saint Antoine, Paris, France|Hôpital Bichat, Paris, France|Hôpital Lariboisière, Paris, France|CHU de Poitiers, Poitiers, France|CH Reims, Reims, France|Ch Remiremont, Remiremont, France|Chu Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de St Etienne, Saint Etienne, France|CH de Saint-Brieuc, Saint-Brieuc, France|CHU Toulouse, Toulouse, France|Ch Troyes, Troyes, France|CH VICHY, Vichy, France|CH Princesse Grace, Monaco, Monaco",,"https://ClinicalTrials.gov/show/NCT04338841"
343,"NCT04323527","Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2","CloroCOVID19","Recruiting","No Results Available","SARS-CoV Infection|Severe Acute Respiratory Syndrome (SARS) Pneumonia","Drug: Chloroquine diphosphate","Absolute mortality at day 28|Absolute mortality on days 7 and 14|Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28|Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization|Duration of supplemental oxygen (if applicable)|Duration of mechanical ventilation (if applicable)|Absolute duration of hospital stay in days|Prevalence of grade 3 and 4 adverse events|Prevalence of serious adverse events|Change in serum creatinine level|Change in serum troponin I level|Change in serum aspartate aminotransferase level|Change in serum CK-MB level|Change in detectable viral load in respiratory tract swabs|Viral concentration in blood samples|Absolute number of causes leading to participant death (if applicable)","Fundação de Medicina Tropical Dr. Heitor Vieira Dourado|Marcus Vinícius Guimarães de Lacerda|Mayla Gabriela Silva Borba|Wuelton Marcelo Monteiro|Gisely Cardoso de Melo|Fernando Fonseca de Almeida e Val|Felipe Gomes Naveca|Maria Paula Gomes Mourão|Ludmila Abrahão Hajjar|Jorge Souza Mendonça","All","18 Years to 100 Years   (Adult, Older Adult)","Phase 2","440","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAAE: 30152620.1.0000.0005","March 23, 2020","August 31, 2020","August 31, 2020","March 26, 2020",,"March 30, 2020","Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil",,"https://ClinicalTrials.gov/show/NCT04323527"
344,"NCT04275388","Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia",,"Not yet recruiting","No Results Available","2019 Novel Coronavirus Pneumonia","Drug: Xiyanping injection|Drug: Lopinavir / ritonavir, alpha-interferon nebulization","Clinical recovery time|Complete fever time|Cough relief time|Virus negative time|Incidence of severe or critical neocoronavirus pneumonia","Jiangxi Qingfeng Pharmaceutical Co. Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","348","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","QF-XYP2001-1","February 14, 2020","May 14, 2020","December 14, 2021","February 19, 2020",,"February 19, 2020",,,"https://ClinicalTrials.gov/show/NCT04275388"
345,"NCT04245631","Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV",,"Recruiting","No Results Available","New Coronavirus","Diagnostic Test: Recombinase aided amplification (RAA) assay","Detection sensitivity is greater than 95%|Detection specificity is greater than 95%|Consistent with existing universal reagent detection rates greater than 95%","Beijing Ditan Hospital","All","1 Year to 90 Years   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","DTXY022","January 1, 2020","December 31, 2020","December 31, 2020","January 29, 2020",,"January 29, 2020","Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04245631"
346,"NCT04283461","Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection",,"Recruiting","No Results Available","Corona Virus Infection|Immunisations","Biological: mRNA-1273","Frequency of solicited local reactogenicity adverse events (AEs)|Frequency of any medically-attended adverse events (MAAEs)|Frequency of any new-onset chronic medical conditions (NOCMCs)|Frequency of any serious adverse events (SAEs)|Frequency of any unsolicited adverse events (AEs)|Frequency of solicited systemic reactogenicity adverse events (AEs)|Grade of any unsolicited adverse events (AEs)|Grade of solicited local reactogenicity adverse events (AEs)|Grade of solicited systemic reactogenicity adverse events (AEs)|Geometric mean fold rise (GMFR) in IgG titer from baseline|Geometric mean titer (GMT) of antibody|Percentage of subjects who seroconverted","National Institute of Allergy and Infectious Diseases (NIAID)","All","18 Years to 55 Years   (Adult)","Phase 1","45","NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","20-0003|1UM1AI148373-01","March 3, 2020","June 1, 2021","June 1, 2021","February 25, 2020",,"March 30, 2020","Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States|National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States|Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04283461"
347,"NCT03331445","Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections","NONTM","Active, not recruiting","No Results Available","Respiratory Tract Infections|Corona Virus Infection","Drug: Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation","Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects|Measure the effect of 160ppm inhaled nitric oxide delivery on lung spirometry in NTM subjects|Measure the antimicrobial effect of 160ppm inhaled nitric oxide on lung NTM bacterial load in the sputum|Measure the effect of 160ppm inhaled nitric oxide on Quality of Life (CRISS) Score","University of British Columbia|Mallinckrodt","All","14 Years and older   (Child, Adult, Older Adult)","Phase 2","20","Other|Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NTM-CTP-01: H17-02107","October 24, 2017","December 31, 2020","March 31, 2021","November 6, 2017",,"March 31, 2020","Diamond Centre, Vancouver, British Columbia, Canada",,"https://ClinicalTrials.gov/show/NCT03331445"
348,"NCT04335630","Cardiovascular Manifestations of COVID-19",,"Recruiting","No Results Available","Cardiovascular Diseases|COVID","Diagnostic Test: Electrocardiogram, telemetry, echocardiogram, laboratory values","Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.|Prevalence of pericarditis, pericardial effusion, valvular disease.|Identification of characteristic electrocardiographic patterns related to COVID-19|Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.|Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19|Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19|Role of insurance type on clinical outcomes of patients with COVID-19|Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications|Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications","Memorial Hermann Health System","All","18 Years and older   (Adult, Older Adult)",,"500","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","HSC-MS-20-0286","March 30, 2020","March 2021","March 2022","April 6, 2020",,"April 7, 2020","Memorial Hermann Hospital-Texas Medical Center, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04335630"
349,"NCT04324736","""Coronavirus SARS-CoV2 and Diabetes Outcomes""","CORONADO","Recruiting","No Results Available","Coronavirus|Diabetes","Other: no interventional study","Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19|describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19|describe the prognosis of hospitalized subjects with diabetes and COVID-19|describe the care management of hospitalized subjects with diabetes and COVID-19","Nantes University Hospital","All","Child, Adult, Older Adult",,"1000","Other","Observational","Observational Model: Cohort|Time Perspective: Other","RC20_0148","March 10, 2020","April 10, 2020","May 8, 2020","March 27, 2020",,"April 8, 2020","CHU Nantes, Nantes, France",,"https://ClinicalTrials.gov/show/NCT04324736"
350,"NCT04322682","Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)","COVID-19","Recruiting","No Results Available","Corona Virus Infection","Drug: Colchicine|Drug: Placebo oral tablet","Number of participants who die or require hospitalization due to COVID-19 infection|Number of participants who die|Number of participants requiring hospitalization due to COVID-19 infection|Number of participants requiring mechanical ventilation","Montreal Heart Institute|DACIMA Software","All","40 Years and older   (Adult, Older Adult)","Phase 3","6000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","MHIPS-2020-001","March 23, 2020","September 2020","September 2020","March 26, 2020",,"March 27, 2020","Montreal Heart Institute, Montreal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04322682"
351,"NCT04255940","2019-nCoV Outbreak and Cardiovascular Diseases",,"Recruiting","No Results Available","Cardiovascular Death; Major Adverse Cardiovascular Events",,"Cardiovascular Death|Major Adverse Cardiovascular Events|Times From symptom onset to hospital arrival|Anxiety","Qilu Hospital of Shandong University","All","Child, Adult, Older Adult",,"12000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","2019nCoV-CVD","January 20, 2020","April 30, 2020","April 30, 2020","February 5, 2020",,"February 5, 2020","Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China|Heze Municipal Hospital, Heze, Shandong, China|Shandong University Qilu Hospital, Jinan, Shandong, China|Jinan Central Hospital, Shandong University, Jinan, Shandong, China|First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China|Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China|The Second Hospital of Shandong University, Jinan, Shandong, China|Jining Hospital of Traditional Chinese Medicine, Jining, Shandong, China|Qihe People's Hospital, Qihe, Shandong, China|Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, China|Weihai Municipal Hospital, Weihai, Shandong, China|Central Hospital of Zibo, Zibo, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04255940"
352,"NCT04315480","Tocilizumab for SARS-CoV2 Severe Pneumonitis",,"Active, not recruiting","No Results Available","SARS Pneumonia","Drug: Tocilizumab","arrest in deterioration of pulmonary function|improving in pulmonary function|need of oro-tracheal intubation|death","Università Politecnica delle Marche|Azienda Ospedaliera Ospedali Riuniti Marche Nord","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","38","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TOCICOV-1","March 12, 2020","April 9, 2020","May 2020","March 19, 2020",,"April 6, 2020","Università Politecnica delle Marche, Ancona, AN, Italy","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf","https://ClinicalTrials.gov/show/NCT04315480"
353,"NCT04322513","Biomarkers for Identification of SARS-COV-2 Infection","B-DT-COV2","Recruiting","No Results Available","Coronavirus","Diagnostic Test: Biomarkers expression","Biomarkers expression|Liver Biomarkers expression|biomarkers expression (microRNAs, oxidative stress, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) after treatment","University of Catanzaro|Azienda Ospedaliera Pugliese Ciaccio|Azienda Ospedaliera Policlinico ""Mater Domini""","All","14 Years to 75 Years   (Child, Adult, Older Adult)",,"110","Other","Observational","Observational Model: Case-Control|Time Perspective: Prospective","covid-19 biomarkers","March 24, 2020","June 30, 2020","August 30, 2020","March 26, 2020",,"March 27, 2020","Luca Gallelli, Catanzaro, Italy",,"https://ClinicalTrials.gov/show/NCT04322513"
354,"NCT04290780","Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus","NOSO-COR","Recruiting","No Results Available","Infection Viral","Other: nosocomial infection/hospital acquired infection","nosocomial infection","Hospices Civils de Lyon","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","69HCL20_0214","March 9, 2020","October 10, 2020","October 30, 2020","March 2, 2020",,"March 13, 2020","Service Hygiène, Epidémiologie et Prévention, Lyon, France|Service Hygiène, Epidémiologie et Prévention, Lyon, France",,"https://ClinicalTrials.gov/show/NCT04290780"
355,"NCT04281693","A New Screening Strategy for 2019 Novel Coronavirus Infection",,"Not yet recruiting","No Results Available","Novel Coronavirus Infection Pneumonia","Diagnostic Test: Standard screening strategy|Diagnostic Test: New screening strategy","Screening accuracy|Cost-effectiveness analysis","Affiliated Hospital to Academy of Military Medical Sciences|The Fifth Medical Center of Chinese PLA General Hospital","All","Child, Adult, Older Adult","Not Applicable","230","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Screening","307-nCoV","February 2020","March 2020","March 2020","February 24, 2020",,"February 24, 2020","the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04281693"
356,"NCT04259892","Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection","Cov-CONTACT","Recruiting","No Results Available","Coronavirus","Biological: 2019-nCoV PCR","Number of Participants with presence of 2019-nCoV in at least one of nasopharyngeal swab|For each participant, time (days) between the last contact with the laboratory-confirmed 2019-nCoV case and the first positive PCR|For each participant, time (days) between the first positive PCR and the first negative PCR|Number of Participants with presence of at least one of the following symptoms: fever > 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhe|Number of Participants with positive serology in the 90 days following last contact","Institut National de la Santé Et de la Recherche Médicale, France","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C20-06|2020-A00280-39","February 4, 2020","October 4, 2020","February 4, 2021","February 7, 2020",,"February 17, 2020","CIC 1425, Paris, France",,"https://ClinicalTrials.gov/show/NCT04259892"
357,"NCT04252274","Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV","DACO-nCoV","Recruiting","No Results Available","Pneumonia, Pneumocystis|Coronavirus","Drug: Darunavir and Cobicistat","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2|The mortality rate of subjects at weeks 2","Shanghai Public Health Clinical Center","All","Child, Adult, Older Adult","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DACO-nCoV","January 30, 2020","August 31, 2020","December 31, 2020","February 5, 2020",,"March 4, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04252274"
358,"NCT04327804","A Longitudinal Study of SARS-CoV-2 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research",,"Recruiting","No Results Available","SARS-CoV Infection","Diagnostic Test: Odd/Even birth year intervention groups","Detection of SARS-CoV-2 virus|Trajectory of COVID-19 and antibody development","Dr. Deneen Vojta|PATH|Mayo Clinic|Bill and Melinda Gates Foundation|UnitedHealth Group","All","Child, Adult, Older Adult",,"120","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","20-002","March 25, 2020","April 3, 2020","April 10, 2020","March 31, 2020",,"March 31, 2020","Everett Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04327804"
359,"NCT04261517","Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )",,"Completed","No Results Available","Pneumonia, Pneumocystis|Coronavirus","Drug: Hydroxychloroquine","The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5|The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7|The mortality rate of subjects at weeks 2|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|The critical illness rate of subjects at weeks 2","Shanghai Public Health Clinical Center","All","18 Years and older   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HC-nCoV","February 6, 2020","February 25, 2020","February 25, 2020","February 7, 2020",,"March 24, 2020","Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT04261517"
360,"NCT04321369","Impact of Swab Site and Sample Collector on Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals",,"Completed","No Results Available","Infections, Respiratory|Fever|Cough","Diagnostic Test: Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals","Accuracy of patient administered tests","Dr. Deneen Vojta|Quest Diagnostics|Bill and Melinda Gates Foundation|UnitedHealth Group","All","Child, Adult, Older Adult",,"533","Industry|Other","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","20-001","March 9, 2020","March 23, 2020","March 23, 2020","March 25, 2020",,"March 25, 2020","Everett Clinic, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT04321369"
361,"NCT04251871","Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection",,"Recruiting","No Results Available","Pneumonia Caused by Human Coronavirus (Disorder)","Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules|Drug: Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)","Time to complete remission of 2019-nCoV infection-associated symptoms|The incidence of dyspnea with low oxygen saturation level and high respiratory rate|Number of subjects who develop complications of 2019-nCoV infection|Time to virus shedding|Time to improvement of abnormalities in Chest radiology|The evaluation of Traditional Chinese Medicine (TCM) symptoms before and after treatment","Beijing 302 Hospital","All","14 Years to 80 Years   (Child, Adult, Older Adult)","Not Applicable","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020001D","January 22, 2020","January 22, 2021","January 22, 2021","February 5, 2020",,"February 5, 2020","The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04251871"
362,"NCT04260308","A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia",,"Recruiting","No Results Available","Virus; Pneumonia",,"GHQ-12(general health questionnaire-12)|IES-R(Impact of Event Scale-Revised)","Huazhong University of Science and Technology","All","Child, Adult, Older Adult",,"30000","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","IRBID:TJ-C 20200107","February 3, 2020","April 15, 2020","April 20, 2020","February 7, 2020",,"February 7, 2020","Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China",,"https://ClinicalTrials.gov/show/NCT04260308"
363,"NCT04275245","Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia",,"Recruiting","No Results Available","2019-nCoVs Infection Pneumonia","Drug: Meplazumab for Injection","2019 nCoV nucleic acid detection|Recovery of body temperature|Recovery of resting respiratory rate|Recovery of SPO2|Chest CT / chest film changes|PaO2 / FiO2|Time to reach the isolation release standard|Changes of inflammatory immune status","Tang-Du Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20200101","February 3, 2020","December 31, 2020","December 31, 2020","February 19, 2020",,"February 19, 2020","Tangdu Hospital, Xi'an, Shaanxi, China",,"https://ClinicalTrials.gov/show/NCT04275245"
364,"NCT04307459","Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life",,"Not yet recruiting","No Results Available","Coronavirus Infections|Respiratory Failure|Ventilator Lung","Other: standard operating procedures","Real life data of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection|in-hospital mortality|30 days mortality|6 months mortality|Intubation rate|Time to Intubation|Time to ventilation|Non invasive to Invasive time|Recovery rate|Recurrence rate|Risk factor for COVID19|Blood tests and outcome|Antiviral therapy|Coinfections|Radiological findings|Ultrasound findings|Myocardial injury|Medical management","University of Milan","All","18 Years and older   (Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","02-PNSNP-2020","March 19, 2020","April 19, 2020","December 31, 2020","March 13, 2020",,"March 17, 2020","Luigi Sacco University Hospital, Milan, Lombardia, Italy",,"https://ClinicalTrials.gov/show/NCT04307459"
365,"NCT04299152","Stem Cell Educator Therapy Treat the Viral Inflammation Caused by Severe Acute Respiratory Syndrome Coronavirus 2",,"Not yet recruiting","No Results Available","Severe Acute Respiratory Syndrome (SARS) Pneumonia","Combination Product: Stem Cell Educator-Treated Mononuclear Cells Apheresis","Determine the number of Covid-19 patients who were unable to complete SCE Therapy|Examine the percentage of activated T cells after SCE therapy by flow cytometry|Assess the percentage of Th17 cells after SCE therapy by flow cytometry|Chest imaging changes by computed tomography (CT) scan of the chest|Quantification of the SARS-CoV-2 viral load by real time RT-PCR","Tianhe Stem Cell Biotechnologies Inc.","All","18 Years to 60 Years   (Adult)","Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment","2020-TH-001","April 10, 2020","October 9, 2020","November 10, 2020","March 6, 2020",,"March 30, 2020",,,"https://ClinicalTrials.gov/show/NCT04299152"
366,"NCT04322279","Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection (CoV-CONTACT-SERO)",,"Recruiting","No Results Available","Coronavirus","Diagnostic Test: Serology|Genetic: Sequencing","Number of Participants with positive serology in the 90 days following last contact|fever > 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea","Institut National de la Santé Et de la Recherche Médicale, France","All","Child, Adult, Older Adult",,"300","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","C20-16|2020-A00609-30","March 9, 2020","May 1, 2020","May 1, 2020","March 26, 2020",,"March 26, 2020","CIC 1425, Paris, France",,"https://ClinicalTrials.gov/show/NCT04322279"
367,"NCT04226157","Home Blood Pressure Study for Recent Stroke Survivors With High Blood Pressure *Due to COVID-19 Outbreak in United States the Investigators Have Paused All In-person Enrollment and Will Re-evaluate on May 1st*","HBPS","Recruiting","No Results Available","Ischemic Stroke|Hypertension","Device: Home Blood Pressure Monitoring Device (Qardio Arm)|Other: Primary Care Provider Blood Pressure Management","Feasibility of blood pressure self management in stroke survivors|Systolic Blood Pressure Difference","MedStar Georgetown University Hospital|Medstar Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Not Applicable","32","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","2018-0718","February 21, 2019","December 31, 2020","March 31, 2021","January 13, 2020",,"March 19, 2020","Medstar Georgetown University Hospital, Washington, District of Columbia, United States",,"https://ClinicalTrials.gov/show/NCT04226157"
368,"NCT04335851","Video-Based Exercises and Well-Being During Social Isolation",,"Not yet recruiting","No Results Available","Social Isolation|Physical Inactivity|Well-Being","Other: Video based aerobic exercise","World Health Organization Quality of Life Questionnaire Bref|Rapid Assessment of Physical Activity|Global Rating of Change Scale","Biruni University|Istanbul University-Cerrahpasa","All","18 Years to 35 Years   (Adult)","Not Applicable","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention","Physical Activity Project","April 6, 2020","May 13, 2020","June 30, 2020","April 6, 2020",,"April 6, 2020","Biruni University, Istanbul, Turkey|Istanbul University Cerrahpasa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04335851"
369,"NCT04336410","Safety, Tolerability and Immunogenicity of INO-4800 in Healthy Volunteers",,"Not yet recruiting","No Results Available","Coronavirus Infection","Drug: INO-4800|Device: CELLECTRA® 2000","Percentage of Participants with Adverse Events (AEs)|Percentage of Participants with Administration (Injection) Site Reactions|Percentage of Participants with Adverse Events of Special Interest (AESIs)|Change from Baseline in Antigen-Specific Binding Antibody Titers|Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response","Inovio Pharmaceuticals|Coalition for Epidemic Preparedness Innovations (CEPI)","All","18 Years to 50 Years   (Adult)","Phase 1","40","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","COVID19-001","April 2020","November 2020","November 2020","April 7, 2020",,"April 7, 2020","Center for Pharmaceutical Research, Kansas City, Missouri, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT04336410"
370,"NCT04319211","Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress","COVID-19","Not yet recruiting","No Results Available","Healthy People","Other: Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.","International Physical Activity Questionnaire (IPAQ)|Health-Related Quality of Life SF-12 Scale|Beck Depression Scale","Istanbul University-Cerrahpasa","All","18 Years to 55 Years   (Adult)",,"200","Other","Observational","Observational Model: Case-Only|Time Perspective: Cross-Sectional","EAvcil|İpek Yeldan","March 25, 2020","May 15, 2020","July 20, 2020","March 24, 2020",,"March 24, 2020","Istanbul University Cerrahpasa, Istanbul, Turkey",,"https://ClinicalTrials.gov/show/NCT04319211"
371,"NCT04331808","CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)","CORIMUNO-TOC","Not yet recruiting","No Results Available","Corona Virus Infection","Drug: Tocilizumab","Survival without needs of ventilator utilization at day 14.|WHO progression scale <=5 at day 4|Cumulative incidence of successful tracheal extubation (defined as duration extubation > 48h) at day 14|WHO progression scale at day 4|WHO progression scale|Survival|28-day ventilator free-days|respiratory acidosis at day 4|PaO2/FiO2 ratio|time to oxygen supply independency|duration of hospitalization|time to negative viral excretion|time to ICU discharge|time to hospital discharge","Assistance Publique - Hôpitaux de Paris","All","18 Years and older   (Adult, Older Adult)","Phase 2","240","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","APHP200375-1","March 31, 2020","March 31, 2021","December 31, 2021","April 2, 2020",,"April 8, 2020",,,"https://ClinicalTrials.gov/show/NCT04331808"
372,"NCT04328467","Pre-exposure Prophylaxis for SARS-Coronavirus-2",,"Recruiting","No Results Available","COVID-19|Corona Virus Infection|ARDS|Acute Respiratory Distress Syndrome","Drug: Hydroxychloroquine|Other: Placebo","COVID-19-free survival|Incidence of confirmed SARS-CoV-2 detection|Incidence of possible COVID-19 symptoms|Incidence of all-cause study medicine discontinuation|Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end|Incidence of Hospitalization for COVID-19 or death|Incidence of study medication-related side effects","University of Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 3","3500","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STUDY00009414","April 6, 2020","August 2020","August 2020","March 31, 2020",,"April 8, 2020","University of Minnesota, Minneapolis, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04328467"
373,"NCT04280913","Clinical Outcomes of Patients With COVID19",,"Withdrawn","No Results Available","Coronavirus Disease 2019","Other: retrospective analysis","Time to negative conversion of severe acute respiratory syndrome coronavirus 2|Length of stay in hospital|Survival|Intubation","Guangzhou Institute of Respiratory Disease|Huizhou Municipal Central Hospital","All","Child, Adult, Older Adult",,"0","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","GZHZ-COVID19","February 22, 2020","March 31, 2020","March 31, 2020","February 21, 2020",,"March 19, 2020","HuiZhou Municipal Central Hospital, Huizhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT04280913"
374,"NCT04333251","Study Testing Convalescent Plasma vs Best Supportive Care",,"Not yet recruiting","No Results Available","Pneumonia, Interstitial","Biological: high-titer anti-Sars-CoV-2 plasma|Other: oxygen therapy","reduction in oxygen and ventilation support","Baylor Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 1","115","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","020-123","April 1, 2020","December 31, 2022","December 31, 2022","April 3, 2020",,"April 6, 2020",,,"https://ClinicalTrials.gov/show/NCT04333251"
375,"NCT04320056","Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During Pneumonia",,"Not yet recruiting","No Results Available","Coronavirus|Pneumonia|Oxygen Toxicity","Other: Standard administration of oxygen flow|Device: Automated oxygen administration - FreeO2","The number of interventions|Duration of interventions|Mean oxygen flow|Time within theSpO2 target|Time with hypoxemia|Time with hyperoxemia|Rate of ICU admission|Rate of needed non invasive respiratory support|Rate of intubation|NEWS 2 score evolution|EWSO2 score evolution|Cost-effectiveness|length of stay","Laval University","All","18 Years and older   (Adult, Older Adult)","Not Applicable","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other","21909","April 6, 2020","April 30, 2021","October 31, 2021","March 24, 2020",,"March 27, 2020",,,"https://ClinicalTrials.gov/show/NCT04320056"
376,"NCT04320862","Pandemic Response Network",,"Recruiting","No Results Available","COVID-19|SARS-CoV-2|Coronavirus|Influenza -Like Illness|Lower Resp Tract Infection|Upper Resp Tract Infection",,"Number of participants who experience inpatient admission|Number of participants admitted to the intensive care unit|Number of participants requiring mechanical ventilation|Number of deceased participants","Duke University","All","Child, Adult, Older Adult",,"200000","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","Pro00105189","April 3, 2020","December 31, 2021","December 31, 2021","March 25, 2020",,"April 8, 2020","Duke University Medical Center, Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT04320862"
377,"NCT04280224","NK Cells Treatment for Novel Coronavirus Pneumonia",,"Recruiting","No Results Available","Novel Coronavirus Pneumonia","Biological: NK Cells","Improvement of clinical symptoms including duration of fever|Improvement of clinical symptoms including respiratory frequency|Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0|Time of virus nucleic acid test negative|CD4+ and CD8+ T cell count|Rate of mortality within 28-days|Size of lesion area by thoracic imaging","Xinxiang medical university|First Affiliated Hospital of Xinjiang Medical University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","xinxiangM","February 20, 2020","September 30, 2020","December 30, 2020","February 21, 2020",,"February 21, 2020","The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China",,"https://ClinicalTrials.gov/show/NCT04280224"
378,"NCT04333875","Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis","AS DEFER","Recruiting","No Results Available","Aortic Valve Stenosis","Device: TAVR or SAVR","Composite of all-cause mortality, disabling and non-disabling stroke, and hospitalization for heart failure","University Hospital Inselspital, Berne","All","18 Years and older   (Adult, Older Adult)",,"100","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","2020-00672","March 20, 2020","December 2020","December 2020","April 3, 2020",,"April 7, 2020","Department of Cardiology, Bern University Hospital, Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT04333875"
379,"NCT04244591","Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure","Steroids-SARI","Recruiting","No Results Available","Coronavirus Infections|Respiratory Infection Virus","Drug: methylprednisolone therapy|Other: Standard care","Lower Murray lung injury score|The difference of PaO2/FiO2 between two groups|Lower Sequential Organ Failure Assessment (SOFA) score|Mechanical ventilation support|Clearance of noval coronavirus|All-cause mortality","Peking Union Medical College Hospital|Zhongda Hospital|Zhongnan Hospital|Renmin Hospital of Wuhan University","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Glucocorticoid nCoV","January 26, 2020","April 25, 2020","December 25, 2020","January 28, 2020",,"February 13, 2020","Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04244591"
380,"NCT04316377","Norwegian Coronavirus Disease 2019 Study","NO COVID-19","Recruiting","No Results Available","Corona Virus Infection","Drug: Hydroxychloroquine Sulfate","Rate of decline in SARS-CoV-2 viral load|Change in National Early Warning Score score|Admission to intensive care unit|In-hospital mortality|Duration of hospital admission|Mortality at 30 and 90 days|Clinical status","University Hospital, Akershus","All","18 Years and older   (Adult, Older Adult)","Phase 4","202","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","REC 121446","March 25, 2020","April 1, 2021","March 3, 2025","March 20, 2020",,"April 3, 2020","Akershus University Hospital, Lørenskog, Norway",,"https://ClinicalTrials.gov/show/NCT04316377"
381,"NCT04276688","Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",,"Recruiting","No Results Available","Novel Coronavirus Infection","Drug: Lopinavir/ritonavir|Drug: Ribavirin|Drug: Interferon Beta-1B","Time to negative NPS|Time to negative saliva|Time to clinical improvement|Hospitalisation|Mortality|Immune reaction|Adverse events|Time to negative all clinical specimens","The University of Hong Kong|Hospital Authority, Hong Kong","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UW-20-074","February 10, 2020","January 31, 2022","July 31, 2022","February 19, 2020",,"February 28, 2020","University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04276688"
382,"NCT04319172","Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients","COVIDSOT","Not yet recruiting","No Results Available","Transplant Recipient|Infections, Coronavirus",,"Incidence of coronavirus infection in Solid Organ Transplant Recipients|Clinical manifestations of coronavirus infection in Solid Organ Transplant Recipients|Presence of other risk factors|Establish the frequency and type of complications related to the net state of the patient immunosuppression|Frequency of co-infections|Mortality|Laboratory characteristics|Determination of coronavirus viral load|Microbiological testing","Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|Spanish Network for Research in Infectious Diseases|GESITRA-IC","All","16 Years and older   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","COVIDSOT","March 2020","March 2022","April 2022","March 24, 2020",,"March 24, 2020",,,"https://ClinicalTrials.gov/show/NCT04319172"
383,"NCT03680274","Lessening Organ Dysfunction With VITamin C","LOVIT","Recruiting","No Results Available","Sepsis|Vitamin C|Intensive Care Unit|COVID-19|Pandemic|Coronavirus","Drug: Vitamin C|Other: Control","Number of deceased participants or with persistent organ dysfunction|Number of participants with persistent organ dysfunction-free days in intensive care unit|Number of participants deceased at 6 months|Score of health related quality of life in 6-month survivors|Global tissue dysoxia|Organ function (including renal function)|Rate of inflammation|Rate of infection|Rate of endothelial injury|Occurrence of stage 3 acute kidney injury|Acute hemolysis|Hypoglycemia|Vitamin C volume of distribution|Vitamin C clearance|Vitamin C plasma concentration","Université de Sherbrooke|Lotte & John Hecht Memorial Foundation","All","18 Years and older   (Adult, Older Adult)","Phase 3","800","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MP-31-2019-2945","November 8, 2018","December 31, 2021","December 31, 2022","September 21, 2018",,"March 24, 2020","Research Center of the CHUS, Sherbrooke, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT03680274"
384,"NCT04326309","Audio Data Collection for Identification and Classification of Coughing",,"Recruiting","No Results Available","COVID-19|Coronavirus Infections|Hay Fever|Asthma|Chronic Obstructive Pulmonary Disease|Influenza|Common Cold|Respiratory Tract Infections|Healthy",,"Dataset size|Cough sound identification|Improvement of the existing model|Evaluate the usability of the application","HealthMode Inc.","All","18 Years and older   (Adult, Older Adult)",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HM070102","March 25, 2020","September 25, 2022","September 25, 2022","March 30, 2020",,"March 30, 2020","Virtual Facility, Bronx, New York, United States",,"https://ClinicalTrials.gov/show/NCT04326309"
385,"NCT04308668","Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2","COVID-19 PEP","Recruiting","No Results Available","Corona Virus Infection|Acute Respiratory Distress Syndrome|SARS-CoV Infection|Coronavirus|Coronavirus Infections","Drug: Hydroxychloroquine|Other: Placebo","Incidence of COVID19 Disease among those who are asymptomatic at trial entry|Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry|Incidence of Hospitalization|Incidence of Death|Incidence of Confirmed SARS-CoV-2 Detection|Incidence of Symptoms Compatible with COVID19 (possible disease)|Incidence of All-Cause Study Medicine Discontinuation or Withdrawal|Overall symptom severity at 5 and 14 day","University of Minnesota|McGill University Health Centre/Research Institute of the McGill University Health Centre|University of Manitoba|University of Alberta","All","18 Years and older   (Adult, Older Adult)","Phase 3","3000","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","STUDY00009267","March 17, 2020","April 21, 2020","May 12, 2020","March 16, 2020",,"April 8, 2020","Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States|Internet, New York, New York, United States|University of Alberta, Edmonton, Alberta, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Research Institute of the McGill University Heath Centre, Montréal, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT04308668"
386,"NCT04262921","Clinical Characterisation Protocol for Severe Emerging Infections","CCP-nCoV","Recruiting","No Results Available","Coronavirus Infections",,"Clinical features|Response to treatment|Pathogen replication, excretion and evolution, within the host|Immune host responses to infection and therapy|Host genetic variants","Institut National de la Santé Et de la Recherche Médicale, France","All","Child, Adult, Older Adult",,"500","Other","Observational","Observational Model: Other|Time Perspective: Prospective","C20-05|2020-A00256-33","February 7, 2020","August 7, 2020","August 7, 2023","February 10, 2020",,"February 11, 2020","CHU Pellegrin, service des Maladies Infectieuses et Tropicales, Bordeaux, France|APHP La Pitié Salpêtrière, service des Maladies Infectieuses et Tropicales, Paris, France|APHP Bichat, Service de réanimation médicale et infectieuse, Paris, France|APHP Bichat, Service des Maladies Infectieuses et Tropicales, Paris, France",,"https://ClinicalTrials.gov/show/NCT04262921"
387,"NCT04329897","Acceptance and Commitment Therapy Delivered by Automated Software Messaging",,"Enrolling by invitation","No Results Available","Hip Osteoarthritis|Knee Osteoarthritis|Mental Stress|Coronavirus","Behavioral: Software Messaging","Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects.|Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects.|Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects.|Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects.","University of Iowa","All","18 Years and older   (Adult, Older Adult)","Not Applicable","82","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care","201412701-1","April 5, 2020","May 30, 2020","June 30, 2020","April 1, 2020",,"April 8, 2020","University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",,"https://ClinicalTrials.gov/show/NCT04329897"
388,"NCT04276987","A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia",,"Not yet recruiting","No Results Available","Coronavirus","Biological: MSCs-derived exosomes","Adverse reaction (AE) and severe adverse reaction (SAE)|Time to clinical improvement (TTIC)|Number of patients weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agents usage|Duration (days) of mechanical ventilation supply|Number of patients with improved organ failure|Rate of mortality","Ruijin Hospital|Shanghai Public Health Clinical Center|Wuhan Jinyintan Hospital, Wuhan, China|Cellular Biomedicine Group Ltd.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Other|Industry","Interventional","Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MEXCOVID","February 15, 2020","May 31, 2020","July 31, 2020","February 19, 2020",,"February 25, 2020",,,"https://ClinicalTrials.gov/show/NCT04276987"
